<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Medical and surgical interventions for the treatment of usual‐type vulval intraepithelial neoplasia - Lawrie, TA - 2016 | Cochrane Library</title> <meta content="Medical and surgical interventions for the treatment of usual‐type vulval intraepithelial neoplasia - Lawrie, TA - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011837.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Medical and surgical interventions for the treatment of usual‐type vulval intraepithelial neoplasia - Lawrie, TA - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011837.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011837.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Medical and surgical interventions for the treatment of usual‐type vulval intraepithelial neoplasia" name="citation_title"/> <meta content="Theresa A Lawrie" name="citation_author"/> <meta content="Royal United Hospital" name="citation_author_institution"/> <meta content="Andy Nordin" name="citation_author"/> <meta content="Queen Elizabeth The Queen Mother Hospital" name="citation_author_institution"/> <meta content="dranordin@aol.com" name="citation_author_email"/> <meta content="Manas Chakrabarti" name="citation_author"/> <meta content="Apollo Gleneagles Cancer Hospital" name="citation_author_institution"/> <meta content="Andrew Bryant" name="citation_author"/> <meta content="Newcastle University" name="citation_author_institution"/> <meta content="Sonali Kaushik" name="citation_author"/> <meta content="Royal Sussex County Hospital" name="citation_author_institution"/> <meta content="Litha Pepas" name="citation_author"/> <meta content="St Bartholomew's Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD011837.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/01/05" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011837.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011837.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011837.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Aminoquinolines [therapeutic use]; Antineoplastic Agents [*therapeutic use]; Carcinoma in Situ [*drug therapy, pathology, *surgery]; Cidofovir; Cytosine [analogs &amp; derivatives, therapeutic use]; Disease Progression; Imiquimod; Indoles [therapeutic use]; Laser Therapy; Neoplasm Recurrence, Local; Organophosphonates [therapeutic use]; Photochemotherapy; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome; Vulvar Neoplasms [*drug therapy, pathology, *surgery]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011837.pub2&amp;doi=10.1002/14651858.CD011837.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011837.pub2&amp;doi=10.1002/14651858.CD011837.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011837.pub2&amp;doi=10.1002/14651858.CD011837.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011837.pub2&amp;doi=10.1002/14651858.CD011837.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011837.pub2&amp;doi=10.1002/14651858.CD011837.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011837.pub2&amp;doi=10.1002/14651858.CD011837.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011837.pub2&amp;doi=10.1002/14651858.CD011837.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011837.pub2&amp;doi=10.1002/14651858.CD011837.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011837.pub2&amp;doi=10.1002/14651858.CD011837.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011837.pub2&amp;doi=10.1002/14651858.CD011837.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011837.pub2&amp;doi=10.1002/14651858.CD011837.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011837.pub2&amp;doi=10.1002/14651858.CD011837.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011837.pub2&amp;doi=10.1002/14651858.CD011837.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011837.pub2&amp;doi=10.1002/14651858.CD011837.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011837.pub2&amp;doi=10.1002/14651858.CD011837.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011837.pub2&amp;doi=10.1002/14651858.CD011837.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011837.pub2&amp;doi=10.1002/14651858.CD011837.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011837.pub2&amp;doi=10.1002/14651858.CD011837.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011837.pub2&amp;doi=10.1002/14651858.CD011837.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011837.pub2&amp;doi=10.1002/14651858.CD011837.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011837.pub2&amp;doi=10.1002/14651858.CD011837.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011837.pub2&amp;doi=10.1002/14651858.CD011837.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011837.pub2&amp;doi=10.1002/14651858.CD011837.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="gpg7sF9V";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011837\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011837\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011837\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011837\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011837.pub2",title:"Medical and surgical interventions for the treatment of usual\\u2010type vulval intraepithelial neoplasia",firstPublishedDate:"Jan 5, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro‐oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=gpg7sF9V&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011837.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011837.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011837.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011837.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011837.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011837.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011837.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011837.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011837.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011837.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>9181 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011837.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011837.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011837.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011837.pub2/full#CD011837-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011837.pub2/full#CD011837-sec-0114"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011837.pub2/full#CD011837-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011837.pub2/full#CD011837-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011837.pub2/full#CD011837-sec-0030"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011837.pub2/full#CD011837-sec-0031"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011837.pub2/full#CD011837-sec-0055"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011837.pub2/full#CD011837-sec-0100"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011837.pub2/appendices#CD011837-sec-0119"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/table_n/CD011837StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/table_n/CD011837StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011837.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011837.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011837.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011837.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011837.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011837.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Medical and surgical interventions for the treatment of usual‐type vulval intraepithelial neoplasia </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011837.pub2/information#CD011837-cr-0002">Theresa A Lawrie</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011837.pub2/information#CD011837-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>Andy Nordin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011837.pub2/information#CD011837-cr-0004">Manas Chakrabarti</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011837.pub2/information#CD011837-cr-0005">Andrew Bryant</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011837.pub2/information#CD011837-cr-0006">Sonali Kaushik</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011837.pub2/information#CD011837-cr-0007">Litha Pepas</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/information/en#CD011837-sec-0127">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 05 January 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011837.pub2">https://doi.org/10.1002/14651858.CD011837.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011837-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011837-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011837-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011837-abs-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011837-abs-0007">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011837-abs-0001" lang="en"> <section id="CD011837-sec-0001"> <h3 class="title" id="CD011837-sec-0001">Background</h3> <p>Usual‐type vulval intraepithelial neoplasia (uVIN) is a pre‐cancerous condition of the vulval skin. Also known as high‐grade VIN, VIN 2/3 or high‐grade vulval squamous intraepithelial lesion (HSIL), uVIN is associated with high‐risk subtype human papilloma virus (HPV) infection. The condition causes distressing vulval symptoms in the majority of affected women and may progress to vulval cancer, therefore is usually actively managed. There is no consensus on the optimal management of uVIN. High morbidity and recurrence rates associated with surgical treatments make less invasive treatments highly desirable. </p> </section> <section id="CD011837-sec-0002"> <h3 class="title" id="CD011837-sec-0002">Objectives</h3> <p>To determine which interventions are the most effective, safe and tolerable for treating women with uVIN. </p> </section> <section id="CD011837-sec-0003"> <h3 class="title" id="CD011837-sec-0003">Search methods</h3> <p>We searched the Cochrane Gynaecological Cancer Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), Issue 8 2015, MEDLINE and EMBASE (up to 1 September 2015). We also searched registers of clinical trials, abstracts of scientific meetings, reference lists of included studies and contacted experts in the field. </p> </section> <section id="CD011837-sec-0004"> <h3 class="title" id="CD011837-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) that assessed medical and surgical interventions in women with uVIN. If no RCTs were available, we included non‐randomised studies (NRSs) with concurrent comparison groups that controlled for baseline case mix in multivariate analysis. </p> </section> <section id="CD011837-sec-0005"> <h3 class="title" id="CD011837-sec-0005">Data collection and analysis</h3> <p>We used Cochrane methodology with two review authors independently extracting data and assessing risk of bias. Where possible, we synthesised data in meta‐analyses using random‐effects methods. Network meta‐analysis was not possible due to insufficient data. </p> </section> <section id="CD011837-sec-0006"> <h3 class="title" id="CD011837-sec-0006">Main results</h3> <p>We included six RCTs involving 327 women and five NRSs involving 648 women. The condition was variously named by investigators as uVIN, VIN2/3 or high‐grade VIN. Five RCTs evaluated medical treatments (imiquimod, cidofovir, indole‐3 carbinol), and six studies (one RCT and five NRSs) evaluated surgical treatments or photodynamic therapy. We judged two RCTs and four NRSs to be at a high or unclear risk of bias; we considered the others at relatively low risk of bias. Types of outcome measures reported in NRSs varied and we were unable to pool NRS data. </p> <p><i>Medical interventions:</i> Topical imiquimod was more effective than placebo in achieving a response (complete or partial) to treatment at five to six months post‐randomisation (three RCTs, 104 women; risk ratio (RR) 11.95, 95% confidence interval (CI) 3.21 to 44.51; <i>high‐quality evidence</i> ). At five to six months, a complete response occurred in 36/62 (58%) and 0/42 (0%) women in the imiquimod and placebo groups, respectively (RR 14.40, 95% CI 2.97 to 69.80). Moderate‐quality evidence suggested that the complete response was sustained at one year (one RCT, nine complete responses out of 52 women (38%)) and beyond, particularly in women with smaller VIN lesions. Histologically confirmed complete response rates with imiquimod versus cidofovir at six months were 45% (41/91) and 46% (41/89), respectively (one RCT, 180 women; RR 1.00, 95% CI 0.73 to 1.37; <i>moderate‐quality evidence</i> ). Twelve‐month data from this trial are awaited; however, interim findings suggested that complete responses were sustained at 12 months. Only one trial reported vulval cancer at one year (1/24 and 2/23 in imiquimod and placebo groups, respectively). Adverse events were more common with imiquimod than placebo and dose reductions occurred more frequently in the imiquimod group than in the placebo group (two RCTs, 83 women; RR 7.77, 95% CI 1.61 to 37.36; <i>high‐quality evidence</i> ). Headache, fatigue and discontinuation were slightly more common with imiquimod than cidofovir (<i>moderate‐quality evidence</i>). Quality of life scores reported in one trial (52 women) were not significantly different for imiquimod and placebo. The evidence of effectiveness of topical treatments in immunosuppressed women was scant. There was insufficient evidence on other medical interventions. </p> <p><i>Surgical and other interventions:</i> Low‐quality evidence from the best included NRS indicated, when data were adjusted for confounders, that there was little difference in the risk of VIN recurrence between surgical excision and laser vaporisation. Recurrence occurred in 51% (37/70) of women overall, at a median of 14 months, and was more common in multifocal than unifocal lesions (66% versus 34%). Vulval cancer occurred in 11 women (15.1%) overall at a median of 71.5 months (9 to 259 months). The risk of vulval cancer did not differ significantly between excision and laser vaporisation in any of the NRSs; however, events were too few for robust findings. Alternative surgical procedures that might be as effective include Cavitron ultrasonic surgical aspiration (CUSA) and loop electrosurgical excision (LEEP) procedures, based on low‐ to very low‐quality evidence, respectively. Very low‐quality evidence also suggested that photodynamic therapy may be a useful treatment option. </p> <p>We found one ongoing RCT of medical treatment (imiquimod) compared with surgical treatment.</p> </section> <section id="CD011837-sec-0007"> <h3 class="title" id="CD011837-sec-0007">Authors' conclusions</h3> <p>Topical treatment (imiquimod or cidofovir) may effectively treat about half of uVIN cases after a 16‐week course of treatment, but the evidence on whether this effect is sustained is limited. Factors predicting response to treatment are not clear, but small lesions may be more likely to respond. The relative risk of progression to vulval cancer is uncertain. However, imiquimod and cidofovir appear to be relatively well tolerated and may be favoured by some women over primary surgical treatment. </p> <p>There is currently no evidence on how medical treatment compares with surgical treatment. Women who undergo surgical treatment for uVIN have about a 50% chance of the condition recurring one year later, irrespective of whether treatment is by surgical excision or laser vaporisation. Multifocal uVIN lesions are at a higher risk of recurrence and progression, and pose greater therapeutic dilemmas than unifocal lesions. If occult cancer is suspected despite a biopsy diagnosis of uVIN, surgical excision remains the treatment of choice. If occult cancer is not a concern, treatment needs to be individualised to take into account the site and extent of disease, and a woman's preferences. Combined modalities may hold the key to optimal treatment of this complex disease. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011837-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011837-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011837-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011837-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011837-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011837-abs-0002" lang="en"> <h3>Medical and surgical treatments for usual‐type vulval intraepithelial neoplasia (uVIN)</h3> <p><i><b>What is the issue?</b> </i> </p> <p>Usual‐type vulval intraepithelial neoplasia (uVIN) is a pre‐malignant condition affecting the vulval skin, which has the potential for progression to vulval cancer. Most patients have distressing symptoms that include itching, burning and soreness of the vulva, and painful intercourse. There may be white, brown, or red colour changes of the skin, breaks in the skin, or skin thickening. Usual‐type VIN is associated with infection with a virus called human papilloma virus (HPV or wart virus). Treatments are aimed at relieving distressing symptoms and ensuring that the condition does not become cancerous. The most common treatment option has been surgery to remove the affected skin areas. Surgery, however, does not guarantee a cure, can be disfiguring, and may result in physical and psychological problems. Alternatives include the use of laser technology to destroy the layer of affected skin, which may give better cosmetic results, but usually does not yield a specimen to exclude cancer. It may also be ineffective in treating uVIN that extends into hair follicles. Non‐surgical treatment alternatives include topical creams and gels, and HPV vaccines. This review aimed to assess the effectiveness and safety of these treatments. </p> <p><i><b>What did we do?</b> </i> <br/> We searched the literature from 1946 to September 2015 for randomised controlled trials (RCTs) and non‐randomised studies (NRSs) of uVIN treatment. </p> <p><i><b>What did we find?</b> </i> </p> <p>We included six RCTs involving 327 women and five NRSs involving 648 women. Five RCTs evaluated medical treatments (imiquimod, cidofovir, indole‐3 carbinol), and six studies (one RCT and five NRSs) evaluated surgical treatments or photodynamic therapy. </p> <p>We pooled data from three similar trials involving 104 women and found topical imiquimod cream to be more effective than placebo in clearing uVIN after a 16‐week course (58% cleared with imiquimod versus 0% with placebo). Most studies did not include long‐term follow‐up, but findings from one small study suggested that most women in whom uVIN was completely cleared at six months were likely to sustain this response by 12 months and beyond; however, more evidence is needed. Moderate‐quality evidence suggested that topical cidofovir gel has a similar effect to imiquimod on clearing uVIN lesions at six months (complete response rates were 46% and 45%, respectively). Again, we are uncertain about the longer‐term effects and more evidence is needed. Side effects of imiquimod included vulval pain, redness and swelling, usually managed by reducing the frequency of applications. Headaches and tiredness occurred more frequently with imiquimod than cidofovir. The evidence for imiquimod was of moderate to high quality, and that for cidofovir was of moderate quality. Very few women were immunosuppressed, therefore we cannot be certain whether these topical treatments will be as effective in these patients. </p> <p>Low‐quality evidence showed that surgical excision and laser vaporisation were probably equally effective in removing uVIN lesions. However, uVIN recurrence after treatment was common, occurring in about half of women treated. The risk of vulval cancer did not differ significantly between these treatments, but there were too few cases for firm conclusions. Alternative surgical procedures that might be as effective include CUSA (ultrasonic surgical aspiration) and LEEP (loop electrosurgical excision procedure), based on low‐ to very low‐quality evidence, respectively. Very low‐quality evidence also suggested that photodynamic therapy may also be a useful treatment option. </p> <p>We found no evidence on the effectiveness of medical treatment versus surgery, or of other treatments, such as HPV vaccines; however, we identified five ongoing trials that may provide important evidence in the future. </p> <p><i><b>Our conclusions</b> </i> </p> <p>Imiquimod or cidofovir as a 16‐week course appears to be effective against uVIN in about half of women treated, but more evidence is needed to prove that this effect is sustained in the longer term. It remains unknown whether topical treatments are as effective as surgery. Surgical excision and laser vaporisation may be equally effective treatments for uVIN, but about half of women will experience uVIN recurrence after either treatment. If cancer is suspected, despite a diagnosis of uVIN, surgical excision remains the treatment of choice. If cancer is not suspected, treatment should be individualised, taking into account a woman's preferences. Long‐term follow‐up after any treatment is essential. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011837-sec-0114" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011837-sec-0114"></div> <h3 class="title" id="CD011837-sec-0115">Implications for practice</h3> <section id="CD011837-sec-0115"> <p>Topical treatment (imiquimod or cidofovir) may effectively treat about half of usual‐type vulval intraepithelial neoplasia (uVIN) cases after a 16‐week course of treatment, but the evidence on whether this effect is sustained is limited, and the risk of progression to vulval cancer is not known. However, topical imiquimod and cidofovir appear to be well tolerated and may be favoured by some women over surgical treatment. Surgical treatment remains available for women who fail to respond to initial medical management. </p> <p>There may be little difference between surgical excision and laser vaporisation in the risk of recurrence and progression. Women who undergo surgical treatment for uVIN have about a 50% chance of the condition recurring, irrespective of whether treatment is by excision or laser vaporisation, and the risk of progression to vulval cancer may be as high as 15%. We found insufficient evidence to show whether one method of surgical excision (cold knife, loop electrosurgical excision (LEEP), laser, Cavitron ultrasonic surgical aspiration (CUSA)) was better than another in terms of effectiveness, adverse effects and quality of life. </p> <p>There is currently no evidence on how medical treatment compares with surgical treatment. Multifocal uVIN lesions are at a higher risk of recurrence and progression, and pose greater therapeutic dilemmas than unifocal lesions. If occult cancer is suspected despite a biopsy diagnosis of uVIN, surgical excision remains the treatment of choice. If occult cancer is not a concern, treatment needs to be individualised to take into account the site and extent of disease and a woman's preferences. All women undergoing treatment for uVIN require biopsies prior to treatment to exclude occult cancer and continued follow‐up after treatment to monitor for disease progression. </p> </section> <h3 class="title" id="CD011837-sec-0116">Implications for research</h3> <section id="CD011837-sec-0116"> <p>Several ongoing randomised controlled trials (RCTs) are due to report results in the next three years and are likely to make important contributions to the body of evidence on uVIN treatment: </p> <p> <ul id="CD011837-list-0026"> <li> <p><a href="./references#CD011837-bbs2-0051" title="PoelgeestM , HelmerhorstT . Clinical and immunological effects of imiquimod and HPV‐vaccination compared to imiquimod alone in female patients with usual type VIN ‐ effects of HPV‐vaccination and imiquimod in VIN patients. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐008251‐42 (accessed 6 February 2015)2009. ">EUCTR2008‐008251‐42‐NL</a>: imiquimod plus human papilloma virus (HPV) vaccination (Gardasil®) versus imiquimod alone </p> </li> <li> <p><a href="./references#CD011837-bbs2-0052" title="BlokL . 5‐Aminolevulinic acid photodynamic therapy for the treatment of pre‐malignant disorders of the vulva. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐003134‐13 (accessed 9 February 2015)2011. ">EUCTR2011‐003134‐13‐NL</a>: photodynamic therapy versus imiquimod </p> </li> <li> <p><a href="./references#CD011837-bbs2-0053" title="KaurB . Phase II clinical trial investigating the use of EPIgallocatechin‐3‐gallate (Veregen) in the treatment of vulval intraepithelial neoplasia. http://www.isrctn.com/ISRCTN98495886 (accessed 9 February 2015)2013. ">ISRCTN98495886</a>: epigallocatechin‐3 (green tea compound) versus placebo </p> </li> <li> <p><a href="./references#CD011837-bbs2-0054" title="TrutnovskyG , TamussinoK . Primary imiquimod treatment versus surgery for vulvar intraepithelial neoplasia. https://clinicaltrials.gov/show/NCT01861535 (accessed 9 February 2015)2013. ">NCT01861535</a>: imiquimod versus surgery </p> </li> <li> <p><a href="./references#CD011837-bbs2-0055" title="KenterG , NijmanHW . Randomised controlled study on the effects of imiquimod, a TLR 7 activating agent, on the HPV16‐specific immune response following HPV16 E6/E.7 synthetic long peptides vaccination in women with HPV16 positive high grade vulvar/vaginal intraepithelial neoplasia. http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1526 (accessed 9 February 2015)2008. ">NTR1526</a>: HPV vaccination (synthetic HPV16 E6/E7 peptides) with imiquimod versus HPV vaccination without imiquimod </p> </li> </ul> </p> <p>In particular, evidence from the trial of imiquimod versus surgery is eagerly awaited. RCTs in this disease are complex and challenging to conduct, due to the variable presentation of the disease, the challenges with treatment compliance, the subjectivity of clinical assessment particularly with regards to disease response, and the pain and discomfort associated with the diagnostic biopsies necessary to confirm disease response at any particular disease site. Due to the difficulty in conducting RCTs for this rare condition, and the anticipated reduction in the incidence of uVIN as a result of routine prophylactic HPV vaccination, further RCTs may not be justified. However, combined interventions may hold the key to the optimal treatment of this complex disease and studies comparing combined interventions with single interventions (e.g. surgery plus imiquimod versus surgery alone) on recurrence and progression would be of value. Longer‐term follow‐up of participants in recent and ongoing RCTs is needed. Factors that predict complete response to medical treatment need further exploration. In addition, there is a need for good qualitative research on the various treatment options for uVIN, with respect to women's satisfaction, quality of life and cosmetic results. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011837-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011837-sec-0022"></div> <div class="table" id="CD011837-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings for imiquimod versus placebo</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Imiquimod compared with placebo for usual‐type vulval intraepithelial neoplasia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with usual‐type vulval intraepithelial neoplasia </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> imiquimod 5% cream </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk (risk in study population)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Imiquimod</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment at 5 to 6 months ‐ overall response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>285 per 1000</b> <br/> (76 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 11.95</b> (3.21 to 44.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment at 5 to 6 months ‐ complete response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 14.40</b> (2.97 to 69.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment at 12 months ‐ overall response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>87 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>791 per 1000</b> <br/> (207 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 9.10</b> (2.38 to 34.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment at 12 months ‐ complete response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 18.24</b> (1.12 to 296.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression to vulval cancer at 12 months</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>56 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> <br/> (3 to 288) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.48</b> (0.05 to 4.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,2</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>HPV DNA persistence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>923 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>397 per 1000</b> </p> <p>(240 to 665)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.43</b> (0.26 to 0.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain ‐ any grade</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>269 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>922 per 1000</b> <br/> (484 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.43</b> (1.80, 6.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose reductions</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>218 per 1000</b> <br/> (45 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 7.77</b> (1.61 to 37.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>The risk in the cidofovir group is based on the assumed risk on the comparison group and the relative effect of the intervention and its 95% CI.<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded due to imprecision. </p> <p><sup>2</sup>Downgraded due to sparse data (few events). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011837-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings for imiquimod versus cidofovir</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Imiquimod compared with cidofovir for usual‐type vulval intraepithelial neoplasia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with usual‐type vulval intraepithelial neoplasia </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> imiquimod 5% cream </p> <p><b>Comparison:</b> 1% cidofovir gel </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk (risk in study population)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Cidofovir</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Imiquimod</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment at 6 months ‐ overall response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>618 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>569 per 1000</b> </p> <p>(451 to 729)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92</b> </p> <p>(0.73 to 1.18)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment at 6 months ‐ complete response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>461 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>461 per 1000</b> <br/> (336 to 631) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b> </p> <p>(0.73 to 1.37)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain ‐ any grade</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>516 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>598 per 1000</b> <br/> (475 to 758) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.16</b> <br/> (0.92 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fatigue ‐ any grade</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>607 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>759 per 1000</b> <br/> (619 to 941) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.25</b> </p> <p>(1.02 to 1.55)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Headache ‐ any grade</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>440 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>656 per 1000</b> <br/> (493 to 871) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.49</b> </p> <p>(1.12 to 1.98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total serious adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>369 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>465 per 1000</b> <br/> (325 to 668) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.26</b> </p> <p>(0.88 to 1.81)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment discontinuation</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>168 per 1000</b> <br/> (82 to 345) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.33</b> </p> <p>(0.65 to 2.74)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>176</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>*The risk in the cidofovir group is based on the assumed risk on the comparison group and the relative effect of the intervention and its 95% CI.<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded due to imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011837-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings for surgical interventions and photodynamic therapy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Surgical interventions compared with photodynamic therapy or other interventions for usual‐type vulval intraepithelial neoplasia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with usual‐type vulval intraepithelial neoplasia </p> <p><b>Settings:</b> hospital or clinic </p> <p><b>Intervention:</b> surgical excision, laser vaporisation or other options </p> <p><b>Comparison:</b> surgical excision, laser vaporisation or other surgical procedure </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Intervention versus comparison</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI) or P value</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b> Surgical excision versus laser vaporisationor other </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Recurrence‐free survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No difference</p> <p><b>P value = 0.142</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 women (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This NRS had a relatively low risk of bias and adjusted appropriately on multivariate analysis </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Laser vaporisation versus CUSA</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Recurrence rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.53</b> </p> <p>(0.56 to 4.15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 women (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>2</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This RCT lacked power to detect a difference</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b> Photodynamic therapy versus laser vaporisationand surgical excision</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Disease‐free survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No difference</p> <p><b>P value = 0.67</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 women</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>3</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This NRS had serious design limitations</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>LEEP versus laser vaporisation and surgical excision</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Recurrence‐free survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No difference</p> <p><b>P value = 0.194</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 women (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>3</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This NRS had serious design limitations</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>CUSA:</b> Cavitron ultrasonic surgical aspiration; <b>LEEP:</b> loop electrosurgical excision procedure; <b>NRS:</b> non‐randomised study; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Evidence from a non‐randomised study that adjusted for confounders. </p> <p><sup>2</sup>Downgraded twice due to imprecision. </p> <p><sup>3</sup>Evidence from a non‐randomised study with a high risk of bias. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011837-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011837-sec-0023"></div> <p>This topic was originally reviewed as two separate Cochrane topics, namely 'Medical interventions for high‐grade vulval intraepithelial neoplasia' (<a href="./references#CD011837-bbs2-0096" title="PepasL , KaushikS , BryantA , NordinA , DickinsonHO . Medical interventions for high‐grade vulval intraepithelial neoplasia. Cochrane Database of Systematic Reviews2015, Issue 8. [DOI: 10.1002/14651858.CD007924.pub2] ">Pepas 2015</a>), and 'Surgical interventions for high‐grade vulval intraepithelial neoplasia' (<a href="./references#CD011837-bbs2-0087" title="KaushikS , PepasL , NordinA , BryantA , DickinsonHO . Surgical interventions for high‐grade vulval intraepithelial neoplasia. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD007928.pub3] ">Kaushik 2014</a>). The original protocols have been combined here to enable comparisons between the various types of interventions (medical, surgical and other interventions) to be made. As the terminology of vulval intraepithelial neoplasia (VIN) has evolved over the years with our understanding of the biology and natural history of the condition (<a href="./references#CD011837-bbs2-0113" title="WilkinsonEJ , CoxJT , SelimMA , O'ConnorDM . Evolution of terminology for human‐papillomavirus‐infection‐related vulvar squamous intraepithelial lesions. Journal of Lower Genital Tract Disease2015;19(1):81‐7. ">Wilkinson 2015</a>; <a href="#CD011837-tbl-0004">Table 1</a>), for the purpose of this new combined review, we used the term usual‐type VIN (uVIN) (2004 terminology; <a href="./references#CD011837-bbs2-0102" title="SideriM , JonesRW , WilkinsonEJ , PretiM , HellerDS , ScurryJ , et al. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. Journal of the Reproductive Medicine2005;50(11):807‐10. ">Sideri 2005</a>), to include lesions also referred to in the literature as VIN 2 and VIN 3, high‐grade VIN and vulval high‐grade squamous intraepithelial lesions (HSIL) (2014 terminology <a href="./references#CD011837-bbs2-0081" title="ISSVD . 2014 Bibliography. Current ISSVD terminology. http://issvd.org/wordpress/wp‐content/uploads/2014/02/2014‐BIBLIOGRAPHY‐CURRENT‐ISSVD‐TERMINOLOGYrev.pdf2014. ">ISSVD 2014</a>). </p> <div class="table" id="CD011837-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Terminology changes for vulval intraepithelial neoplasia (VIN)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ISSVD 1986</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ISSVD 2004</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LAST 2012</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VIN 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flat condyloma or HPV effect</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LSIL</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VIN 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>VIN, usual type</p> <p>a. VIN, warty type</p> <p>b. VIN, basaloid type</p> <p>c. VIN, mixed</p> <p>(warty/basaloid) type</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HSIL</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VIN 3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Differentiated VIN</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VIN, differentiated type</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> </table> <div class="table-footnote"> <p>Table derived from <a href="./references#CD011837-bbs2-0081" title="ISSVD . 2014 Bibliography. Current ISSVD terminology. http://issvd.org/wordpress/wp‐content/uploads/2014/02/2014‐BIBLIOGRAPHY‐CURRENT‐ISSVD‐TERMINOLOGYrev.pdf2014. ">ISSVD 2014</a>. </p> <p>Abbreviations: HSIL: high‐grade squamous intraepithelial lesion; ISSVD: International Society for the Study of Vulvovaginal Disease; LSIL: low‐grade squamous intraepithelial lesions </p> </div> </div> <section id="CD011837-sec-0024"> <h3 class="title" id="CD011837-sec-0024">Description of the condition</h3> <p>Vulval intraepithelial neoplasia (VIN) is a term used for chronic pre‐cancerous skin conditions affecting the vulva. It can affect women at any age but the peak incidence occurs under the age of 50 (<a href="./references#CD011837-bbs2-0030" title="JonesRW , RowanDM , StewartAW . Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstetrics and Gynecology2005;106(6):1319‐26. ">Jones 2005</a>; <a href="./references#CD011837-bbs2-0095" title="NygårdM , HansenBT , DillnerJ , MunkC , OddssonK , TryggvadottirL , et al. Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre‐invasive neoplasia: establishing the baseline for surveillance. PloS One2014;9(2):e88323. ">Nygard 2014</a>; <a href="./references#CD011837-bbs2-0064" title="deSanjoseS , AlemanyL , OrdiJ , TousS , AlejoM , BigbySM , et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. European Journal of Cancer2013;49(16):3450‐61. ">de Sanjose 2013</a>). There are two distinct types, a type related to human papilloma virus (HPV) infection (usual‐type VIN (uVIN)) and a type related to chronic skin conditions such as lichen sclerosis (differentiated‐type VIN (dVIN)); clinicopathological overlap occurs in a small proportion of cases (less than 1%) (<a href="./references#CD011837-bbs2-0064" title="deSanjoseS , AlemanyL , OrdiJ , TousS , AlejoM , BigbySM , et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. European Journal of Cancer2013;49(16):3450‐61. ">de Sanjose 2013</a>; <a href="./references#CD011837-bbs2-0090" title="McCluggageWG . Recent developments in vulvovaginal pathology. Histopathology2009;54(2):156‐73. ">McCluggage 2009</a>). uVIN accounts for approximately 90% of VIN lesions. It has previously been graded as low‐grade (VIN 1) or high‐grade (VIN 2/3) depending on the thickness of vulval epithelium containing undifferentiated cells; however, VIN 1 was removed from the 2004 VIN classification as these lesions have little known risk of invasive carcinoma (<a href="./references#CD011837-bbs2-0102" title="SideriM , JonesRW , WilkinsonEJ , PretiM , HellerDS , ScurryJ , et al. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. Journal of the Reproductive Medicine2005;50(11):807‐10. ">Sideri 2005</a>; <a href="./references#CD011837-bbs2-0113" title="WilkinsonEJ , CoxJT , SelimMA , O'ConnorDM . Evolution of terminology for human‐papillomavirus‐infection‐related vulvar squamous intraepithelial lesions. Journal of Lower Genital Tract Disease2015;19(1):81‐7. ">Wilkinson 2015</a>). uVIN is associated with high‐risk HPV types, particularly HPV 16 (<a href="./references#CD011837-bbs2-0099" title="ReyesMC , CooperK . An update on vulvar intraepithelial neoplasia: terminology and a practical approach to diagnosis. Journal of Clinical Pathology2014;67:290‐4. ">Reyes 2014</a>; <a href="./references#CD011837-bbs2-0064" title="deSanjoseS , AlemanyL , OrdiJ , TousS , AlejoM , BigbySM , et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. European Journal of Cancer2013;49(16):3450‐61. ">de Sanjose 2013</a>), and precedes almost all vulval squamous cell carcinomas (SCC) in younger women (<a href="./references#CD011837-bbs2-0099" title="ReyesMC , CooperK . An update on vulvar intraepithelial neoplasia: terminology and a practical approach to diagnosis. Journal of Clinical Pathology2014;67:290‐4. ">Reyes 2014</a>; <a href="./references#CD011837-bbs2-0102" title="SideriM , JonesRW , WilkinsonEJ , PretiM , HellerDS , ScurryJ , et al. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. Journal of the Reproductive Medicine2005;50(11):807‐10. ">Sideri 2005</a>; <a href="./references#CD011837-bbs2-0109" title="van derAvoortI , ShirangoH , HoevenaarsBM , GrefteJM , deHulluJA , deWildePC , et al. Vulvar squamous cell carcinoma is a multifactorial disease following two separate and independent pathways. International Journal of Gynecological Pathology2006;25(1):22‐9. ">van der Avoort 2006</a>). </p> <p>Recently the International Society for the Study of Vulvovaginal Disease (ISSVD) recommended new terminology, with VIN 1 renamed low‐grade squamous intraepithelial lesions (LSIL) and uVIN renamed high‐grade squamous intraepithelial lesions (HSIL) (<a href="./references#CD011837-bbs2-0081" title="ISSVD . 2014 Bibliography. Current ISSVD terminology. http://issvd.org/wordpress/wp‐content/uploads/2014/02/2014‐BIBLIOGRAPHY‐CURRENT‐ISSVD‐TERMINOLOGYrev.pdf2014. ">ISSVD 2014</a>; <a href="./references#CD011837-bbs2-0113" title="WilkinsonEJ , CoxJT , SelimMA , O'ConnorDM . Evolution of terminology for human‐papillomavirus‐infection‐related vulvar squamous intraepithelial lesions. Journal of Lower Genital Tract Disease2015;19(1):81‐7. ">Wilkinson 2015</a>); however, VIN 2/3 and uVIN are still widely used terms in the United Kingdom (UK) and elsewhere. </p> <p>uVIN has a variable appearance on clinical examination, frequently presenting as multifocal raised plaques or papules, which may be white, brown or red (<a href="./references#CD011837-bbs2-0099" title="ReyesMC , CooperK . An update on vulvar intraepithelial neoplasia: terminology and a practical approach to diagnosis. Journal of Clinical Pathology2014;67:290‐4. ">Reyes 2014</a>; <a href="./references#CD011837-bbs2-0097" title="PretiM , IgidbashianS , CostaS , CristoforoniP , MarianiL , OrigoniM , et al. VIN usual type ‐ from the past to the future. ecancermedicalscience2015;29(9):531. [DOI: 10.3332/ecancer.2015.531] ">Preti 2015</a>). Other visible changes including skin thickening (hyperkeratosis), splitting (fissuring) and ulceration. Women usually present with distressing vulval symptoms, including itching, pain, burning and dyspareunia, therefore impaired sexual functioning and psychological morbidity are frequent associated features (<a href="./references#CD011837-bbs2-0069" title="Dominiak‐FeldenG , CohetC , Atrux‐TallauS , GilletH , TristramA , FianderA . Impact of human papillomavirus‐related genital diseases on quality of life and psychosocial wellbeing: results of an observational, health‐related quality of life study in the UK. BMC Public Health2013;13:1065. ">Dominiak‐Felden 2013</a>; <a href="./references#CD011837-bbs2-0101" title="ShylasreeTS , KaranjgaokarV , TristramA , WilkesAR , MacLeanAB , FianderAN . Contributions of demographic, psychological and disease‐related factors to quality of life in women with high‐grade vulval intraepithelial neoplasia. Gynecologic Oncology2008;110:185‐9. ">Shylasree 2008</a>). Recurrence after treatment is common, with studies reporting recurrence rates of between 25% and 51% (<a href="./references#CD011837-bbs2-0002" title="FehrMK , BaumannM , MuellerM , FinkD , HeinzlS , ImeschP , et al. Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia. Journal of Gynecologic Oncology2013;24(3):236‐41. ">Fehr 2013</a>; <a href="./references#CD011837-bbs2-0030" title="JonesRW , RowanDM , StewartAW . Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstetrics and Gynecology2005;106(6):1319‐26. ">Jones 2005</a>; <a href="./references#CD011837-bbs2-0008" title="VanEschEMG , DamMCI , OsseMEM , PutterH , TrimbosB , FleurenG , et al. Clinical characteristics associated with development of recurrence and progression in usual‐type vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2013;23(8):1476‐83. ">van Esch 2013</a>; <a href="./references#CD011837-bbs2-0044" title="WallbillichJJ , RhodesHE , MilbourneAM , MunsellMF , FrumovitzM , BrownJ , et al. Vulvar intraepithelial neoplasia (VIN 2/3): comparing clinical outcomes and evaluating risk factors for recurrence. Gynecologic Oncology2012;127(2):312‐5. ">Wallbillich 2012</a>). </p> <p>Vulval SCC in younger women is increasing, driven primarily by the increasing incidence of uVIN (<a href="./references#CD011837-bbs2-0065" title="DeVuystH , CliffordGM , NascimentoMC , MadeleineMM , FranceschiS . Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta‐analysis. International Journal of Cancer2009;124(7):1626‐36. ">De Vuyst 2009</a>; <a href="./references#CD011837-bbs2-0068" title="DittmerC , KatalinicA , MundhenkeC , ThillM , FischerD . Epidemiology of vulvar and vaginal cancer in Germany. Archives of Gynecology and Obstetrics2011;284(1):169‐74. ">Dittmer 2011</a>; <a href="./references#CD011837-bbs2-0083" title="JouraEA , LöschA , Haider‐AngelerMG , BreiteneckerG , LeodolterS . Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women. Journal of Reproductive Medicine2000;45(8):613‐5. ">Joura 2000</a>; <a href="./references#CD011837-bbs2-0089" title="LaiJ , EllerayR , NordinA , HirschowitzL , RousB , GildeaC , et al. Vulval cancer incidence, mortality and survival in England: age‐related trends. BJOG2014;121(6):728‐38. ">Lai 2014</a>; <a href="./references#CD011837-bbs2-0099" title="ReyesMC , CooperK . An update on vulvar intraepithelial neoplasia: terminology and a practical approach to diagnosis. Journal of Clinical Pathology2014;67:290‐4. ">Reyes 2014</a>). In England, there has been a statistically significant increase in the age‐standardised risk of vulval cancer from approximately 2 to 2.5 per 100,000 women from 1990 to 2009 (<a href="./references#CD011837-bbs2-0089" title="LaiJ , EllerayR , NordinA , HirschowitzL , RousB , GildeaC , et al. Vulval cancer incidence, mortality and survival in England: age‐related trends. BJOG2014;121(6):728‐38. ">Lai 2014</a>), in agreement with similar trends noted in other countries (<a href="./references#CD011837-bbs2-0058" title="BaandrupL , VarboA , MunkC , JohansenC , FrischM , KjaerSK . In situ and invasive squamous cell carcinoma of the vulva in Denmark 1978‐2007 ‐ a nationwide population‐based study. Gynecologic Oncology2011;122(1):45‐9. ">Baandrup 2011</a>; <a href="./references#CD011837-bbs2-0068" title="DittmerC , KatalinicA , MundhenkeC , ThillM , FischerD . Epidemiology of vulvar and vaginal cancer in Germany. Archives of Gynecology and Obstetrics2011;284(1):169‐74. ">Dittmer 2011</a>; <a href="./references#CD011837-bbs2-0082" title="JonesRW , BaranyaiJ , StablesS . Trends in squamous cell carcinoma of the vulva: the influence of vulvar intraepithelial neoplasia. Obstetrics and Gynecology1997;90(3):448‐52. ">Jones 1997</a>; <a href="./references#CD011837-bbs2-0083" title="JouraEA , LöschA , Haider‐AngelerMG , BreiteneckerG , LeodolterS . Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women. Journal of Reproductive Medicine2000;45(8):613‐5. ">Joura 2000</a>; <a href="./references#CD011837-bbs2-0085" title="JudsonPL , HabermannEB , BaxterNN , DurhamSB , VirnigBA . Trends in the incidence of invasive and in situ vulvar carcinoma. Obstetrics and Gynecology2006;107(5):1018‐22. ">Judson 2006</a>). Reported vulval cancer rates after treatment range from 2% to 15% (<a href="./references#CD011837-bbs2-0002" title="FehrMK , BaumannM , MuellerM , FinkD , HeinzlS , ImeschP , et al. Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia. Journal of Gynecologic Oncology2013;24(3):236‐41. ">Fehr 2013</a>; <a href="./references#CD011837-bbs2-0030" title="JonesRW , RowanDM , StewartAW . Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstetrics and Gynecology2005;106(6):1319‐26. ">Jones 2005</a>; <a href="./references#CD011837-bbs2-0008" title="VanEschEMG , DamMCI , OsseMEM , PutterH , TrimbosB , FleurenG , et al. Clinical characteristics associated with development of recurrence and progression in usual‐type vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2013;23(8):1476‐83. ">van Esch 2013</a>; <a href="./references#CD011837-bbs2-0112" title="vanSetersM , vanBeurdenM , deCraenAJ . Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. Gynecologic Oncology2005;97(2):645‐51. ">Van Seters 2005</a>; <a href="./references#CD011837-bbs2-0044" title="WallbillichJJ , RhodesHE , MilbourneAM , MunsellMF , FrumovitzM , BrownJ , et al. Vulvar intraepithelial neoplasia (VIN 2/3): comparing clinical outcomes and evaluating risk factors for recurrence. Gynecologic Oncology2012;127(2):312‐5. ">Wallbillich 2012</a>). </p> <p>Recurrence and progression of uVIN have been associated with smoking (<a href="./references#CD011837-bbs2-0002" title="FehrMK , BaumannM , MuellerM , FinkD , HeinzlS , ImeschP , et al. Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia. Journal of Gynecologic Oncology2013;24(3):236‐41. ">Fehr 2013</a>), multifocality (lesions at more than one site) (<a href="./references#CD011837-bbs2-0002" title="FehrMK , BaumannM , MuellerM , FinkD , HeinzlS , ImeschP , et al. Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia. Journal of Gynecologic Oncology2013;24(3):236‐41. ">Fehr 2013</a>; <a href="./references#CD011837-bbs2-0008" title="VanEschEMG , DamMCI , OsseMEM , PutterH , TrimbosB , FleurenG , et al. Clinical characteristics associated with development of recurrence and progression in usual‐type vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2013;23(8):1476‐83. ">van Esch 2013</a>), and large lesion size (<a href="./references#CD011837-bbs2-0044" title="WallbillichJJ , RhodesHE , MilbourneAM , MunsellMF , FrumovitzM , BrownJ , et al. Vulvar intraepithelial neoplasia (VIN 2/3): comparing clinical outcomes and evaluating risk factors for recurrence. Gynecologic Oncology2012;127(2):312‐5. ">Wallbillich 2012</a>). The evidence for an association with positive surgical margins is conflicting (<a href="./references#CD011837-bbs2-0030" title="JonesRW , RowanDM , StewartAW . Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstetrics and Gynecology2005;106(6):1319‐26. ">Jones 2005</a>; <a href="./references#CD011837-bbs2-0091" title="ModesittSC , WatersAB , WaltonL , FowlerW , VanLeL . Vulvar intraepithelial neoplasia III: occult cancer and the impact of margin status on recurrence. Obstetrics and Gynecology1998;92(6):962‐6. ">Modesitt 1998</a>; <a href="./references#CD011837-bbs2-0044" title="WallbillichJJ , RhodesHE , MilbourneAM , MunsellMF , FrumovitzM , BrownJ , et al. Vulvar intraepithelial neoplasia (VIN 2/3): comparing clinical outcomes and evaluating risk factors for recurrence. Gynecologic Oncology2012;127(2):312‐5. ">Wallbillich 2012</a>; <a href="./references#CD011837-bbs2-0047" title="YuG , LanZ , LiXC , JinHM , WangCY , LangJH . Surgical treatment of usual type vulvar intraepithelial neoplasia: a study at three academic hospitals. Chinese Medical Journal2014;127(4):784‐6. ">Yu 2014</a>). Higher recurrence and progression rates have been reported in immunocompromised women (<a href="./references#CD011837-bbs2-0002" title="FehrMK , BaumannM , MuellerM , FinkD , HeinzlS , ImeschP , et al. Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia. Journal of Gynecologic Oncology2013;24(3):236‐41. ">Fehr 2013</a>; <a href="./references#CD011837-bbs2-0008" title="VanEschEMG , DamMCI , OsseMEM , PutterH , TrimbosB , FleurenG , et al. Clinical characteristics associated with development of recurrence and progression in usual‐type vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2013;23(8):1476‐83. ">van Esch 2013</a>; <a href="./references#CD011837-bbs2-0044" title="WallbillichJJ , RhodesHE , MilbourneAM , MunsellMF , FrumovitzM , BrownJ , et al. Vulvar intraepithelial neoplasia (VIN 2/3): comparing clinical outcomes and evaluating risk factors for recurrence. Gynecologic Oncology2012;127(2):312‐5. ">Wallbillich 2012</a>), supporting the increasing interest in the immunological aspects of VIN, both as predictors of recurrence and progression, and to facilitate new immunotherapeutic approaches (<a href="./references#CD011837-bbs2-0110" title="vanEschEM , WeltersMJ , JordanovaES , TrimbosJB , van derBurgSH , vanPoelgeestMI . Treatment failure in patients with HPV 16‐induced vulvar intraepithelial neoplasia: understanding different clinical responses to immunotherapy. Expert Review of Vaccines2012;11(7):821‐40. ">van Esch 2012</a>; <a href="./references#CD011837-bbs2-0111" title="vanEschEM , vanPoelgeestMI , TrimbosJB , FleurenGJ , JordanovaES , van derBurgSH . Intraepithelial macrophage infiltration is related to a high number of regulatory T cells and promotes a progressive course of HPV‐induced vulvar neoplasia. International Journal of Cancer2015;136(4):E85‐94. ">van Esch 2015</a>). </p> </section> <section id="CD011837-sec-0025"> <h3 class="title" id="CD011837-sec-0025">Description of the intervention</h3> <section id="CD011837-sec-0026"> <h4 class="title">Surgical interventions</h4> <p>VIN lesions have historically been managed by surgical excision or ablative techniques to remove visible lesions (<a href="./references#CD011837-bbs2-0086" title="KauffmanRH . Intraepithelial neoplasia of the vulva. Gynecological Oncology1995;15(1):8‐21. ">Kauffman 1995</a>). Surgical excision remains the standard of care for small, well‐circumscribed uVIN lesions (<a href="./references#CD011837-bbs2-0060" title="Clinical Effectiveness Unit of the British Association of Sexual Health and HIV. National guidelines on the management of vulval conditions. http://www.bashh.org/documents/UK%20national%20guideline%20for%20the%20management%20of%20vulval%20conditions%202014.pdf (accessed 3 February 2015). ">BASHH guidelines 2014</a>), but is not optimal for treating multifocal lesions, which are common and more problematic (<a href="./references#CD011837-bbs2-0104" title="SternPL , van derBurgSH , HampsonIN , BrokerT , FianderA , LaceyCJ , et al. Therapy of human papillomavirus‐related disease. Vaccine2012;30:F71‐82. ">Stern 2012</a>); these tend to require more extensive surgery to remove all affected skin, e.g. skinning or simple vulvectomy. Surgical excision disrupts the normal structure of the vulva, often having a negative impact on sexual function and quality of life (<a href="./references#CD011837-bbs2-0057" title="AndreassonB , MothI , JensenSB , BockJE . Sexual function and somatopsychic reactions in vulvectomy‐operated women and their partners. Acta Obstetricia et Gynecologica Scandinavica1986;65(1):7‐10. ">Andreasson 1986</a>; <a href="./references#CD011837-bbs2-0056" title="AertsL , EnzlinP , VergoteI , VerhaegheJ , PoppeW , AmantF . Sexual, psychological, and relational functioning in women after surgical treatment for vulvar malignancy: a literature review. Journal of Sexual Medicine2012;9(2):361‐71. ">Aerts 2012</a>) </p> <p>Ablative techniques, such as carbon dioxide laser vaporisation, whereby a focused laser beam destroys the affected vulval skin, may offer greater precision and better cosmetic results, but some studies have reported a greater risk of treatment failure and recurrence with laser vaporisation (<a href="./references#CD011837-bbs2-0041" title="SteinerPH , JochumsenKM . Treatment of vulvar intraepithelial neoplasia‐laser ablation or surgical resection?. International Journal of Gynecological Cancer, 14th Biennial Meeting of the International Gynecologic Cancer Society, IGCS 2012 Vancouver, BC Canada. 2012. ">Steiner 2012</a>; <a href="./references#CD011837-bbs2-0044" title="WallbillichJJ , RhodesHE , MilbourneAM , MunsellMF , FrumovitzM , BrownJ , et al. Vulvar intraepithelial neoplasia (VIN 2/3): comparing clinical outcomes and evaluating risk factors for recurrence. Gynecologic Oncology2012;127(2):312‐5. ">Wallbillich 2012</a>). Laser vaporisation may not be appropriate for hair‐bearing areas, where hair follicle depth can extend to 3 mm or more (<a href="./references#CD011837-bbs2-0061" title="The Committee in Gynecologic Practice of the American College of Obstetricians and Gynecologists and the American Society for Colposcopy and Cervical Pathology. Management of vulvar intraepithelial neoplasia. American Society for Colposcopy and Cervical Pathology2011;Number 509:1‐4. ">Committee 2011</a>). A further disadvantage of ablative techniques is that, unlike surgical excision, no tissue is yielded for histological examination. Hence, when ablative procedures are planned, multiple biopsies of the lesion/s are necessary before the procedure to exclude microinvasion (<a href="./references#CD011837-bbs2-0097" title="PretiM , IgidbashianS , CostaS , CristoforoniP , MarianiL , OrigoniM , et al. VIN usual type ‐ from the past to the future. ecancermedicalscience2015;29(9):531. [DOI: 10.3332/ecancer.2015.531] ">Preti 2015</a>). </p> <p>Cavitron ultrasonic surgical aspiration (CUSA) is a technique that uses a handheld device to aspirate the affected epidermal tissue (<a href="./references#CD011837-bbs2-0011" title="vonGruenigenVE , GibbonsHE , GibbinsK , JenisonEL , HopkinsMP . Surgical treatments for vulvar and vaginal dysplasia: a randomized controlled trial. Obstetrics and Gynecology2007;109(4):942‐7. ">von Gruenigen 2007</a>). This technique yields a specimen for histology, therefore may have an advantage over laser vaporisation. </p> </section> <section id="CD011837-sec-0027"> <h4 class="title">Medical interventions</h4> <p>Several medical interventions have been used to treat VIN in the past. Agents utilised prior to the 1990s have largely been disregarded due to either their inefficacy or their unacceptable side effect profile. These include chemotherapeutic agents such as topical 5‐fluorouracil (<a href="./references#CD011837-bbs2-0103" title="SillmanFH , SedlisA , BoyceJG . A review of lower genital intraepithelial neoplasia and the use of topical 5‐fluorouracil. Obstetrical and Gynecological Survey1985;40(4):190‐220. ">Sillman 1985</a>), bleomycin (<a href="./references#CD011837-bbs2-0100" title="RobertsJA , WatringWG , LagasseLD . Treatment of vulvar intraepithelial neoplasia (VIN) with local bleomycin. Cancer Clinical Trials1980;3(4):351‐4. ">Roberts 1980</a>), and trinitrochlorobenzene (<a href="./references#CD011837-bbs2-0074" title="FosterDC , WoodruffJD . The use of dinitrochlorobenzene in the treatment of vulvar carcinoma in situ. Gynecological Oncology1981;11(3):330‐9. ">Foster 1981</a>). Alpha‐interferon (α‐IFN) was investigated in the 1980s and early 1990s; however, its high cost and side effects limited its use (<a href="./references#CD011837-bbs2-0040" title="SpirtosNM , SmithLH , TengNN . Prospective randomized trial of topical alpha‐interferon (alpha‐interferon gels) for the treatment of vulvar intraepithelial neoplasia III. Gynecologic Oncology1990;37(1):34‐8. SpirtosNM , SmithLH , TengNNH . A prospective, randomized trial of topical interferon‐alpha (INF) gels for the treatment of vulvar intraepithelial neoplasia III (VIN III) [abstract]. Gynecologic Oncology1989;32(1):112, Abstract 76. ">Spirtos 1990</a>). </p> <p>In recent decades, various other medical interventions have been investigated. These include the immune response modulator, imiquimod, which was developed and licensed for the treatment of genital warts (<a href="./references#CD011837-bbs2-0092" title="MooreRA , EdwardsJE , HopwoodJ , HicksD . Imiquimod for the treatment of genital warts: a quantitative systematic review. BMC Infectious Diseases2001;1:3. ">Moore 2001</a>). In an associated Cochrane review of medical interventions for VIN (<a href="./references#CD011837-bbs2-0096" title="PepasL , KaushikS , BryantA , NordinA , DickinsonHO . Medical interventions for high‐grade vulval intraepithelial neoplasia. Cochrane Database of Systematic Reviews2015, Issue 8. [DOI: 10.1002/14651858.CD007924.pub2] ">Pepas 2015</a>), we found good evidence that imiquimod was better than placebo in achieving a complete response at five to six months after treatment; however, longer‐term efficacy and safety data were lacking. In the UK, uVIN is an unlicensed indication for imiquimod (<a href="./references#CD011837-bbs2-0060" title="Clinical Effectiveness Unit of the British Association of Sexual Health and HIV. National guidelines on the management of vulval conditions. http://www.bashh.org/documents/UK%20national%20guideline%20for%20the%20management%20of%20vulval%20conditions%202014.pdf (accessed 3 February 2015). ">BASHH guidelines 2014</a>). </p> <p><a href="./references#CD011837-bbs2-0096" title="PepasL , KaushikS , BryantA , NordinA , DickinsonHO . Medical interventions for high‐grade vulval intraepithelial neoplasia. Cochrane Database of Systematic Reviews2015, Issue 8. [DOI: 10.1002/14651858.CD007924.pub2] ">Pepas 2015</a> also included a small randomised controlled trial (RCT) that compared two doses of phytochemical indole‐3‐carbinol (I3C), a natural compound that is present in large concentrations in cruciferous vegetables (cabbage, broccoli, Brussels sprouts and cauliflower); however, the review found insufficient evidence on the effectiveness of this compound (<a href="./references#CD011837-bbs2-0005" title="NaikR , NixonS , LopesA , GodfreyK , HatemMH , MonaghanJM . A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2006;16(2):786‐90. ">Naik 2006</a>). </p> <p>Another agent, cidofovir, a potent antiviral, has been used with some success in treating high‐grade anal intra‐epithelial neoplasia (AIN) (<a href="./references#CD011837-bbs2-0106" title="StierEA , GoldstoneSE , EinsteinMH , JayN , BerryJM , WilkinT , et al. Safety and efficacy of topical cidofovir to treat high‐grade perianal and vulvar intraepithelial neoplasia in HIV‐positive men and women. AIDS2013;27(4):545‐51. ">Stier 2013</a>), but few studies have been conducted to demonstrate its efficacy in treating VIN (<a href="./references#CD011837-bbs2-0108" title="TristramA , FianderA . Clinical responses to cidofovir applied topically to women with high grade vulval intraepithelial neoplasia. Gynecologic Oncology2005;99(3):652‐5. ">Tristram 2005</a>). Recently, a randomised phase 2 trial of cidofovir compared with imiquimod reported promising activity, safety and feasibility results (<a href="./references#CD011837-bbs2-0007" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a>), and longer‐term follow‐up data are expected. </p> <p>Prophylactic vaccination with the quadrivalent vaccine (HPV 6/11/16/18) has been shown to reduce the risk of HPV‐related disease including uVIN and vaccination programmes are expected to lead to future reductions in uVIN prevalence (<a href="./references#CD011837-bbs2-0084" title="JouraEA , LeodolterS , Hernandez‐AvilaM , WheelerCM , PerezG , KoutskyLA , et al. Efficacy of a quadrivalent prophylactic human papilloma virus (types 6, 11, 16, and 18) L1 virus‐like particle vaccine against high‐grade vulval and vaginal lesions: a combined analysis of three clinical trials. Lancet2007;369:1693‐702. ">Joura 2007</a>). Vaccines may also have a role to play in the treatment of uVIN and various types, including peptide (<a href="./references#CD011837-bbs2-0088" title="KenterGG , WeltersMJ , ValentijnAR , LowikMJ , Berends‐van der MeerDM , VloonAP , et al. Vaccination against HPV‐16 oncoproteins for vulvar intraepithelial neoplasia. New England Journal of Medicine2009;361(19):1838‐47. ">Kenter 2009</a>), and recombinant virus vaccines (<a href="./references#CD011837-bbs2-0059" title="BaldwinPJ , van derBurgSH , BoswellCM , OffringaR , HicklingJK , DobsonJ , et al. Vaccinia‐expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clinical Cancer Research2003;9(14):5205‐13. ">Baldwin 2003</a>), have been investigated. Limited evidence suggests that vaccination with a synthetic peptide vaccine targeting specific HPV 16/18 onco proteins can induce clinical responses, as well as clear HPV infection, in women with uVIN (<a href="./references#CD011837-bbs2-0088" title="KenterGG , WeltersMJ , ValentijnAR , LowikMJ , Berends‐van der MeerDM , VloonAP , et al. Vaccination against HPV‐16 oncoproteins for vulvar intraepithelial neoplasia. New England Journal of Medicine2009;361(19):1838‐47. ">Kenter 2009</a>). </p> <p>Photodynamic therapy, not strictly a medical intervention, has been evaluated in a number of small non‐randomised studies with variable results (<a href="./references#CD011837-bbs2-0070" title="DoughertyTJ , GomerCJ , HendersonBW , JoriG , KesselD , KorbelikM , et al. Photodynamic therapy. Journal of National Cancer Institute1998;90(12):889‐905. ">Dougherty 1998</a>; <a href="./references#CD011837-bbs2-0001" title="FehrMK , HornungR , SchwarzVA , SimeonR , HallerU , WyssP . Photodynamic therapy of vulvar intraepithelial neoplasia III using topically applied 5‐aminolevulinic acid. Gynecologic Oncology2001;80(1):62‐6. ">Fehr 2001</a>; <a href="./references#CD011837-bbs2-0079" title="HillemannsP , UntchM , DanneckerC , BaumgartnerR , SteppH , DieboldJ , et al. Photodynamic therapy of vulvar intraepithelial neoplasia using 5‐aminolevulinic acid. International Journal of Cancer2000;85(5):649‐53. ">Hillemanns 2000</a>). Proponents of this modality report that it is well tolerated and has the advantage over surgical modalities in that the appearance of the vulva is preserved (<a href="./references#CD011837-bbs2-0001" title="FehrMK , HornungR , SchwarzVA , SimeonR , HallerU , WyssP . Photodynamic therapy of vulvar intraepithelial neoplasia III using topically applied 5‐aminolevulinic acid. Gynecologic Oncology2001;80(1):62‐6. ">Fehr 2001</a>). A non‐randomised phase II trial evaluating sequential imiquimod and photodynamic therapy has reported encouraging results (<a href="./references#CD011837-bbs2-0114" title="WintersU , DaayanaS , LearJT , TomilsonAE , ElkordE , SternPL , et al. Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia. Clinical Cancer Research2008;14(16):5292‐9. ">Winters 2008</a>). </p> </section> </section> <section id="CD011837-sec-0028"> <h3 class="title" id="CD011837-sec-0028">How the intervention might work</h3> <p>Surgical interventions aim to remove or destroy the abnormal tissue. However, as uVIN is linked to persistent HPV infection, surgery does not consistently affect a cure and may miss non‐visible lesions. Immune response modifiers, such as imiquimod, α‐IFN and vaccines, aim to destroy abnormal cells indirectly by enhancing the body's immune response to HPV. Topical imiquimod does this by activating dendritic cells and increasing local cytokine secretion including interferons, tumour necrosis factor α and interleukins (<a href="./references#CD011837-bbs2-0110" title="vanEschEM , WeltersMJ , JordanovaES , TrimbosJB , van derBurgSH , vanPoelgeestMI . Treatment failure in patients with HPV 16‐induced vulvar intraepithelial neoplasia: understanding different clinical responses to immunotherapy. Expert Review of Vaccines2012;11(7):821‐40. ">van Esch 2012</a>), whereas vaccines need to stimulate a broad HPV‐specific cytotoxic T‐cell response to be effective against uVIN (<a href="./references#CD011837-bbs2-0059" title="BaldwinPJ , van derBurgSH , BoswellCM , OffringaR , HicklingJK , DobsonJ , et al. Vaccinia‐expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clinical Cancer Research2003;9(14):5205‐13. ">Baldwin 2003</a>; <a href="./references#CD011837-bbs2-0104" title="SternPL , van derBurgSH , HampsonIN , BrokerT , FianderA , LaceyCJ , et al. Therapy of human papillomavirus‐related disease. Vaccine2012;30:F71‐82. ">Stern 2012</a>; <a href="./references#CD011837-bbs2-0110" title="vanEschEM , WeltersMJ , JordanovaES , TrimbosJB , van derBurgSH , vanPoelgeestMI . Treatment failure in patients with HPV 16‐induced vulvar intraepithelial neoplasia: understanding different clinical responses to immunotherapy. Expert Review of Vaccines2012;11(7):821‐40. ">van Esch 2012</a>). Cidofovir is a broad‐spectrum antiviral agent that inhibits viral replication, and probably mediates its effect in uVIN by causing apoptosis of HPV‐infected cells (<a href="./references#CD011837-bbs2-0104" title="SternPL , van derBurgSH , HampsonIN , BrokerT , FianderA , LaceyCJ , et al. Therapy of human papillomavirus‐related disease. Vaccine2012;30:F71‐82. ">Stern 2012</a>; <a href="./references#CD011837-bbs2-0108" title="TristramA , FianderA . Clinical responses to cidofovir applied topically to women with high grade vulval intraepithelial neoplasia. Gynecologic Oncology2005;99(3):652‐5. ">Tristram 2005</a>). </p> <p>Natural compounds such as I3C and green tea extract (sinecatechins) have antioxidant properties. I3C has been shown to increase production of the anti‐proliferative metabolite 2‐hydroxyestrone, whilst decreasing production of 16‐alpha‐hydroxyestrone (a carcinogen) in rodents and humans (<a href="./references#CD011837-bbs2-0094" title="NewfieldL , BradlowHL , SepkovicDW , AubornK . Estrogen metabolism and the malignant potential of human papilloma virus immortalised keratinocytes. Proceedings of the Society for Experimental Biology and Medicine1998;217:322‐6. ">Newfield 1998</a>). Photodynamic therapy causes direct destruction of uVIN lesions using the interaction between a tumour‐localising photo‐sensitiser, e.g. 5‐aminolaevulinic acid (ALA), and light of an appropriate wavelength to bring about molecular oxygen‐induced cell death (<a href="./references#CD011837-bbs2-0070" title="DoughertyTJ , GomerCJ , HendersonBW , JoriG , KesselD , KorbelikM , et al. Photodynamic therapy. Journal of National Cancer Institute1998;90(12):889‐905. ">Dougherty 1998</a>). In addition to lesion destruction, photodynamic therapy also induces local inflammation and activates T cells (<a href="./references#CD011837-bbs2-0110" title="vanEschEM , WeltersMJ , JordanovaES , TrimbosJB , van derBurgSH , vanPoelgeestMI . Treatment failure in patients with HPV 16‐induced vulvar intraepithelial neoplasia: understanding different clinical responses to immunotherapy. Expert Review of Vaccines2012;11(7):821‐40. ">van Esch 2012</a>), therefore has both ablative and immunogenic modes of action. </p> </section> <section id="CD011837-sec-0029"> <h3 class="title" id="CD011837-sec-0029">Why it is important to do this review</h3> <p>There is currently no consensus on the optimal and most acceptable management of uVIN, largely due to a lack of high‐quality evidence to guide practice. The management of women with uVIN is complicated by the broad age range of women affected, the frequently multifocal nature of this condition and the high risk of recurrence. Surgical interventions are often disfiguring and associated with significant psychosexual morbidity, whereas medical interventions and photodynamic therapy have the advantage in that there is minimal alteration in the appearance of the vulva. uVIN is increasingly being diagnosed in younger women for whom surgical options may not be acceptable. Although new medical options have been developed to target uVIN, to date only limited evidence has emerged regarding their effectiveness and safety, and none are currently licensed in the UK for uVIN treatment. In addition, medical treatments generally require treatment to be administered over a prolonged course of time, and are frequently associated with significant distressing treatment‐related side effects. </p> <p>A Cochrane review of surgical interventions for VIN, by this author team, found insufficient evidence from RCTs to determine the effectiveness and safety of CO₂ laser vaporisation versus CUSA, and no evidence regarding the comparative effectiveness and safety of other surgical approaches (<a href="./references#CD011837-bbs2-0087" title="KaushikS , PepasL , NordinA , BryantA , DickinsonHO . Surgical interventions for high‐grade vulval intraepithelial neoplasia. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD007928.pub3] ">Kaushik 2014</a>). Another review of RCTs of medical interventions concluded that whilst imiquimod appeared to be effective in the short term, longer‐term data on effectiveness and safety were needed (<a href="./references#CD011837-bbs2-0096" title="PepasL , KaushikS , BryantA , NordinA , DickinsonHO . Medical interventions for high‐grade vulval intraepithelial neoplasia. Cochrane Database of Systematic Reviews2015, Issue 8. [DOI: 10.1002/14651858.CD007924.pub2] ">Pepas 2015</a>). Neither of these previous reviews had the scope to compare medical and surgical interventions. Since the previous Cochrane reviews were published, several new studies have been registered with online trial registries and one ongoing study has published results. Therefore, an updated review of both surgical and non‐surgical approaches was needed to determine which treatments are the most effective, safe and acceptable for uVIN, and to guide future research into treatment options for this increasingly common condition. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011837-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011837-sec-0030"></div> <p>To determine which interventions are the most effective, safe and tolerable for treating women with high‐grade VIN (uVIN). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011837-sec-0031" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011837-sec-0031"></div> <section id="CD011837-sec-0032"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011837-sec-0033"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) preferentially. Where we did not identify RCTs for treatment comparisons, we included non‐randomised studies (NRSs) with concurrent comparison groups, namely quasi‐randomised trials, non‐randomised trials, prospective and retrospective cohort studies, and case series of 20 or more women. We excluded case‐control studies, uncontrolled observational studies and case series of fewer than 20 women. In order to minimise selection bias we only included studies that used statistical adjustment for baseline case mix (age, VIN grade, lesion size/focality, immune system status) using multivariate analysis. </p> </section> <section id="CD011837-sec-0034"> <h4 class="title">Types of participants</h4> <p>Women aged over 18 years with a confirmed histological diagnosis of uVIN, VIN 2 or 3, high‐grade VIN or vulval HSIL, which was either unifocal or multifocal. We excluded studies of women with a histological diagnosis of Paget's disease, vulval carcinoma and VIN 1. </p> </section> <section id="CD011837-sec-0035"> <h4 class="title">Types of interventions</h4> <p>1. Surgical interventions</p> <p> <ul id="CD011837-list-0001"> <li> <p>Excision (including wide local excision and simple vulvectomy)</p> </li> <li> <p>Ablation (e.g. CO₂ laser vaporisation, CUSA, cryotherapy)</p> </li> </ul> </p> <p>2. Medical interventions</p> <p> <ul id="CD011837-list-0002"> <li> <p>Immune modulating drugs, e.g. imiquimod</p> </li> <li> <p>Antiviral drugs, e.g. cidofovir</p> </li> <li> <p>HPV vaccines</p> </li> <li> <p>Other drug treatments, e.g. I3C</p> </li> </ul> </p> <p>3. Other interventions, e.g. photodynamic therapy</p> <p>We included studies comparing any, or combinations, of the above interventions with each other or no active intervention (observation only or placebo). </p> </section> <section id="CD011837-sec-0036"> <h4 class="title">Types of outcome measures</h4> <section id="CD011837-sec-0037"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD011837-list-0003"> <li> <p>Response to treatment (based on clinical or histological, or clinical and histological assessment of resolution, regression, persistence or progression of VIN) </p> </li> <li> <p>Recurrence of VIN on long‐term follow‐up</p> </li> <li> <p>Progression to vulval cancer</p> </li> </ol> </p> </section> <section id="CD011837-sec-0038"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD011837-list-0004"> <li> <p>HPV‐DNA persistence</p> </li> <li> <p>Quality of life, as measured by a validated scale, e.g. European Quality of Life Index Version 5D (EQ‐5D) (<a href="./references#CD011837-bbs2-0073" title="The EuroQoL Group. EuroQol – a new facility for the measurement of health‐related quality of life. Health Policy1990;16:199‐208. ">EuroQoL 1990</a>) </p> </li> <li> <p>Sexual function, assessed using a validated tool, e.g. the Sabbatsberg sexual self rating scoring system (<a href="./references#CD011837-bbs2-0075" title="GarratAM , TorgersonDJ , WynessJ , HallMH , ReidDM . Measuring sexual function in premenopausal women. British Journal of Obstetrics and Gynaecology1995;102:311‐5. ">Garrat 1995</a>; <a href="./references#CD011837-bbs2-0093" title="NarayansinghGV , CummingGP , ParkinDP , McConellDT , HoneyE , KolhePS . Flap repair: an effective strategy for minimising sexual morbidity associated with the surgical management of vulval intraepithelial neoplasia. Journal of the Royal College of Surgeons of Edinburgh2000;45(2):81‐4. ">Naransingh 2000</a>) </p> </li> <li> <p>Control of local symptoms (pain, pruritis, erosion/ulceration, superficial dyspareunia, other); and systemic symptoms (fatigue, headache, other) </p> </li> <li> <p>Severe adverse events classified according to <a href="./references#CD011837-bbs2-0062" title="CTCAE . Common Terminology Criteria for Adverse Events v3.0. http://ctep.cancer.gov/forms/CTCAEv3.pdf (accessed 9 August 2006). ">CTCAE 2006</a>: </p> <ol id="CD011837-list-0005"> <li> <p>direct surgical morbidity (death within 30 days; injury to bladder, ureter, vascular system, small bowel or rectum; wound healing; febrile morbidity; haematoma; local infection; indwelling catheter) </p> </li> <li> <p>surgically related systemic morbidity (chest infection, thromboembolic event (deep vein thrombosis and pulmonary embolism), cardiac event (cardiac ischaemia and cardiac failure), cerebrovascular accident) </p> </li> <li> <p>drug‐ or photodynamic therapy‐related toxicity, including pain, ulceration, skin reactions, fatigue and other effects </p> </li> <li> <p>long‐term pain</p> </li> <li> <p>recovery: unscheduled re‐admission to hospital, delayed discharge</p> </li> <li> <p>other</p> </li> </ol> </li> <li> <p>Treatment discontinuation or dose reductions</p> </li> <li> <p>Patient satisfaction (as measured by investigators)</p> </li> </ol> </p> <p>Due to differences in types of interventions, not all outcomes apply to all interventions, e.g. response to treatment is usually assessed for medical not surgical treatments. </p> </section> </section> </section> <section id="CD011837-sec-0039"> <h3 class="title">Search methods for identification of studies</h3> <p>We did not apply language restrictions to any of the searches.</p> <section id="CD011837-sec-0040"> <h4 class="title">Electronic searches</h4> <p>Please refer to the methods of the Cochrane Gynaecological, Neuro‐oncology and Orphan Cancers (CGNOC) Group (<a href="http://gnoc.cochrane.org/" target="_blank">http://gnoc.cochrane.org/</a>). The following electronic databases were searched: </p> <p> <ul id="CD011837-list-0006"> <li> <p>Cochrane Gynaecological Cancer Review Group Trial Register;</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL);Issue 8, 2015</p> </li> <li> <p>MEDLINE to September 2015</p> </li> <li> <p>EMBASE to September 2015</p> </li> </ul> </p> <p>The MEDLINE, EMBASE and CENTRAL search strategies aimed to identify all RCTs and NRSs involving interventions in women with high‐grade VIN (<a href="./appendices#CD011837-sec-0120">Appendix 1</a>; <a href="./appendices#CD011837-sec-0121">Appendix 2</a>; <a href="./appendices#CD011837-sec-0122">Appendix 3</a>). In addition, we identified studies for classification on PubMed and, using the 'related articles' feature, we carried out further searches for published articles. </p> </section> <section id="CD011837-sec-0041"> <h4 class="title">Searching other resources</h4> <section id="CD011837-sec-0042"> <h5 class="title">Unpublished and grey literature</h5> <p>We searched <a href="http://www.controlled-trials.com/rct" target="_blank">www.controlled‐trials.com/rct</a>, <a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>, <a href="http://www.cancer.gov/clinicaltrials" target="_blank">www.cancer.gov/clinicaltrials</a> and the World Health Organization (WHO) International Clinical Trials Registry Platform (<a href="http://www.who.int/ictpr" target="_blank">www.who.int/ictpr</a>) for ongoing trials. We approached the principal investigators of ongoing trials to confirm trial end dates and, where appropriate, to obtain unpublished data. </p> </section> <section id="CD011837-sec-0043"> <h5 class="title">Reference lists and correspondence</h5> <p>We checked the reference lists of included studies and contacted experts in the field to identify further reports of trials. </p> </section> </section> </section> <section id="CD011837-sec-0044"> <h3 class="title" id="CD011837-sec-0044">Data collection and analysis</h3> <section id="CD011837-sec-0045"> <h4 class="title">Selection of studies</h4> <p>We downloaded all titles and abstracts retrieved by electronic searching to the reference management database Endnote® (<a href="./references#CD011837-bbs2-0072" title="Thomas Reuters. Website Endnote.com. EndNote X7. Version 7.02. Thomas Reuters. Website Endnote.com, 2013. ">EndNote 2013</a>). Theresa Lawrie (TL) removed duplicates and those studies that clearly did not meet the inclusion criteria; two review authors (TL and Andy Bryant (AB)) independently examined the remaining references. We obtained copies of the full papers of 54 potentially relevant references. Two review authors assessed the eligibility of retrieved papers independently (TL and AB or Manas Chakrabarti (MC)). We resolved disagreements by discussion or by appeal to a fourth review author (Andy Nordin (AN)). We documented reasons for excluding studies. </p> </section> <section id="CD011837-sec-0046"> <h4 class="title">Data extraction and management</h4> <p>We recorded the following data from included studies on a pre‐designed Microsoft Excel® spreadsheet: </p> <p> <ul id="CD011837-list-0007"> <li> <p>author, year of publication and journal citation (including language)</p> </li> <li> <p>country</p> </li> <li> <p>setting</p> </li> <li> <p>inclusion and exclusion criteria</p> </li> <li> <p>study design and methodology</p> </li> <li> <p>study population:</p> <ul id="CD011837-list-0008"> <li> <p>total number of participants enrolled;</p> </li> <li> <p>total number of participants analysed;</p> </li> <li> <p>mean (standard deviation (SD)) or median (range) age of participants;</p> </li> <li> <p>proportion of participants with recurrent uVIN;</p> </li> <li> <p>proportion of participants with previous anogenital neoplasia;</p> </li> <li> <p>proportion of smokers (previous and current);</p> </li> <li> <p>proportion immunocompromised</p> </li> </ul> </li> </ul> <ul id="CD011837-list-0009"> <li> <p>VIN details:</p> <ul id="CD011837-list-0010"> <li> <p>VIN terminology used</p> </li> <li> <p>proportion of high‐grade lesions (uVIN)</p> </li> <li> <p>proportion of lesions HPV‐DNA positive</p> </li> <li> <p>lesion size (mean (SD) or median (range))</p> </li> <li> <p>proportion of unifocal and multifocal lesions</p> </li> </ul> </li> </ul> <ul id="CD011837-list-0011"> <li> <p>intervention details: surgical (excision/ablation), medical (immune modulators/antivirals/vaccine/other), photodynamic therapy, or other versus observation/control </p> </li> </ul> <ul id="CD011837-list-0012"> <li> <p>risk of bias in study (see below)</p> </li> <li> <p>duration of follow‐up</p> </li> <li> <p>outcomes – response to treatment, quality of life, sexual function, symptom assessment and adverse events: </p> <ul id="CD011837-list-0013"> <li> <p>for each outcome: outcome definition (with diagnostic criteria if relevant); sample size; missing participants; number of participants allocated to each intervention group </p> </li> <li> <p>for scales: unit of measurement, upper and lower limits, and whether high or low score is good </p> </li> </ul> </li> </ul> </p> <p>We extracted outcome data as follows:</p> <p> <ul id="CD011837-list-0014"> <li> <p>For dichotomous outcomes (e.g. adverse events or number of participants with disease recurrence), we extracted the number of participants in each treatment arm who experienced the outcome of interest and the number of participants assessed at endpoint, in order to estimate a risk ratio (RR). </p> </li> <li> <p>For continuous outcomes (e.g. subjective pain), we extracted the final value and standard deviation of the outcome of interest and the number of participants assessed at endpoint in each treatment arm at the end of follow‐up at one year, in order to estimate the mean difference (MD; if trials measured outcomes on the same scale) or standardised mean differences (SMD; if trials measured outcomes on different scales) between treatment arms and the standard error. </p> </li> </ul> </p> <p>We extracted both unadjusted and adjusted statistics for RCTs, where reported, and adjusted statistics only for non‐RCTs in accordance with inclusion criteria. Where possible, all data extracted were those relevant to an intention‐to‐treat analysis, in which participants were analysed in the groups to which they were assigned. We noted the time points at which outcomes were collected and reported. We resolved differences between review authors by discussion or by appeal to a third review author when necessary. </p> <p>We managed data in the same way as for the two previous Cochrane reviews of medical and surgical interventions for high‐grade VIN (<a href="./references#CD011837-bbs2-0096" title="PepasL , KaushikS , BryantA , NordinA , DickinsonHO . Medical interventions for high‐grade vulval intraepithelial neoplasia. Cochrane Database of Systematic Reviews2015, Issue 8. [DOI: 10.1002/14651858.CD007924.pub2] ">Pepas 2015</a> and <a href="./references#CD011837-bbs2-0087" title="KaushikS , PepasL , NordinA , BryantA , DickinsonHO . Surgical interventions for high‐grade vulval intraepithelial neoplasia. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD007928.pub3] ">Kaushik 2014</a> respectively); therefore, where possible, we shared previously extracted data from studies included in these separate reviews with this new review. </p> </section> <section id="CD011837-sec-0047"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias of included RCTs using Cochrane's tool and the criteria specified in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011837-bbs2-0078" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) (<a href="./appendices#CD011837-sec-0123">Appendix 4</a>). This included assessment of: </p> <p> <ul id="CD011837-list-0015"> <li> <p>sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective reporting of outcomes;</p> </li> <li> <p>other possible sources of bias.</p> </li> </ul> </p> <p>For non‐randomised controlled studies, provided study findings were adjusted for important differences in baseline characteristics, we assessed the risk of bias for primary outcomes using the Cochrane 'Risk of bias' tool for non‐randomised studies of interventions (ACROBAT‐NRSI) (<a href="./references#CD011837-bbs2-0105" title="SterneJAC , HigginsJPT , ReevesBC , on behalf of the development group for ACROBAT‐NRSI. A Cochrane risk of bias tool: for non randomised studies of interventions (ACROBAT‐NRSI). Version 1.0.0. Available from http://www.riskofbias.info 2014 (accessed 1 December 2014). ">Sterne 2014</a>) (<a href="./appendices#CD011837-sec-0124">Appendix 5</a>): </p> <p> <ul id="CD011837-list-0016"> <li> <p>confounding;</p> </li> <li> <p>selection of participants;</p> </li> <li> <p>measurement of interventions;</p> </li> <li> <p>departure from interventions;</p> </li> <li> <p>missing data;</p> </li> <li> <p>measurement of outcomes;</p> </li> <li> <p>selective reporting of outcomes.</p> </li> </ul> </p> <p>Two review authors applied the 'Risk of bias' tools independently and resolved differences by discussion or by appeal to a third review author. We excluded NRSs assessed as having a critical risk of bias. We summarised results in risk of bias summaries for RCTs and included NRSs. We interpreted and graded the results of meta‐analyses in light of the findings with respect to risk of bias. </p> </section> <section id="CD011837-sec-0048"> <h4 class="title">Measures of treatment effect</h4> <p>We used the following measures of the effect of treatment:</p> <p> <ul id="CD011837-list-0017"> <li> <p>For dichotomous data, we used the RR with 95% confidence intervals (CIs).</p> </li> <li> <p>For continuous data, we used the MD or SMD between treatment arms with 95% CIs.</p> </li> </ul> </p> </section> <section id="CD011837-sec-0049"> <h4 class="title">Dealing with missing data</h4> <p>We did not impute missing outcome data. Where possible we attempted to contact trial authors to request missing data. </p> </section> <section id="CD011837-sec-0050"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity between studies in each meta‐analysis by visual inspection of forest plots: by estimation of the percentage heterogeneity between trials that cannot be ascribed to sampling variation (<a href="./references#CD011837-bbs2-0077" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>), by a formal statistical test of the significance of the heterogeneity (<a href="./references#CD011837-bbs2-0066" title="DeeksJJ , AltmanDG , BradburnMJ . Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis. In: EggerM , Davey SmithG , AltmanDG editor(s). Systematic Reviews in Health Care: Meta‐Analysis in Context :. 2nd Edition. London: BMJ Publication Group, 2001. ">Deeks 2001</a>), and, where possible, by subgroup analyses. If there was evidence of substantial heterogeneity, we investigated and reported the possible reasons for this. </p> </section> <section id="CD011837-sec-0051"> <h4 class="title">Assessment of reporting biases</h4> <p>If there were 10 or more studies in meta‐analyses we planned to investigate reporting biases (such as publication bias) using funnel plots; however, there were fewer than 10 studies in all meta‐analysis. </p> </section> <section id="CD011837-sec-0052"> <h4 class="title">Data synthesis</h4> <p>We carried out statistical analysis using the Review Manager software (<a href="./references#CD011837-bbs2-0098" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), using random‐effects models with inverse variance weighting for all meta‐analyses (<a href="./references#CD011837-bbs2-0067" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7:177‐88. ">DerSimonian 1986</a>). Results are presented as the average treatment effect with its 95% CI, and the estimates of T² and I². We planned multiple‐treatments meta‐analyses to synthesise studies making different comparisons of interventions. However, due to a lack of data for several key comparisons, this was not possible. In addition, the data from NRSs could not be pooled and are presented as a narrative. </p> <p>We created a 'Summary of findings' table in <a href="./references#CD011837-bbs2-0098" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a> using the GRADE approach (<a href="./references#CD011837-bbs2-0076" title="Jan Brozek, Andrew Oxman, Holger Schünemann. GRADEpro. Version 3.6 for Windows. Jan Brozek, Andrew Oxman, Holger Schünemann, 2008. ">GRADE 2008</a>). For assessments of the overall quality of evidence for each outcome that included pooled data from RCTs only, we downgraded the evidence from 'high quality' by one level for serious (or by two for very serious) study limitations (risk of bias), indirectness of evidence, serious inconsistency, imprecision of effect estimates or potential publication bias. We graded evidence from sound NRSs as low quality, and downgraded this to very low quality for serious limitations. We included the following outcomes in the 'Summary of findings' table: </p> <p> <ul id="CD011837-list-0018"> <li> <p>Response to treatment</p> </li> <li> <p>Recurrence</p> </li> <li> <p>Progression to vulval cancer</p> </li> <li> <p>Severe adverse events</p> </li> </ul> </p> </section> <section id="CD011837-sec-0053"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>It was not possible to perform subgroup analyses according to lesion size and focality. We considered factors such as age, stage, HPV DNA status, immune status, length of follow‐up and risk of bias status in interpretation of any heterogeneity. When we identified substantial heterogeneity, we investigated it using sensitivity analyses and considered whether an overall summary was meaningful. </p> </section> <section id="CD011837-sec-0054"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analysis by excluding studies at high risk of bias.</p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011837-sec-0055" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011837-sec-0055"></div> <section id="CD011837-sec-0056"> <h3 class="title">Description of studies</h3> <section id="CD011837-sec-0057"> <h4 class="title">Results of the search</h4> <p>We conducted electronic searches in June 2014 (3352 records), on 30 March 2015 (171 records) and on 1 September 2015 (118 records), which yielded a total of 3641 de‐duplicated records. We searched Medline from 1946 to August week 3 2015 and Embase from 1980 to week 35 2015. After excluding obviously irrelevant records on title and abstract, a shortlist of 246 records remained. On further screening by two review authors (TL and AB), we identified 54 records for full‐text retrieval and classification. Two authors (TL and AB or MC) classified 14 full texts (pertaining to 11 studies) as included studies, and excluded 39 full texts (pertaining to 38 studies). One conference abstract of a NRS remains unclassified whilst we await publication of the full study manuscript (<a href="./references#CD011837-bbs2-0050" title="SatmaryW , NatarajanS , BebchukJD , HolschneiderCH . A retrospective analysis of 788 patients with vulvar intraepithelial Neoplasia: clinical, demographic and pathologic factors associated with disease persistence, recurrence and progression to cancer. Journal of Lower Genital Tract Disease, 22nd World Congress of the International Society for the Study of Vulvovaginal Disease, ISSVD 2013 Rome, Italy. 2013. ">Satmary 2013</a>). See <a href="#CD011837-fig-0001">Figure 1</a>. Searches of clinical trial registries identified five ongoing trials (<a href="./references#CD011837-bbs2-0051" title="PoelgeestM , HelmerhorstT . Clinical and immunological effects of imiquimod and HPV‐vaccination compared to imiquimod alone in female patients with usual type VIN ‐ effects of HPV‐vaccination and imiquimod in VIN patients. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐008251‐42 (accessed 6 February 2015)2009. ">EUCTR2008‐008251‐42‐NL</a>; <a href="./references#CD011837-bbs2-0052" title="BlokL . 5‐Aminolevulinic acid photodynamic therapy for the treatment of pre‐malignant disorders of the vulva. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐003134‐13 (accessed 9 February 2015)2011. ">EUCTR2011‐003134‐13‐NL</a>; <a href="./references#CD011837-bbs2-0053" title="KaurB . Phase II clinical trial investigating the use of EPIgallocatechin‐3‐gallate (Veregen) in the treatment of vulval intraepithelial neoplasia. http://www.isrctn.com/ISRCTN98495886 (accessed 9 February 2015)2013. ">ISRCTN98495886</a>; <a href="./references#CD011837-bbs2-0054" title="TrutnovskyG , TamussinoK . Primary imiquimod treatment versus surgery for vulvar intraepithelial neoplasia. https://clinicaltrials.gov/show/NCT01861535 (accessed 9 February 2015)2013. ">NCT01861535</a>; <a href="./references#CD011837-bbs2-0055" title="KenterG , NijmanHW . Randomised controlled study on the effects of imiquimod, a TLR 7 activating agent, on the HPV16‐specific immune response following HPV16 E6/E.7 synthetic long peptides vaccination in women with HPV16 positive high grade vulvar/vaginal intraepithelial neoplasia. http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1526 (accessed 9 February 2015)2008. ">NTR1526</a>). </p> <div class="figure" id="CD011837-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram (searches to September 2015)." data-id="CD011837-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram (searches to September 2015).</p> </div> </div> </div> </section> <section id="CD011837-sec-0058"> <h4 class="title">Included studies</h4> <p>We included six RCTs (<a href="./references#CD011837-bbs2-0004" title='MathiesenO . "Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double blinded study" ‐ an answer. Gynecologic Oncology2008;109(3):431. MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. '>Mathiesen 2007</a>; <a href="./references#CD011837-bbs2-0005" title="NaikR , NixonS , LopesA , GodfreyK , HatemMH , MonaghanJM . A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2006;16(2):786‐90. ">Naik 2006</a>; <a href="./references#CD011837-bbs2-0006" title="SterlingJC , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, doubleblind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod [Abstract]. Journal of the European Academy of Dermatology and Venereology: JEADV. 12‐15th October, The 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 2005; Vol. 19(Suppl 2):22. ">Sterling 2005</a>; <a href="./references#CD011837-bbs2-0007" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a>; <a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>; <a href="./references#CD011837-bbs2-0011" title="vonGruenigenVE , GibbonsHE , GibbinsK , JenisonEL , HopkinsMP . Surgical treatments for vulvar and vaginal dysplasia: a randomized controlled trial. Obstetrics and Gynecology2007;109(4):942‐7. ">von Gruenigen 2007</a>), and five NRSs (<a href="./references#CD011837-bbs2-0001" title="FehrMK , HornungR , SchwarzVA , SimeonR , HallerU , WyssP . Photodynamic therapy of vulvar intraepithelial neoplasia III using topically applied 5‐aminolevulinic acid. Gynecologic Oncology2001;80(1):62‐6. ">Fehr 2001</a>; <a href="./references#CD011837-bbs2-0002" title="FehrMK , BaumannM , MuellerM , FinkD , HeinzlS , ImeschP , et al. Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia. Journal of Gynecologic Oncology2013;24(3):236‐41. ">Fehr 2013</a>; <a href="./references#CD011837-bbs2-0003" title="LeufflenL , BaermannP , RauchP , RoutiotT , BezdetnavaL , GuilleminF , et al. Treatment of vulvar intraepithelial neoplasia with CO2 laser vaporization and excision surgery. Journal of Lower Genital Tract Disease2013;17(4):446‐51. ">Leufflen 2013</a>; <a href="./references#CD011837-bbs2-0008" title="VanEschEMG , DamMCI , OsseMEM , PutterH , TrimbosB , FleurenG , et al. Clinical characteristics associated with development of recurrence and progression in usual‐type vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2013;23(8):1476‐83. ">van Esch 2013</a>; <a href="./references#CD011837-bbs2-0010" title="VlastosAT , LevyLB , MalpicaA , FollenM . Loop electrosurgical excision procedure in vulvar intraepithelial neoplasia treatment. Journal of Lower Genital Tract Disease2002;6(4):232‐8. ">Vlastos 2002</a>). </p> <section id="CD011837-sec-0059"> <h5 class="title">RCTs</h5> <p>Five RCTs evaluated medical treatments and one evaluated surgical treatments as follows:</p> <p> <ul id="CD011837-list-0019"> <li> <p><a href="./references#CD011837-bbs2-0004" title='MathiesenO . "Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double blinded study" ‐ an answer. Gynecologic Oncology2008;109(3):431. MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. '>Mathiesen 2007</a> (31 participants), <a href="./references#CD011837-bbs2-0006" title="SterlingJC , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, doubleblind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod [Abstract]. Journal of the European Academy of Dermatology and Venereology: JEADV. 12‐15th October, The 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 2005; Vol. 19(Suppl 2):22. ">Sterling 2005</a> (21 participants) and <a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> (52 participants) evaluated topical imiquimod versus placebo; </p> </li> <li> <p><a href="./references#CD011837-bbs2-0007" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a> (180 participants) evaluated topical cidofovir versus imiquimod; </p> </li> <li> <p><a href="./references#CD011837-bbs2-0005" title="NaikR , NixonS , LopesA , GodfreyK , HatemMH , MonaghanJM . A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2006;16(2):786‐90. ">Naik 2006</a> (13 participants) evaluated different doses of the natural compound I3C; and </p> </li> <li> <p><a href="./references#CD011837-bbs2-0011" title="vonGruenigenVE , GibbonsHE , GibbinsK , JenisonEL , HopkinsMP . Surgical treatments for vulvar and vaginal dysplasia: a randomized controlled trial. Obstetrics and Gynecology2007;109(4):942‐7. ">von Gruenigen 2007</a> (30 participants) evaluated carbon dioxide (CO<sub>2</sub>) laser vaporisation versus ultrasonic surgical aspiration (CUSA). </p> </li> </ul> </p> <p><a href="./references#CD011837-bbs2-0004" title='MathiesenO . "Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double blinded study" ‐ an answer. Gynecologic Oncology2008;109(3):431. MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. '>Mathiesen 2007</a>, <a href="./references#CD011837-bbs2-0006" title="SterlingJC , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, doubleblind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod [Abstract]. Journal of the European Academy of Dermatology and Venereology: JEADV. 12‐15th October, The 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 2005; Vol. 19(Suppl 2):22. ">Sterling 2005</a> and <a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> were conducted in Denmark, the United Kingdom (UK) and the Netherlands, respectively, and were double‐blinded, placebo‐controlled trials. The <a href="./references#CD011837-bbs2-0006" title="SterlingJC , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, doubleblind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod [Abstract]. Journal of the European Academy of Dermatology and Venereology: JEADV. 12‐15th October, The 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 2005; Vol. 19(Suppl 2):22. ">Sterling 2005</a> trial was published as an abstract only, with scant information. We contacted the authors in October 2010 for a previous review (<a href="./references#CD011837-bbs2-0096" title="PepasL , KaushikS , BryantA , NordinA , DickinsonHO . Medical interventions for high‐grade vulval intraepithelial neoplasia. Cochrane Database of Systematic Reviews2015, Issue 8. [DOI: 10.1002/14651858.CD007924.pub2] ">Pepas 2015</a>); however, we did not receive any further details. <a href="./references#CD011837-bbs2-0007" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a> was an open‐label, multi‐centre, phase 2 trial conducted in 32 centres in the UK. <a href="./references#CD011837-bbs2-0005" title="NaikR , NixonS , LopesA , GodfreyK , HatemMH , MonaghanJM . A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2006;16(2):786‐90. ">Naik 2006</a> was a randomised, open‐label trial conducted in a single centre in Gateshead, UK, in which participants were randomised to receive one of two different dosage regimens of I3C without a placebo control. <a href="./references#CD011837-bbs2-0011" title="vonGruenigenVE , GibbonsHE , GibbinsK , JenisonEL , HopkinsMP . Surgical treatments for vulvar and vaginal dysplasia: a randomized controlled trial. Obstetrics and Gynecology2007;109(4):942‐7. ">von Gruenigen 2007</a> was conducted in the United States of America (USA) and included 110 participants with vulval or vaginal dysplasia, of whom 30 were classified as having VIN 2/3 by the investigators and are included in this review. </p> <section id="CD011837-sec-0060"> <h6 class="title">Patient characteristics</h6> <p>All six trials randomised women with histologically proven VIN. The investigators of all RCTs used the older histological definitions, namely VIN 2 or 3 (<a href="./references#CD011837-bbs2-0004" title='MathiesenO . "Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double blinded study" ‐ an answer. Gynecologic Oncology2008;109(3):431. MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. '>Mathiesen 2007</a>; <a href="./references#CD011837-bbs2-0007" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a>; <a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>; <a href="./references#CD011837-bbs2-0011" title="vonGruenigenVE , GibbonsHE , GibbinsK , JenisonEL , HopkinsMP . Surgical treatments for vulvar and vaginal dysplasia: a randomized controlled trial. Obstetrics and Gynecology2007;109(4):942‐7. ">von Gruenigen 2007</a>), or high‐grade VIN (<a href="./references#CD011837-bbs2-0005" title="NaikR , NixonS , LopesA , GodfreyK , HatemMH , MonaghanJM . A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2006;16(2):786‐90. ">Naik 2006</a>; <a href="./references#CD011837-bbs2-0006" title="SterlingJC , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, doubleblind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod [Abstract]. Journal of the European Academy of Dermatology and Venereology: JEADV. 12‐15th October, The 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 2005; Vol. 19(Suppl 2):22. ">Sterling 2005</a>). None of the studies used the term uVIN or HSIL. The proportion of women with HPV DNA detected were reported for <a href="./references#CD011837-bbs2-0004" title='MathiesenO . "Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double blinded study" ‐ an answer. Gynecologic Oncology2008;109(3):431. MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. '>Mathiesen 2007</a>, <a href="./references#CD011837-bbs2-0007" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a>, and <a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> as 58%, 84% and 96%, respectively, with test results missing for a few women in <a href="./references#CD011837-bbs2-0004" title='MathiesenO . "Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double blinded study" ‐ an answer. Gynecologic Oncology2008;109(3):431. MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. '>Mathiesen 2007</a> and <a href="./references#CD011837-bbs2-0007" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a>. One HPV DNA positive woman in the imiquimod arm of <a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> had co‐existing lichen sclerosis and one had a histological diagnosis of VIN 1. <a href="./references#CD011837-bbs2-0006" title="SterlingJC , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, doubleblind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod [Abstract]. Journal of the European Academy of Dermatology and Venereology: JEADV. 12‐15th October, The 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 2005; Vol. 19(Suppl 2):22. ">Sterling 2005</a> reported that "HPV was detected in almost all women...with the majority shown to harbour HPV 16". HPV DNA status was not reported in <a href="./references#CD011837-bbs2-0005" title="NaikR , NixonS , LopesA , GodfreyK , HatemMH , MonaghanJM . A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2006;16(2):786‐90. ">Naik 2006</a>. Limited data on 30 women with VIN2/3 were provided to us by trial authors of <a href="./references#CD011837-bbs2-0011" title="vonGruenigenVE , GibbonsHE , GibbinsK , JenisonEL , HopkinsMP . Surgical treatments for vulvar and vaginal dysplasia: a randomized controlled trial. Obstetrics and Gynecology2007;109(4):942‐7. ">von Gruenigen 2007</a> (this trial also included women with VIN 1 and vaginal intraepithelial neoplasia (VAIN)) on request in 2010 and it is not clear what proportion of these women were HPV DNA‐positive. Data on the separate characteristics of these 30 participants were not available. </p> <p>There were no significant differences in most reported baseline characteristics between the study groups of these RCTs. Women in most studies had a mean or median age of between 45 and 50 years old, except for <a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>, in which the median age of enrolled women was between 39 and 44 years. In <a href="./references#CD011837-bbs2-0004" title='MathiesenO . "Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double blinded study" ‐ an answer. Gynecologic Oncology2008;109(3):431. MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. '>Mathiesen 2007</a>, <a href="./references#CD011837-bbs2-0005" title="NaikR , NixonS , LopesA , GodfreyK , HatemMH , MonaghanJM . A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2006;16(2):786‐90. ">Naik 2006</a>, <a href="./references#CD011837-bbs2-0007" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a> and <a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>, active smokers accounted for approximately 80%, 75%, 60% and 88% of the samples, respectively. The proportion of active smokers was not reported in <a href="./references#CD011837-bbs2-0006" title="SterlingJC , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, doubleblind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod [Abstract]. Journal of the European Academy of Dermatology and Venereology: JEADV. 12‐15th October, The 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 2005; Vol. 19(Suppl 2):22. ">Sterling 2005</a>. </p> <p>Nine women (three in the cidofovir arm and six in the imiquimod arm) were 'immunocompromised' in <a href="./references#CD011837-bbs2-0007" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a>, and two women in <a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> had received corticosteroid cream prior to enrolment in the study. Immune deficiency or immunosuppressive treatment were exclusion criteria for <a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> and <a href="./references#CD011837-bbs2-0004" title='MathiesenO . "Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double blinded study" ‐ an answer. Gynecologic Oncology2008;109(3):431. MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. '>Mathiesen 2007</a>, respectively. Participants in <a href="./references#CD011837-bbs2-0006" title="SterlingJC , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, doubleblind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod [Abstract]. Journal of the European Academy of Dermatology and Venereology: JEADV. 12‐15th October, The 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 2005; Vol. 19(Suppl 2):22. ">Sterling 2005</a> were described as immunocompetent. <a href="./references#CD011837-bbs2-0005" title="NaikR , NixonS , LopesA , GodfreyK , HatemMH , MonaghanJM . A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2006;16(2):786‐90. ">Naik 2006</a> similarly noted that women were immunocompetent and there was no significant difference in menopausal status between women randomised to the two study arms. </p> <p>The proportion of women with recurrent VIN lesions was 46% and 71% in <a href="./references#CD011837-bbs2-0007" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a> and <a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>, respectively, and multifocal lesions were present in 51%, and 100% of participants in these trials, respectively. In addition, 40% and 62% of women in <a href="./references#CD011837-bbs2-0007" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a> and <a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> had previous anogenital neoplasia, respectively. In <a href="./references#CD011837-bbs2-0004" title='MathiesenO . "Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double blinded study" ‐ an answer. Gynecologic Oncology2008;109(3):431. MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. '>Mathiesen 2007</a>, 29% of participants had multifocal lesions (five of 21 in the imiquimod group and four of 10 in the control group). Multifocal lesions occurred in three out of 12 women (25%) in <a href="./references#CD011837-bbs2-0005" title="NaikR , NixonS , LopesA , GodfreyK , HatemMH , MonaghanJM . A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2006;16(2):786‐90. ">Naik 2006</a>. Fifty‐three per cent of all participants in <a href="./references#CD011837-bbs2-0011" title="vonGruenigenVE , GibbonsHE , GibbinsK , JenisonEL , HopkinsMP . Surgical treatments for vulvar and vaginal dysplasia: a randomized controlled trial. Obstetrics and Gynecology2007;109(4):942‐7. ">von Gruenigen 2007</a> had received prior therapy for intraepithelial disease and most (93%) had multifocal disease. Focality and previous VIN were not reported in <a href="./references#CD011837-bbs2-0006" title="SterlingJC , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, doubleblind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod [Abstract]. Journal of the European Academy of Dermatology and Venereology: JEADV. 12‐15th October, The 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 2005; Vol. 19(Suppl 2):22. ">Sterling 2005</a>. </p> <p>However, significantly more women reported vulval pain at baseline in the imiquimod group compared with the placebo group of <a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>. Similarly, more women reported vulval pain at baseline in the cidofovir group of the <a href="./references#CD011837-bbs2-0007" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a> trial, compared with the imiquimod group. </p> </section> <section id="CD011837-sec-0061"> <h6 class="title">Interventions</h6> <p><a href="./references#CD011837-bbs2-0004" title='MathiesenO . "Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double blinded study" ‐ an answer. Gynecologic Oncology2008;109(3):431. MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. '>Mathiesen 2007</a>, <a href="./references#CD011837-bbs2-0006" title="SterlingJC , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, doubleblind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod [Abstract]. Journal of the European Academy of Dermatology and Venereology: JEADV. 12‐15th October, The 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 2005; Vol. 19(Suppl 2):22. ">Sterling 2005</a> and <a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> randomised participants to receive either topical imiquimod 5% cream or placebo. In <a href="./references#CD011837-bbs2-0004" title='MathiesenO . "Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double blinded study" ‐ an answer. Gynecologic Oncology2008;109(3):431. MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. '>Mathiesen 2007</a>, 21 women received imiquimod and 10 received placebo. All participants applied topical treatment for 16 weeks. The regimen involved application once a week for two weeks, twice a week during the following two weeks and, if tolerated, three times a week for the last 12 weeks. The endpoint of the study was two months after the end of treatment (24 weeks from randomisation). </p> <p>In <a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>, 26 women received imiquimod and 26 received placebo. The women applied the treatment overnight twice a week for a period of 16 weeks. They were advised to use topical sulphur precipitate 5% in zinc oxide the day after treatment application to avoid superinfection. In both these trials, women were reviewed every fourth week and a post‐treatment biopsy was taken after six months (24 weeks from randomisation). Further assessments were performed at seven months and 12 months following treatment, after which the randomisation code was revealed. </p> <p>In <a href="./references#CD011837-bbs2-0006" title="SterlingJC , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, doubleblind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod [Abstract]. Journal of the European Academy of Dermatology and Venereology: JEADV. 12‐15th October, The 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 2005; Vol. 19(Suppl 2):22. ">Sterling 2005</a>, 15 women received imiquimod and six received placebo. It was not possible to ascertain the frequency of application, however active treatment continued for 16 weeks. Histological assessment was carried out eight weeks after the start of treatment and four weeks after the completion of treatment (20 weeks from randomisation). </p> <p><a href="./references#CD011837-bbs2-0007" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a> randomised women to receive either 1% cidofovir gel or topical 5% imiquimod cream self applied overnight three times a week for a maximum of 24 weeks. Women were assessed at 6, 12, 18 and 24 weeks during treatment. Post‐treatment assessment was either six weeks after the end of treatment or six weeks after a complete response or disease progression. Two biopsy specimens were taken to assess histological response and test for HPV DNA. Women with a complete response were followed up every six months (6, 12, 18, 24 months) to the end of the study; however, at the time of writing, only the six‐week follow‐up results were available. Cross‐over to the other modality was allowed for women who failed to respond to the primary randomised treatment. </p> <p>In <a href="./references#CD011837-bbs2-0005" title="NaikR , NixonS , LopesA , GodfreyK , HatemMH , MonaghanJM . A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2006;16(2):786‐90. ">Naik 2006</a>, of the women completing the trial (three women dropped out, one could not access the medication and two did not attend the six‐month follow‐up), six were randomised to receive I3C 200 mg/day and seven received 400 mg/day. Vitamin C was also administered at the discretion of the treating clinician and five patients were prescribed this. Participants were reviewed at six weeks, three months and six months. Histological assessment was performed at six months (24 weeks). </p> <p><a href="./references#CD011837-bbs2-0011" title="vonGruenigenVE , GibbonsHE , GibbinsK , JenisonEL , HopkinsMP . Surgical treatments for vulvar and vaginal dysplasia: a randomized controlled trial. Obstetrics and Gynecology2007;109(4):942‐7. ">von Gruenigen 2007</a> compared CO<sub>2</sub> laser vaporisation with CUSA. CO<sub>2</sub> laser surgery was performed to a depth of tissue destruction of 1 mm in non‐hairy vulval regions and 3 mm in hairy regions. CUSA was performed using the Cavitron Ultrasonic Surgical Aspirator Excel System (Valley‐lab, Boulder, Colorado, USA), which is a handheld device that vibrates and aspirates tissue to the reticular layer of the dermis. Procedures were performed in an outpatient setting, with participants given standard discharge instructions regarding postoperative care. </p> </section> <section id="CD011837-sec-0062"> <h6 class="title">Outcomes</h6> <p>Response to treatment was the primary outcome in all RCTs, with the exception of <a href="./references#CD011837-bbs2-0011" title="vonGruenigenVE , GibbonsHE , GibbinsK , JenisonEL , HopkinsMP . Surgical treatments for vulvar and vaginal dysplasia: a randomized controlled trial. Obstetrics and Gynecology2007;109(4):942‐7. ">von Gruenigen 2007</a>. Histological response was determined by a repeat biopsy either from the lesion or lesions, if still present, or from the area where a lesion had been at initial assessment, when it had regressed entirely. Clinical response was varyingly defined as a reduction of the size of the lesion(s) at vulvoscopic assessment. </p> <p><a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> classified clinical responses as either a complete response or partial response. Partial responses were further subdivided into a strong partial response (76% to 99% reduction in lesion size) or a weak partial response (26% to 75% reduction in lesion size), or no response (reduction in lesion size of 25% or less). Histological response was described as change from high‐grade VIN to a lower grade or complete clearance. <a href="./references#CD011837-bbs2-0004" title='MathiesenO . "Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double blinded study" ‐ an answer. Gynecologic Oncology2008;109(3):431. MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. '>Mathiesen 2007</a> and <a href="./references#CD011837-bbs2-0006" title="SterlingJC , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, doubleblind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod [Abstract]. Journal of the European Academy of Dermatology and Venereology: JEADV. 12‐15th October, The 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 2005; Vol. 19(Suppl 2):22. ">Sterling 2005</a> both defined responses as either complete response, which was defined as complete histological and clinical clearance, partial response (&gt; 50% clearance) and no response (&lt; 50% clearance). <a href="./references#CD011837-bbs2-0007" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a> defined response according to adapted RECIST (Response Evaluation Criteria in Solid Tumours) criteria, whereby a partial response was at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters, and progressive disease is at least a 20% increase in the sum of the diameters, or the appearance of one or more new lesions (<a href="./references#CD011837-bbs2-0071" title="EisenhauerEA , TherasseP , BogaertsJ , SchwartzLH , SargentD , FordR , et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer2009;45:228‐47. ">Eisenhauer 2009</a>). <a href="./references#CD011837-bbs2-0005" title="NaikR , NixonS , LopesA , GodfreyK , HatemMH , MonaghanJM . A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2006;16(2):786‐90. ">Naik 2006</a> commented on the size of the lesions and histological assessments without grouping responses further. </p> <p>The only trial to report progression to invasive cancer 12 months after randomisation was <a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>, which also described the proportion of initially HPV‐positive women who cleared the virus at the end of the study period, and measured quality of life by means of validated questionnaires administered at baseline, 20 weeks and 12 months. The questionnaires used to assess quality of life were: the mental health scale of the Medical Outcomes Study 36‐Item Short‐Form General Health Survey (ranging from 0 to 100, with higher numbers indicating a better health‐related quality of life); the overall quality of life scale of the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ‐C30) used to assess generic and cancer‐specific health‐related quality of life; and the EORTC QLQBR23 to assess body image and sexuality. </p> <p>Outcomes in <a href="./references#CD011837-bbs2-0011" title="vonGruenigenVE , GibbonsHE , GibbinsK , JenisonEL , HopkinsMP . Surgical treatments for vulvar and vaginal dysplasia: a randomized controlled trial. Obstetrics and Gynecology2007;109(4):942‐7. ">von Gruenigen 2007</a> were recurrence after one year of follow‐up, pain, scarring, wound healing and adverse effects. Pain was assessed using a visual analogue scale one week after treatment. </p> <p>Participants in <a href="./references#CD011837-bbs2-0007" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a>, <a href="./references#CD011837-bbs2-0004" title='MathiesenO . "Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double blinded study" ‐ an answer. Gynecologic Oncology2008;109(3):431. MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. '>Mathiesen 2007</a> and <a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> were asked to keep a diary of compliance with treatment and side effects. Adherence was reported as an outcome in <a href="./references#CD011837-bbs2-0007" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a> and was assessed at six weeks and 24 weeks in terms of the median number of applications up to those time points. All studies reported side effects, with the exception of <a href="./references#CD011837-bbs2-0006" title="SterlingJC , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, doubleblind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod [Abstract]. Journal of the European Academy of Dermatology and Venereology: JEADV. 12‐15th October, The 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 2005; Vol. 19(Suppl 2):22. ">Sterling 2005</a>. <a href="./references#CD011837-bbs2-0007" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a> graded adverse effects according to <a href="./references#CD011837-bbs2-0062" title="CTCAE . Common Terminology Criteria for Adverse Events v3.0. http://ctep.cancer.gov/forms/CTCAEv3.pdf (accessed 9 August 2006). ">CTCAE 2006</a> criteria, whereas <a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> did not grade most adverse effects, but distinguished erythema and erosion as mild‐to‐moderate or severe. <a href="./references#CD011837-bbs2-0005" title="NaikR , NixonS , LopesA , GodfreyK , HatemMH , MonaghanJM . A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2006;16(2):786‐90. ">Naik 2006</a> asked women to report symptoms of pruritus and pain using a visual analogue scale at recruitment and at each subsequent visit. </p> </section> </section> <section id="CD011837-sec-0063"> <h5 class="title">NRSs</h5> <p>Two or more treatment options were assessed in these five studies, most of which have critical design limitations (see <a href="#CD011837-sec-0047">Assessment of risk of bias in included studies</a>) for the evaluation of relative effectiveness: </p> <p><a href="./references#CD011837-bbs2-0001" title="FehrMK , HornungR , SchwarzVA , SimeonR , HallerU , WyssP . Photodynamic therapy of vulvar intraepithelial neoplasia III using topically applied 5‐aminolevulinic acid. Gynecologic Oncology2001;80(1):62‐6. ">Fehr 2001</a> was a prospective feasibility study of <b>photodynamic therapy</b> (15 women with VIN 3) from a university hospital in Switzerland conducted between 1997 and 1999, compared with a retrospective cohort as controls (from 1992 to 1998) that included 37 women with VIN 3 who underwent <b>laser vaporisation</b> (30 procedures) or <b>surgical excision</b> (27 procedures). The photodynamic therapy intervention involved the use of 10 g of 10% ALA gel spread over the entire vulva. The vulva was then covered with a nonadherent dressing. Light application was performed using a dye laser; thereafter, women were advised to apply silver sulfadiazine cream after sitz baths twice a day. Women in the control group underwent one or more procedures and the mean duration of follow‐up was 35 months, compared with 12 months in the photodynamic therapy group. Women undergoing laser vaporisation were more likely than those undergoing photodynamic therapy to have multifocal disease at baseline (77% versus 60%; P value = 0.08). Authors performed multivariate analysis by treatment modality for the outcome 'disease‐free survival at 12 months after treatment'. Other study outcomes, including pain and response to treatment, were assessed for the photodynamic therapy group only. </p> <p><a href="./references#CD011837-bbs2-0002" title="FehrMK , BaumannM , MuellerM , FinkD , HeinzlS , ImeschP , et al. Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia. Journal of Gynecologic Oncology2013;24(3):236‐41. ">Fehr 2013</a> was a retrospective study of a series of 411 women with high‐grade VIN or VAIN who were treated at four colposcopy clinics in Switzerland between 1977 and 2011. Women underwent <b>laser vaporisation</b> (270 women),<b>surgical excision</b> (114 women), <b>vulvectomy</b> (19 women) and <b>other</b> treatments, e.g. photodynamic therapy or imiquimod (eight women). Mean follow‐up time was 85 months and primary outcomes were biopsy‐proven recurrence (≥ 12 months) and progression to vulval cancer. Multifocality at baseline was 25%; however, baseline characteristics were not reported separately for the treatment groups. Multivariate analyses were performed and multinomial logistic regression models (stepwise backward) were used to control for potential confounders including age, immune status, focality, grade, type of treatment and smoking behaviour on discrete outcomes. </p> <p><a href="./references#CD011837-bbs2-0003" title="LeufflenL , BaermannP , RauchP , RoutiotT , BezdetnavaL , GuilleminF , et al. Treatment of vulvar intraepithelial neoplasia with CO2 laser vaporization and excision surgery. Journal of Lower Genital Tract Disease2013;17(4):446‐51. ">Leufflen 2013</a> was a retrospective study of a series of 50 women with high‐grade VIN (41 with uVIN and nine with dVIN) who underwent treatment at a French hospital between 1995 and 1999, involving <b>surgery</b> (cold knife or laser including partial or total vulvectomy; 24 women) or <b>laser vaporisation</b> (26 women). Follow‐up was every four to six months after treatment for two years; thereafter, it varied. Younger age, uVIN, smoking, multifocality and multicentricity were all significantly more common in the laser vaporisation group at baseline (P value &lt; 0.5). Surgery was the first choice in treating unifocal VIN and dVIN, and laser vaporisation was used for all women with multicentric VIN. Mean follow‐up time was 5.6 years and primary outcomes were response to treatment, recurrence and progression to vulval cancer. Risk of recurrence according to patient characteristics and treatments was estimated using Cox proportional hazards regression models. Recurrence‐free survival was compared using the log‐rank test. </p> <p><a href="./references#CD011837-bbs2-0008" title="VanEschEMG , DamMCI , OsseMEM , PutterH , TrimbosB , FleurenG , et al. Clinical characteristics associated with development of recurrence and progression in usual‐type vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2013;23(8):1476‐83. ">van Esch 2013</a> was a retrospective study of 73 women with uVIN who were treated at a Dutch university hospital between 1990 to 2012. Treatments included <b>surgical excision</b> (31 women),<b>laser vaporisation</b> (25 women), <b>imiquimod</b> (six women) and <b>laser vaporisation plus excision</b> (eight women). As with <a href="./references#CD011837-bbs2-0003" title="LeufflenL , BaermannP , RauchP , RoutiotT , BezdetnavaL , GuilleminF , et al. Treatment of vulvar intraepithelial neoplasia with CO2 laser vaporization and excision surgery. Journal of Lower Genital Tract Disease2013;17(4):446‐51. ">Leufflen 2013</a>, more unifocal lesions were treated with excision compared with other modalities (P value = 0.105). Median follow‐up time was 49 months and primary outcomes were recurrence, recurrence‐free survival and progression to vulval cancer. uVIN was multifocal in 44% of women. Baseline characteristics were not reported separately for the treatment groups; however, recurrence‐free survival was adjusted for multifocal disease, smoking, HPV status, immune status and body mass index (BMI). </p> <p><a href="./references#CD011837-bbs2-0010" title="VlastosAT , LevyLB , MalpicaA , FollenM . Loop electrosurgical excision procedure in vulvar intraepithelial neoplasia treatment. Journal of Lower Genital Tract Disease2002;6(4):232‐8. ">Vlastos 2002</a> was a retrospective study of a series of 62 women with multifocal VIN 2 and VIN 3 with no previous treatment who underwent treatment between 1995 and 1999 in the USA. Treatments included loop electrosurgical excision procedure (<b>LEEP</b> ) (20 women), <b>surgical excision</b> (22 women) and <b>laser vaporisation</b> (20 women). Median follow‐up time was 37 months and outcomes included recurrence, time to recurrence, response rates and progression to vulval cancer. Multifocality was present in 50%, 68% and 75% of women in the LEEP, excision and laser vaporisation groups, respectively. Authors used Cox proportional hazards methods and logistic regression to compare the significance of variables predicting response to treatment. </p> <p>For more details of these included studies see <a href="./references#CD011837-sec-0132" title="">Characteristics of included studies</a>. </p> </section> </section> <section id="CD011837-sec-0064"> <h4 class="title">Excluded studies</h4> <p>We excluded 39 studies for the following reasons:</p> <p> <ul id="CD011837-list-0020"> <li> <p>an uncontrolled observational study (four studies; <a href="./references#CD011837-bbs2-0012" title="AbdullahS , HanafiahA , McNallyO . A clinicopathological review of VIN: a retrospective review of the management of vulvar intraepithelial neoplasia (VIN) over a 15 year period. BJOG, RCOG World Congress 2015 Brisbane, QLD Australia. 2015. ">Abdullah 2015</a>; <a href="./references#CD011837-bbs2-0021" title="CaglarH , DelgadoG , HreshchyshynMM . Partial and total skinning vulvectomy in treatment of carcinoma in situ of the vulva. Obstetrics and Gynecology1986;68(4):504‐7. ">Caglar 1986</a>; <a href="./references#CD011837-bbs2-0022" title="DaayanaS , WintersU , SternP , KitchenerH . Vulval intraepithelial neoplasia‐immunotherapy phase II clinical trials. International Journal of Gynaecology and Obstetrics2009;107 Suppl 2:S148. ">Daayana 2009</a>; <a href="./references#CD011837-bbs2-0046" title="WrightVC , DaviesE . Laser surgery for vulvar intraepithelial neoplasia: principles and results. American Journal of Obstetrics and Gynecology1987;156(2):374‐8. ">Wright 1987</a>); </p> </li> <li> <p>a NRS of more than one treatment with no appropriate statistical adjustment for confounders (27 studies; <a href="./references#CD011837-bbs2-0015" title="Bar‐AmA , LessingJB , NivJ , BrennerSH , PeyserMR . High‐ and low‐power CO2 lasers comparison of results for three clinical indications. Journal of Reproductive Medicine1993;38(6):455‐8. ">Bar‐Am 1993</a>; <a href="./references#CD011837-bbs2-0016" title="Ben DavidY , LickrishGM , RosenBP , MurphyJK , WaltersM , DepetrilloAD . Vulvar intra‐epithelial neoplasia‐treatment outcome. International Journal of Gynecological Cancer1996;6(2):145‐8. ">Ben David 1996</a>; <a href="./references#CD011837-bbs2-0017" title="BrownJV3rd , GoldsteinBH , RettenmaierMA , AylwardMM , GrahamCL , MichaJP . Laser ablation of surgical margins after excisional partial vulvectomy for VIN: effect on recurrence. Journal of Reproductive Medicine2005;50(5):345‐50. ">Brown 2005</a>; <a href="./references#CD011837-bbs2-0018" title="BruchimI , GotliebWH , MahmudS , TunitskyE , GrzywaczK , FerenczyA . HPV‐related vulvar intraepithelial neoplasia: outcome of different management modalities. International Journal of Gynaecology and Obstetrics2007;99(1):23‐7. ">Bruchim 2007</a>; <a href="./references#CD011837-bbs2-0019" title="Cabrera DiazS , Bradbury LobatoM , Centeno MediavillaC , FontalbaRojas , M , XercavinsJ , Gil‐MorenoA . Vulvar intraepithelial neoplasia: risk factors, recurrence and progression in 101 cases. International Journal of Gynecological Cancer, 17th International Meeting of the European Society of Gynaecological Oncology, ESGO 2011, Milan, Italy. Lippincott Williams and Wilkins, 2011. ">Cabrera Diaz 2011</a>; <a href="./references#CD011837-bbs2-0020" title="CaglarH , TamerS , HreshchyshynMM . Vulvar intraepithelial neoplasia. Obstetrics and Gynecology1982;60(3):346‐9. ">Caglar 1982</a>; <a href="./references#CD011837-bbs2-0023" title="FerenczyA , Wright JrTC , RichartRM . Comparison of CO2 laser surgery and loop electrosurgical excision/fulguration procedure (LEEP) for the treatment of vulvar intraepithelial neoplasia (VIN). International Journal of Gynecological Cancer1994;4(1):22‐8. ">Ferenczy 1994</a>; <a href="./references#CD011837-bbs2-0024" title="FioricaJV , CavanaghD , MarsdenDE , ShepherdJH , RuffoloEH , SongsterCL . Carcinoma in situ of the vulva: 24 years' experience in southwest Florida. Southern Medical Journal1988;81(5):589‐93. ">Fiorica 1988</a>; <a href="./references#CD011837-bbs2-0025" title="FregaA , SestiF , SopracordevoleF , BiamontiA , ScirpaP , MilazzoGN , et al. Imiquimod 5% cream versus cold knife excision for treatment of VIN 2/3: a five‐year follow‐up. European Review for Medical and Pharmacological Sciences2013;17(7):936‐40. ">Frega 2013</a>; <a href="./references#CD011837-bbs2-0027" title="HillemannsP , WangX , StaehleS , MichelsW , DanneckerC . Evaluation of different treatment modalities for vulvar intraepithelial neoplasia (VIN): CO(2) laser vaporization, photodynamic therapy, excision and vulvectomy. Gynecologic Oncology2006;100(2):271‐5. ">Hillemanns 2006</a>; <a href="./references#CD011837-bbs2-0029" title="JonesRW , RowanDM . Vulvar intraepithelial neoplasia III: a clinical study of the outcome in 113 cases with relation to the later development of invasive vulvar carcinoma. Obstetrics and Gynecology1994;84(5):741‐5. ">Jones 1994</a>; <a href="./references#CD011837-bbs2-0030" title="JonesRW , RowanDM , StewartAW . Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstetrics and Gynecology2005;106(6):1319‐26. ">Jones 2005</a>; <a href="./references#CD011837-bbs2-0033" title="LeuchterRS , TownsendDE , HackerNF , PretoriusRG , LagasseLD , WadeME . Treatment of vulvar carcinoma in situ with the CO2 laser. Gynecologic Oncology1984;19(3):314‐22. ">Leuchter 1984</a>; <a href="./references#CD011837-bbs2-0034" title="LiH , ZhangWH , WuLY , ZnangR , BaiP . Clinicopathologic study of 24 patiens with vulvar intraepithelial neoplasia III [Chinese]. Chung‐Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]2005;27(5):306‐8. ">Li 2005</a>; <a href="./references#CD011837-bbs2-0035" title="PennaC , FallaniMG , FambriniM , ZipoliE , MarchionniM . CO2 laser surgery for vulvar intraepithelial neoplasia. Excisional, destructive and combined techniques. Journal of Reproductive Medicine2002;47(11):913‐8. ">Penna 2002</a>; <a href="./references#CD011837-bbs2-0036" title="RibeiroF , FigueiredoA , PaulaT , BorregoJ . Vulvar intraepithelial neoplasia: evaluation of treatment modalities. Journal of Lower Genital Tract Disease2012;16(3):313‐7. ">Ribeiro 2012</a>; <a href="./references#CD011837-bbs2-0037" title="RodolakisA , DiakomanolisE , VlachosG , IconomouT , ProtopappasA , StefanidisC , et al. Vulvar intraepithelial neoplasia (VIN)‐‐diagnostic and therapeutic challenges. European Journal of Gynaecological Oncology2003;24(3‐4):317‐22. ">Rodolakis 2003</a>; <a href="./references#CD011837-bbs2-0038" title="ShafiMI , LuesleyDM , ByrneP , SamraJS , RedmanCW , JordanJA , et al. Vulval intraepithelial neoplasia‐‐management and outcome. British Journal of Obstetrics and Gynaecology1989;96(11):1339‐44. ">Shafi 1989</a>; <a href="./references#CD011837-bbs2-0039" title="SideriM , SpinaciL , SpoltiN , SchettinoF . Evaluation of CO(2) laser excision or vaporization for the treatment of vulvar intraepithelial neoplasia. Gynecologic Oncology1999;75(2):277‐81. ">Sideri 1999</a>; <a href="./references#CD011837-bbs2-0041" title="SteinerPH , JochumsenKM . Treatment of vulvar intraepithelial neoplasia‐laser ablation or surgical resection?. International Journal of Gynecological Cancer, 14th Biennial Meeting of the International Gynecologic Cancer Society, IGCS 2012 Vancouver, BC Canada. 2012. ">Steiner 2012</a>; <a href="./references#CD011837-bbs2-0042" title="VanBeurdenM , Van DerVangeN , TenKateFJW , DeCraenAJM , SchilthuisMS , LammesFB . Restricted surgical management of vulvar intraepithelial neoplasia 3: Focus on exclusion of invasion and on relief of symptoms. International Journal of Gynecological Cancer1998;8(1):73‐7. ">Van Beurden 1998</a>; <a href="./references#CD011837-bbs2-0044" title="WallbillichJJ , RhodesHE , MilbourneAM , MunsellMF , FrumovitzM , BrownJ , et al. Vulvar intraepithelial neoplasia (VIN 2/3): comparing clinical outcomes and evaluating risk factors for recurrence. Gynecologic Oncology2012;127(2):312‐5. ">Wallbillich 2012</a>; <a href="./references#CD011837-bbs2-0045" title="Wee‐SteklyWW , ChiaYN , YamKL . Vulvar intraepithelial neoplasia: our experience on diagnosis and treatment. BJOG, RCOG World Congress 2013 Liverpool, United Kingdom. Blackwell Publishing Ltd, 2013. ">Wee‐Stekly 2013</a>; <a href="./references#CD011837-bbs2-0046" title="WrightVC , DaviesE . Laser surgery for vulvar intraepithelial neoplasia: principles and results. American Journal of Obstetrics and Gynecology1987;156(2):374‐8. ">Wright 1987</a>; <a href="./references#CD011837-bbs2-0047" title="YuG , LanZ , LiXC , JinHM , WangCY , LangJH . Surgical treatment of usual type vulvar intraepithelial neoplasia: a study at three academic hospitals. Chinese Medical Journal2014;127(4):784‐6. ">Yu 2014</a>; <a href="./references#CD011837-bbs2-0048" title="ZawislakAA , PriceJH , DobbsSP , McClellandHR , McCluggageWG . The management of vulval intraepithelial neoplasia in Northern Ireland. International Journal of Gynecological Cancer2006;16:780‐5. ">Zawislak 2006</a>; <a href="./references#CD011837-bbs2-0049" title="ZhangGY . Clinical analysis of 35 cases of vulvar intraepithelial neoplasia grade III [Chinese]. Chung‐Hua Fu Chan Ko Tsa Chih [Chinese Journal of Obstetrics &amp; Gynecology]2009;44(3):163‐6. ">Zhang 2009</a>); </p> </li> <li> <p>type of participants did not match review criteria (three studies; <a href="./references#CD011837-bbs2-0026" title="GarlandSM . Efficacy of the HPV‐16/18 AS04‐adjuvanted vaccine against vulvar/vaginal intraepithelial Neoplasia. Journal of Lower Genital Tract Disease, 22nd World Congress of the International Society for the Study of Vulvovaginal Disease, ISSVD 2013 Rome, Italy2013;17(6 Suppl 2):s110. ">Garland 2013</a>; <a href="./references#CD011837-bbs2-0031" title="JouraEA , GarlandSM , PaavonenJ , FerrisDG , PerezG , AultKA , et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ2012;344:e1401. ">Joura 2012</a>; <a href="./references#CD011837-bbs2-0032" title="KrebsHB . Prophylactic topical 5‐fluorouracil following treatment of human papillomavirus‐associated lesions of the vulva and vagina. Obstetrics and Gynecology1986;68(6):837‐41. ">Krebs 1986</a>). </p> </li> <li> <p>a review (one study; <a href="./references#CD011837-bbs2-0028" title="IavazzoC , PitsouniE , AthanasiouS , FalagasME . Imiquimod for treatment of vulvar and vaginal intraepithelial neoplasia. International Journal of Gynaecology and Obstetrics2008;101(1):3‐10. ">Iavazzo 2008</a>); </p> </li> <li> <p>a case report (one study; <a href="./references#CD011837-bbs2-0014" title="BallesterI , BelinchonI , GuijarroJ , OltraF , ToledoF , CuestaL . Photodynamic therapy of vulvar intraepithelial neoplasia using methyl aminolevulinate. Journal of Dermatological Treatment2012;23(2):156‐8. ">Ballester 2012</a>); </p> </li> <li> <p>a cross‐over RCT with critical design flaws in which all participants received the active treatment and were analysed as a single cohort (one study; <a href="./references#CD011837-bbs2-0040" title="SpirtosNM , SmithLH , TengNN . Prospective randomized trial of topical alpha‐interferon (alpha‐interferon gels) for the treatment of vulvar intraepithelial neoplasia III. Gynecologic Oncology1990;37(1):34‐8. SpirtosNM , SmithLH , TengNNH . A prospective, randomized trial of topical interferon‐alpha (INF) gels for the treatment of vulvar intraepithelial neoplasia III (VIN III) [abstract]. Gynecologic Oncology1989;32(1):112, Abstract 76. ">Spirtos 1990</a>). </p> </li> <li> <p>a letter to the editor (two studies; <a href="./references#CD011837-bbs2-0013" title="BakriY , DimitrievichE . Vulvar intraepithelial neoplasia III: a clinical study of the outcome in 113 cases with relation to the later development of invasive vulvar carcinoma. Obstetrics and Gynecology1995;85(3):481‐2. ">Bakri 1995</a>; <a href="./references#CD011837-bbs2-0043" title="vanBogaertLJ . Anogenital preinvasive and invasive lesions in the Limpopo Province of South Africa. Sexually Transmitted Infections2015;91(4):293. ">van Bogaert 2015</a>). </p> </li> </ul> </p> </section> </section> <section id="CD011837-sec-0065"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD011837-sec-0066"> <h4 class="title">RCTs</h4> <p>We assessed RCTs using the Cochrane 'Risk of bias' tool in <a href="./appendices#CD011837-sec-0123">Appendix 4</a>. We judged two imiquimod versus placebo trials to be at a low risk of bias overall (<a href="./references#CD011837-bbs2-0004" title='MathiesenO . "Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double blinded study" ‐ an answer. Gynecologic Oncology2008;109(3):431. MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. '>Mathiesen 2007</a>; <a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>). We judged the trials <a href="./references#CD011837-bbs2-0005" title="NaikR , NixonS , LopesA , GodfreyK , HatemMH , MonaghanJM . A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2006;16(2):786‐90. ">Naik 2006</a> and <a href="./references#CD011837-bbs2-0006" title="SterlingJC , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, doubleblind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod [Abstract]. Journal of the European Academy of Dermatology and Venereology: JEADV. 12‐15th October, The 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 2005; Vol. 19(Suppl 2):22. ">Sterling 2005</a> to be at potentially high risk of bias as they provided scant methodological details on which to base risk of bias judgements. <a href="./references#CD011837-bbs2-0006" title="SterlingJC , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, doubleblind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod [Abstract]. Journal of the European Academy of Dermatology and Venereology: JEADV. 12‐15th October, The 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 2005; Vol. 19(Suppl 2):22. ">Sterling 2005</a> has only been published in abstract form so we were unable to properly assess its risk of bias. To our knowledge the complete details of this study remain unpublished. Both <a href="./references#CD011837-bbs2-0007" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a> and <a href="./references#CD011837-bbs2-0011" title="vonGruenigenVE , GibbonsHE , GibbinsK , JenisonEL , HopkinsMP . Surgical treatments for vulvar and vaginal dysplasia: a randomized controlled trial. Obstetrics and Gynecology2007;109(4):942‐7. ">von Gruenigen 2007</a> were open‐label trials; however, we did not consider the lack of blinding as a serious design limitation in these trials (see <a href="#CD011837-fig-0002">Figure 2</a>) and we judged these trials to be at low risk of bias overall. </p> <div class="figure" id="CD011837-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011837-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>Four trials reported the method of generation of the sequence of random numbers used to allocate women to treatment arms and this allocation was adequately concealed (<a href="./references#CD011837-bbs2-0004" title='MathiesenO . "Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double blinded study" ‐ an answer. Gynecologic Oncology2008;109(3):431. MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. '>Mathiesen 2007</a>; <a href="./references#CD011837-bbs2-0007" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a>; <a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>; <a href="./references#CD011837-bbs2-0011" title="vonGruenigenVE , GibbonsHE , GibbinsK , JenisonEL , HopkinsMP . Surgical treatments for vulvar and vaginal dysplasia: a randomized controlled trial. Obstetrics and Gynecology2007;109(4):942‐7. ">von Gruenigen 2007</a>). These trials also had minimal attrition. </p> <p><a href="./references#CD011837-bbs2-0004" title='MathiesenO . "Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double blinded study" ‐ an answer. Gynecologic Oncology2008;109(3):431. MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. '>Mathiesen 2007</a> and <a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> were both double‐blind trials in which the participants, healthcare professionals and outcome assessors were blinded; <a href="./references#CD011837-bbs2-0007" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a> was an open‐label trial, and blinding was unclear in the remaining four trials. It was not clear whether all trials reported all the outcomes that they assessed and it was unclear whether any other bias may have been present. Intention‐to‐treat data were not reported in full in <a href="./references#CD011837-bbs2-0007" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a>. We were unsuccessful in obtaining these data from the investigators. </p> </section> <section id="CD011837-sec-0067"> <h4 class="title">NRSs</h4> <p>We assessed NRSs using the Cochrane 'Risk of bias' tool for non‐randomised studies of interventions (ACROBAT‐NRSI; <a href="./appendices#CD011837-sec-0124">Appendix 5</a>). We considered most to have serious design limitations and we judged them to be at high (<a href="./references#CD011837-bbs2-0001" title="FehrMK , HornungR , SchwarzVA , SimeonR , HallerU , WyssP . Photodynamic therapy of vulvar intraepithelial neoplasia III using topically applied 5‐aminolevulinic acid. Gynecologic Oncology2001;80(1):62‐6. ">Fehr 2001</a>; <a href="./references#CD011837-bbs2-0002" title="FehrMK , BaumannM , MuellerM , FinkD , HeinzlS , ImeschP , et al. Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia. Journal of Gynecologic Oncology2013;24(3):236‐41. ">Fehr 2013</a>; <a href="./references#CD011837-bbs2-0010" title="VlastosAT , LevyLB , MalpicaA , FollenM . Loop electrosurgical excision procedure in vulvar intraepithelial neoplasia treatment. Journal of Lower Genital Tract Disease2002;6(4):232‐8. ">Vlastos 2002</a>), or unclear (<a href="./references#CD011837-bbs2-0003" title="LeufflenL , BaermannP , RauchP , RoutiotT , BezdetnavaL , GuilleminF , et al. Treatment of vulvar intraepithelial neoplasia with CO2 laser vaporization and excision surgery. Journal of Lower Genital Tract Disease2013;17(4):446‐51. ">Leufflen 2013</a>), risk of bias for assessing the effectiveness of treatment on VIN recurrence. We considered <a href="./references#CD011837-bbs2-0008" title="VanEschEMG , DamMCI , OsseMEM , PutterH , TrimbosB , FleurenG , et al. Clinical characteristics associated with development of recurrence and progression in usual‐type vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2013;23(8):1476‐83. ">van Esch 2013</a> to be at a low risk of bias relative to the other NRSs (see <a href="./references#CD011837-sec-0132" title="">Characteristics of included studies</a>). </p> <p><a href="./references#CD011837-bbs2-0001" title="FehrMK , HornungR , SchwarzVA , SimeonR , HallerU , WyssP . Photodynamic therapy of vulvar intraepithelial neoplasia III using topically applied 5‐aminolevulinic acid. Gynecologic Oncology2001;80(1):62‐6. ">Fehr 2001</a> compared prospective cases of women undergoing photodynamic therapy with retrospective cases of laser vaporisation or surgical excision. In this study, confounders were reported separately by treatment group and adjusted for in multivariate analysis. However, no effect estimates of the multivariate findings are reported and the authors stated that the power of the analysis was low. Intervention status was not well defined as 15 women in the control group had more than one type of procedure, i.e. the unit of analysis was procedures, not women. Therefore, re‐treatment of a patient on recurrence with the same or a different intervention was entered as a separate intervention/patient. The duration of follow‐up differed substantially between the photodynamic therapy and control arms. There was insufficient information to make a firm judgement but this study was potentially at a high risk of bias due to possible selective reporting bias, missing information and the other design limitations. </p> <p><a href="./references#CD011837-bbs2-0002" title="FehrMK , BaumannM , MuellerM , FinkD , HeinzlS , ImeschP , et al. Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia. Journal of Gynecologic Oncology2013;24(3):236‐41. ">Fehr 2013</a> compared laser vaporisation with surgical excision, vulvectomy and other treatments. We had risk of bias concerns about the measurement of interventions and outcomes in this study. Women who received both laser vaporisation and excision in the first year were analysed in the laser vaporisation group and the actual number of women who received both treatments was not reported. Women in the laser vaporisation group may therefore have had more extensive treatment during the course of the first year and, therefore, this group may not be comparable to the excision only group. Early recurrences and progressions occurring in the first year were not counted but rather considered to have had inappropriate or insufficient initial treatment requiring immediate re‐treatment. We also had concerns about selective reporting bias with possible multiple intervention outcome testing to produce the odds ratios (ORs) for recurrence and progressions. The number of women included in these analyses was not reported in Table 2 of the article, and the findings for excision versus laser vaporisation was reported, not surgery (excision + vulvectomy) versus laser vaporisation, as in Table 1 of the article. These limitations might have biased results in the direction of laser vaporisation. We therefore judged this study to be at a high risk of bias. </p> <p><a href="./references#CD011837-bbs2-0003" title="LeufflenL , BaermannP , RauchP , RoutiotT , BezdetnavaL , GuilleminF , et al. Treatment of vulvar intraepithelial neoplasia with CO2 laser vaporization and excision surgery. Journal of Lower Genital Tract Disease2013;17(4):446‐51. ">Leufflen 2013</a> compared laser vaporisation with surgical excision. Interventions and outcomes were clearly defined, but participants included nine women with dVIN, which was more likely to be treated with surgical excision (seven out of nine women). Women in the laser vaporisation group were more likely to be younger and to have uVIN, multicentric and multifocal disease. We assessed risk of bias in relation to the outcome recurrence‐free survival as unclear risk as the report does not state which baseline variables were adjusted for, and it was not clear whether the reported recurrence‐free survival was adjusted for multifocality and the other important variables that differed significantly between the treatment groups. </p> <p><a href="./references#CD011837-bbs2-0008" title="VanEschEMG , DamMCI , OsseMEM , PutterH , TrimbosB , FleurenG , et al. Clinical characteristics associated with development of recurrence and progression in usual‐type vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2013;23(8):1476‐83. ">van Esch 2013</a> compared surgical excision with laser vaporisation, excision and laser vaporisation combined, and imiquimod. Outcomes were clearly defined. Women with unifocal lesions were more likely to have excision than other modalities; however, this and other main confounders (smoking, HPV status, immune status and BMI) were adjusted for in a multivariate analysis of recurrence‐free survival. Precise effect estimates were not reported and analyses were probably underpowered. However, we judged this study to be at a relatively low risk of bias for the multivariate recurrence‐free survival analysis. </p> <p><a href="./references#CD011837-bbs2-0010" title="VlastosAT , LevyLB , MalpicaA , FollenM . Loop electrosurgical excision procedure in vulvar intraepithelial neoplasia treatment. Journal of Lower Genital Tract Disease2002;6(4):232‐8. ">Vlastos 2002</a> compared LEEP, surgical excision and laser vaporisation. In this study report, the text stated that all women had multifocal disease, which was contradicted by tabulated data, indicating that 10/20, 15/22 and 15/20 women in the LEEP, excision and laser vaporisation groups had multifocal VIN, respectively. These data on multifocality were not statistically significantly different between groups (P value = 0.27). The authors stated that they controlled for age, age at first intercourse and number of sexual partners; however, it was unclear whether findings were adjusted for multifocality and other important factors. We considered the potential for bias in the measurement of outcomes to represent a serious risk as there was no information on how recurrence was monitored or measured. Median duration of follow‐up was significantly longer for the laser vaporisation group compared with the other treatment groups and there were more recurrences in this group. Precise data on the effect of treatments on recurrence were missing from the report. We judged this study to be at a potentially high risk of bias. </p> </section> </section> <section id="CD011837-sec-0068"> <h3 class="title" id="CD011837-sec-0068">Effects of interventions</h3> <p>See: <a href="./full#CD011837-tbl-0001"><b>Summary of findings for the main comparison</b> Summary of findings for imiquimod versus placebo</a>; <a href="./full#CD011837-tbl-0002"><b>Summary of findings 2</b> Summary of findings for imiquimod versus cidofovir</a>; <a href="./full#CD011837-tbl-0003"><b>Summary of findings 3</b> Summary of findings for surgical interventions and photodynamic therapy</a> </p> <section id="CD011837-sec-0069"> <h4 class="title">Evidence from randomised controlled trials (RCTs)</h4> <section id="CD011837-sec-0070"> <h5 class="title">1. Topical imiquimod versus placebo</h5> <section id="CD011837-sec-0071"> <h6 class="title">Response to treatment at five to six months after randomisation</h6> <p>Three RCTs assessed 104 participants (<a href="./references#CD011837-bbs2-0004" title='MathiesenO . "Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double blinded study" ‐ an answer. Gynecologic Oncology2008;109(3):431. MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. '>Mathiesen 2007</a>; <a href="./references#CD011837-bbs2-0006" title="SterlingJC , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, doubleblind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod [Abstract]. Journal of the European Academy of Dermatology and Venereology: JEADV. 12‐15th October, The 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 2005; Vol. 19(Suppl 2):22. ">Sterling 2005</a>; <a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>). At five to six months after randomisation, women in the imiquimod group were more likely to have experienced a complete or partial response to treatment than women in the placebo group (risk ratio (RR) 11.95, 95% confidence interval (CI) 3.21 to 44.51; <i>high‐quality evidence</i>). There were 36/62 and 0/42 complete responders in the topical imiquimod and placebo groups, respectively (RR 14.40, 95% CI 2.97 to 69.80; <a href="./references#CD011837-fig-0003" title="">Analysis 1.1</a>). </p> </section> <section id="CD011837-sec-0072"> <h6 class="title">Response to treatment at 12 months after randomisation</h6> <p>One study reported 12‐month data (<a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>). Two women in the imiquimod group and three women in the placebo group were lost to follow‐up. Overall response (complete or partial response) to treatment at 12 months was higher in the imiquimod group than the placebo group (RR 9.10, 95% CI 2.38 to 34.77; <a href="./references#CD011837-fig-0004" title="">Analysis 1.2</a>; <i>moderate‐quality evidence</i>). There were 9/24 and 0/23 complete responders in the topical imiquimod and placebo groups, respectively. Women in the imiquimod arm of this trial were followed up for at least five years (median 7.2 years) and, out of the nine complete responders, one developed vulval intraepithelial neoplasia (VIN) recurrence four years after randomisation (<a href="./references#CD011837-bbs2-0107" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. ">Terlou 2011</a>); the others remained disease‐free. The authors noted that lesion size at study entry was smaller in these complete responders. </p> </section> <section id="CD011837-sec-0073"> <h6 class="title">Progression to vulval cancer at 12 months after randomisation</h6> <p>Only one trial reported this outcome (<a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>). There was no difference in rates of progression to vulval cancer at 12 months between the imiquimod and placebo groups (1/24 versus 2/23 events, respectively; RR 0.50, 95% CI 0.05 to 5.18; <a href="./references#CD011837-fig-0005" title="">Analysis 1.3</a>; <i>low‐quality evidence</i>). </p> </section> <section id="CD011837-sec-0074"> <h6 class="title">HPV DNA persistence</h6> <p>One trial reported HPV clearance, which occurred significantly more often in the imiquimod group than the placebo group. Eleven out of 26 women in the imiquimod group and 24/26 women in the placebo group had HPV DNA persistence, respectively; RR 0.43, 95% CI 0.26 to 0.72; <a href="./references#CD011837-fig-0006" title="">Analysis 1.4</a>; <i>high‐quality evidence</i>). </p> </section> <section id="CD011837-sec-0075"> <h6 class="title">Quality of life</h6> <p>One study reported quality of life and did not find any differences between the treatment and the placebo groups in any of the quality of life outcomes, including self reported health‐related quality of life, body image or sexuality scores at baseline, 20 weeks and at 12 months (<a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>). None of the other trials reported on quality of life. </p> </section> <section id="CD011837-sec-0076"> <h6 class="title">Severe adverse events (SAE)</h6> <p>Severe adverse events were not reported; however, one study with 52 participants reported 'side effects' data for fatigue, headache, erythema, erosion, oedema, pain and pruritis (<a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>); however, the severity of these was not graded according to <a href="./references#CD011837-bbs2-0062" title="CTCAE . Common Terminology Criteria for Adverse Events v3.0. http://ctep.cancer.gov/forms/CTCAEv3.pdf (accessed 9 August 2006). ">CTCAE 2006</a>. <a href="./references#CD011837-bbs2-0004" title='MathiesenO . "Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double blinded study" ‐ an answer. Gynecologic Oncology2008;109(3):431. MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. '>Mathiesen 2007</a> (31 participants) reported 'local side effects' (<a href="./references#CD011837-fig-0014" title="">Analysis 1.12</a>), and <a href="./references#CD011837-bbs2-0006" title="SterlingJC , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, doubleblind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod [Abstract]. Journal of the European Academy of Dermatology and Venereology: JEADV. 12‐15th October, The 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 2005; Vol. 19(Suppl 2):22. ">Sterling 2005</a> did not report adverse event data. </p> <p>There was no difference between imiquimod and placebo for the following outcomes (all low‐quality evidence): </p> <p> <ul id="CD011837-list-0021"> <li> <p>Fatigue: RR 2.00, 95% CI 0.69 to 5.83 (<a href="./references#CD011837-fig-0007" title="">Analysis 1.5</a>). </p> </li> <li> <p>Headache: RR 1.41, 95% CI 0.51 to 3.85 (<a href="./references#CD011837-fig-0008" title="">Analysis 1.6</a>). </p> </li> </ul> </p> <p>The following outcomes were different and favoured the placebo group (moderate‐quality evidence): </p> <p> <ul id="CD011837-list-0022"> <li> <p>Erythema (redness): RR 10.00, 95% CI 2.60 to 38.50 (<a href="./references#CD011837-fig-0009" title="">Analysis 1.7</a>). </p> </li> <li> <p>Erosion/ulceration: RR 3.40, 95% CI 1.47 to 7.84 (<a href="./references#CD011837-fig-0010" title="">Analysis 1.8</a>). </p> </li> <li> <p>Oedema: RR 23.00, 95% CI 1.43 to 371.00 (<a href="./references#CD011837-fig-0011" title="">Analysis 1.9</a>). </p> </li> <li> <p>Pain or pruritis (itchiness): RR 3.43, 95% CI 1.80 to 6.52 (<a href="./references#CD011837-fig-0012" title="">Analysis 1.10</a>; <a href="./references#CD011837-fig-0013" title="">Analysis 1.11</a>). </p> </li> <li> <p>Local side effects: RR 6.67, 95% CI 1.01 to 43.86 (<a href="./references#CD011837-fig-0014" title="">Analysis 1.12</a>). </p> </li> <li> <p>No side effects: RR 0.08, 95% CI 0.01 to 0.55 (<a href="./references#CD011837-fig-0015" title="">Analysis 1.13</a>). </p> </li> </ul> </p> </section> <section id="CD011837-sec-0077"> <h6 class="title">Dose reductions</h6> <p>Women who received imiquimod were more likely to require dose reductions compared with the placebo group (two studies, 83 participants; RR 7.77, 95% CI 1.61 to 37.36; I<sup>2</sup> = 0%; <a href="./references#CD011837-fig-0016" title="">Analysis 1.14</a>). </p> <p>Other review outcomes were not reported.</p> </section> </section> <section id="CD011837-sec-0078"> <h5 class="title">2. Topical imiquimod versus topical cidofovir</h5> <p>One randomised trial with 180 participants evaluated this comparison, comparing topical 5% imiquimod cream with 1% cidofovir gel applied three times per week for 24 weeks (<a href="./references#CD011837-bbs2-0007" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a>). The results are reported below. We considered most of the resulting evidence to be of a moderate quality, mainly due to imprecision. </p> <section id="CD011837-sec-0079"> <h6 class="title">Response to treatment at six months after randomisation</h6> <p>There was no difference in overall response between the imiquimod and cidofovir study groups (180 participants; RR 0.92, 95% CI 0.73 to 1.18; <a href="./references#CD011837-fig-0017" title="">Analysis 2.1</a>; <i>moderate‐quality evidence</i>), or for complete and partial response data separately. This phase two study was not powered to demonstrate a difference in response rates between the two treatment modalities. The histologically confirmed complete response rate at six months was 45% (41/91) and 46% (41/89), respectively (RR 1.00, 95% CI 0.73 to 1.37). </p> </section> <section id="CD011837-sec-0080"> <h6 class="title">Response to treatment at 12 months after randomisation</h6> <p>Twelve‐month follow‐up of all participants was incomplete at the time of writing. However, interim findings suggested that complete responders in both treatment groups at six months were likely to sustain the complete response at 12 months. A sustained complete response at 12 months was reported in 25/32 women (78%) who responded at six months in the imiquimod group and 20/23 women (87%) in the cidofovir group. Thus, 82% of 55 women with a complete response at six months after randomisation sustained the complete response at 12 months. More data are expected from this trial. </p> </section> <section id="CD011837-sec-0081"> <h6 class="title">Progressive disease</h6> <p>There was no difference between imiquimod and cidofovir study groups in the proportion of women experiencing an increase in lesion size despite treatment (180 participants; RR 1.30, 95% CI 0.55 to 3.11, <a href="./references#CD011837-fig-0018" title="">Analysis 2.2</a>; <i>low‐quality evidence</i>). </p> <p>Investigators also reported that fewer women in the imiquimod group developed new lesions during treatment compared with the cidofovir group (RR 0.55, 95% CI 0.28 to 1.09; <a href="./references#CD011837-fig-0019" title="">Analysis 2.3</a>, not statistically significant). However, due to flaws in the data collection process they were uncertain whether these lesions occurred at the site of treatment, therefore it was not possible to establish whether these data represented new or progressive disease. </p> </section> <section id="CD011837-sec-0082"> <h6 class="title">HPV DNA persistence</h6> <p>These data were not collected in this trial.</p> </section> <section id="CD011837-sec-0083"> <h6 class="title">Severe adverse events (SAEs)</h6> <p>There was no difference between imiquimod and cidofovir for the following outcomes (all <i>moderate‐quality evidence</i>): </p> <p> <ul id="CD011837-list-0023"> <li> <p>Total SAEs: RR 1.26, 95% CI 0.88 to 1.81 (<a href="./references#CD011837-fig-0020" title="">Analysis 2.4</a>). </p> </li> <li> <p>Vulval pain: RR 1.08, 95% CI 0.93 to 1.25 (<a href="./references#CD011837-fig-0021" title="">Analysis 2.5</a>). </p> </li> <li> <p>Pruritis: RR 1.03, 95% CI 0.90 to 1.17 (<a href="./references#CD011837-fig-0022" title="">Analysis 2.6</a>). </p> </li> <li> <p>Erosion: RR 0.88, 95% CI 0.63 to 1.22 (<a href="./references#CD011837-fig-0023" title="">Analysis 2.7</a>). </p> </li> <li> <p>Skin reactions: RR 0.88, 95% CI 0.46 to 1.68 (<a href="./references#CD011837-fig-0026" title="">Analysis 2.10</a>). </p> </li> </ul> </p> <p>The following outcomes favoured cidofovir over imiquimod:</p> <p> <ul id="CD011837-list-0024"> <li> <p>Fatigue: RR 1.25, 95% CI 1.02 to 1.55 (<a href="./references#CD011837-fig-0024" title="">Analysis 2.8</a>). </p> </li> <li> <p>Headache: RR 1.49, 95% CI 1.12 to 1.98 (<a href="./references#CD011837-fig-0025" title="">Analysis 2.9</a>). </p> </li> </ul> </p> </section> <section id="CD011837-sec-0084"> <h6 class="title">Treatment discontinuation</h6> <p>There was no difference between the imiquimod and cidofovir study groups in the proportion of women requiring a dosage reduction or treatment cessation (15/89 versus 11/87, respectively; RR 1.33, 95% CI 0.65 to 2.74; <a href="./references#CD011837-fig-0027" title="">Analysis 2.11</a>; <i>moderate‐quality evidence</i>). </p> <p>Other review outcomes were not reported.</p> </section> </section> <section id="CD011837-sec-0085"> <h5 class="title">3. Laser vaporisation versus Cavitron ultrasonic surgical aspiration (CUSA)</h5> <p>Only one trial, including 30 women, contributed data for this comparison (<a href="./references#CD011837-bbs2-0011" title="vonGruenigenVE , GibbonsHE , GibbinsK , JenisonEL , HopkinsMP . Surgical treatments for vulvar and vaginal dysplasia: a randomized controlled trial. Obstetrics and Gynecology2007;109(4):942‐7. ">von Gruenigen 2007</a>). </p> <section id="CD011837-sec-0086"> <h6 class="title">Disease recurrence after one year of follow‐up</h6> <p>There was no difference in disease recurrence after one year of follow‐up between women who had laser vaporisation and those who had CUSA (RR 1.53, 95% CI 0.56 to 4.15; <a href="./references#CD011837-fig-0028" title="">Analysis 3.1</a>), even when the findings were adjusted for age, history of dysplasia and smoking status (adjusted odds ratio 0.68, 95% CI 0.27 to 1.83; <i>low‐quality evidence</i>). The trial lacked statistical power due to the small number of women in each group and the low number of observed events. </p> </section> <section id="CD011837-sec-0087"> <h6 class="title">Severe adverse events</h6> <p>The severity of these adverse events was not graded according to <a href="./references#CD011837-bbs2-0062" title="CTCAE . Common Terminology Criteria for Adverse Events v3.0. http://ctep.cancer.gov/forms/CTCAEv3.pdf (accessed 9 August 2006). ">CTCAE 2006</a>. There was no difference between laser surgery and CUSA in the following reported outcomes: </p> <p> <ul id="CD011837-list-0025"> <li> <p>Pain: mean difference (MD) 1.70, 95% CI ‐26.80 to 23.40 (<a href="./references#CD011837-fig-0029" title="">Analysis 3.2</a>). </p> </li> <li> <p>Scarring: 5/16 versus 0/14 in the laser and CUSA groups, respectively.</p> </li> <li> <p>Dysuria or burning on micturition: RR 0.66, 95% CI 0.18 to 2.44 (<a href="./references#CD011837-fig-0030" title="">Analysis 3.3</a>). </p> </li> <li> <p>Adhesions: 1/16 versus 0/14 in the laser and CUSA groups, respectively.</p> </li> <li> <p>Infection (yeast, urinary tract infection, other): RR 0.88, 95% CI 0.14 to 5.42 (<a href="./references#CD011837-fig-0031" title="">Analysis 3.4</a>). </p> </li> <li> <p>Abnormal discharge: RR 1.75, 95% CI 0.18 to 17.29 (<a href="./references#CD011837-fig-0032" title="">Analysis 3.5</a>). </p> </li> <li> <p>Eschar: RR 0.88, 95% CI 0.14 to 5.42 (<a href="./references#CD011837-fig-0033" title="">Analysis 3.6</a>). </p> </li> </ul> </p> <p>Other review outcomes were not reported.</p> </section> </section> <section id="CD011837-sec-0088"> <h5 class="title">4. Indole‐3‐carbinol (I3C) 200 mg/day versus 400 mg/day</h5> <p>The trial of <a href="./references#CD011837-bbs2-0005" title="NaikR , NixonS , LopesA , GodfreyK , HatemMH , MonaghanJM . A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2006;16(2):786‐90. ">Naik 2006</a> reported that there were no differences in any of the outcomes between the six women taking 200 mg/day of I3C and the six on 400 mg/day. Both groups reported significant improvement in symptoms of pruritus and pain. However, nine out of 10 women followed up for six months still had high‐grade VIN after biopsy. The authors did not report to which of the two doses these women had been randomised. The trial reported only one case of mild bowel upset, which was in a woman who received the high‐dose regimen. </p> </section> </section> <section id="CD011837-sec-0089"> <h4 class="title">Evidence from non‐randomised studies (NRSs)</h4> <section id="CD011837-sec-0090"> <h5 class="title">5. Photodynamic therapy (PDT) versus laser vaporisation and surgical excision</h5> <p>One study evaluated this comparison (<a href="./references#CD011837-bbs2-0001" title="FehrMK , HornungR , SchwarzVA , SimeonR , HallerU , WyssP . Photodynamic therapy of vulvar intraepithelial neoplasia III using topically applied 5‐aminolevulinic acid. Gynecologic Oncology2001;80(1):62‐6. ">Fehr 2001</a>). Comparative data for disease‐free survival (DFS) were described in the study report without effect estimates, as follows: "Analysis of DFS after treatment revealed no statistically significant difference between patients treated with PDT and patients treated with laser evaporation or local excision (P=0.67)." "In the laser group, 52% were recurrence free at 12 months versus 60% in the local excision group and 50% in the PDT group." "In … multivariate analysis, treatment modality was not associated with reduced DFS." We judged this to be very low‐quality evidence, due to design limitations. </p> </section> <section id="CD011837-sec-0091"> <h5 class="title">6. Laser vaporisation versus excision</h5> <p>Three NRSs evaluated this comparison with respect to VIN recurrence and progression to vulval cancer (<a href="./references#CD011837-bbs2-0002" title="FehrMK , BaumannM , MuellerM , FinkD , HeinzlS , ImeschP , et al. Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia. Journal of Gynecologic Oncology2013;24(3):236‐41. ">Fehr 2013</a>; <a href="./references#CD011837-bbs2-0003" title="LeufflenL , BaermannP , RauchP , RoutiotT , BezdetnavaL , GuilleminF , et al. Treatment of vulvar intraepithelial neoplasia with CO2 laser vaporization and excision surgery. Journal of Lower Genital Tract Disease2013;17(4):446‐51. ">Leufflen 2013</a>; <a href="./references#CD011837-bbs2-0008" title="VanEschEMG , DamMCI , OsseMEM , PutterH , TrimbosB , FleurenG , et al. Clinical characteristics associated with development of recurrence and progression in usual‐type vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2013;23(8):1476‐83. ">van Esch 2013</a>). Treatment effect findings for these outcomes were reported in different ways and it was not possible to pool these data. </p> <section id="CD011837-sec-0092"> <h6 class="title">Recurrence</h6> <p><a href="./references#CD011837-bbs2-0003" title="LeufflenL , BaermannP , RauchP , RoutiotT , BezdetnavaL , GuilleminF , et al. Treatment of vulvar intraepithelial neoplasia with CO2 laser vaporization and excision surgery. Journal of Lower Genital Tract Disease2013;17(4):446‐51. ">Leufflen 2013</a> reported recurrence‐free survival at one year follow‐up as time to recurrence (laser vaporisation versus excision; hazard ratio (HR) 5.9, 95% CI 1.3 to 26.3; P value &lt; 0.01), and the findings favoured excision over laser vaporisation as initial VIN treatment. It is not clear whether the recurrence‐free survival data reported in <a href="./references#CD011837-bbs2-0003" title="LeufflenL , BaermannP , RauchP , RoutiotT , BezdetnavaL , GuilleminF , et al. Treatment of vulvar intraepithelial neoplasia with CO2 laser vaporization and excision surgery. Journal of Lower Genital Tract Disease2013;17(4):446‐51. ">Leufflen 2013</a> were adjusted for all important confounders (including differentiated‐type VIN (dVIN) and multifocality); therefore this finding should be interpreted with caution. The overall recurrence rate one year after treatment was 22% (11 women) and the mean time to recurrence following either treatment was 21.7 months (95% CI 15.1 to 21.3 months). </p> <p>In <a href="./references#CD011837-bbs2-0002" title="FehrMK , BaumannM , MuellerM , FinkD , HeinzlS , ImeschP , et al. Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia. Journal of Gynecologic Oncology2013;24(3):236‐41. ">Fehr 2013</a>, 123/411 women (30%) experienced recurrent disease at least one year after initial diagnosis. The authors reported that the relative odds of recurrence favoured laser vaporisation over excision (excision versus laser vaporisation; odds ratio (OR) 1.79, 95% CI 1.11 to 2.91; P value = 0.017<i>).</i> </p> <p>In <a href="./references#CD011837-bbs2-0008" title="VanEschEMG , DamMCI , OsseMEM , PutterH , TrimbosB , FleurenG , et al. Clinical characteristics associated with development of recurrence and progression in usual‐type vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2013;23(8):1476‐83. ">van Esch 2013</a>, 37/73 women (51%) experienced recurrence at a median time of 14 months (range, 1 to 168 months) after initial treatment. Sixteen recurrences occurred out of 33 women in the excision group (48.5%) and 14 occurred out of 25 women in the laser vaporisation treated group (56%). Overall, time to recurrence was longer in the excision group and, on univariate analysis, recurrence‐free survival favoured excision as first treatment. However, on multivariate analysis (adjusted for multifocal disease, smoking, human papilloma virus (HPV) status, immune status and body mass index) there was no difference in recurrence‐free survival according to treatment type (P value = 0.142), which also included imiquimod and laser plus excision options. The authors presented the data as a Kaplan Meier curve with a P value and not as a comparative effect estimate (HR). </p> <p>The evidence from <a href="./references#CD011837-bbs2-0002" title="FehrMK , BaumannM , MuellerM , FinkD , HeinzlS , ImeschP , et al. Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia. Journal of Gynecologic Oncology2013;24(3):236‐41. ">Fehr 2013</a> and <a href="./references#CD011837-bbs2-0003" title="LeufflenL , BaermannP , RauchP , RoutiotT , BezdetnavaL , GuilleminF , et al. Treatment of vulvar intraepithelial neoplasia with CO2 laser vaporization and excision surgery. Journal of Lower Genital Tract Disease2013;17(4):446‐51. ">Leufflen 2013</a> of treatment effect on recurrence is contradictory and of a very low quality, mainly due to design limitations of the NRSs. The evidence in <a href="./references#CD011837-bbs2-0008" title="VanEschEMG , DamMCI , OsseMEM , PutterH , TrimbosB , FleurenG , et al. Clinical characteristics associated with development of recurrence and progression in usual‐type vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2013;23(8):1476‐83. ">van Esch 2013</a> of no difference between the types of treatment in recurrence‐free survival is of a better quality than the other two studies and we graded this evidence as higher quality than that from the other two NRSs (low‐quality evidence). However, this finding lacks power and should be interpreted with caution. </p> </section> <section id="CD011837-sec-0093"> <h6 class="title">Progression to vulval cancer</h6> <p>In <a href="./references#CD011837-bbs2-0002" title="FehrMK , BaumannM , MuellerM , FinkD , HeinzlS , ImeschP , et al. Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia. Journal of Gynecologic Oncology2013;24(3):236‐41. ">Fehr 2013</a> and <a href="./references#CD011837-bbs2-0008" title="VanEschEMG , DamMCI , OsseMEM , PutterH , TrimbosB , FleurenG , et al. Clinical characteristics associated with development of recurrence and progression in usual‐type vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2013;23(8):1476‐83. ">van Esch 2013</a>, 24 women (5.8%) and 11 women (15.1%) developed invasive disease during follow‐up, respectively. The mean time to invasive disease was 82 months (standard deviation (SD) 74; range 13 to 290 months) in <a href="./references#CD011837-bbs2-0002" title="FehrMK , BaumannM , MuellerM , FinkD , HeinzlS , ImeschP , et al. Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia. Journal of Gynecologic Oncology2013;24(3):236‐41. ">Fehr 2013</a>, and the median time to invasive disease was 71.5 months (range 9 to 259 months) in <a href="./references#CD011837-bbs2-0008" title="VanEschEMG , DamMCI , OsseMEM , PutterH , TrimbosB , FleurenG , et al. Clinical characteristics associated with development of recurrence and progression in usual‐type vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2013;23(8):1476‐83. ">van Esch 2013</a>. The risk of progression to invasive disease (PFS) did not differ significantly according to treatment type in either study (<a href="./references#CD011837-bbs2-0002" title="FehrMK , BaumannM , MuellerM , FinkD , HeinzlS , ImeschP , et al. Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia. Journal of Gynecologic Oncology2013;24(3):236‐41. ">Fehr 2013</a>: excision versus laser vaporisation; OR 2.09, 95% CI 0.89 to 5.37; P value = 0.126; and <a href="./references#CD011837-bbs2-0008" title="VanEschEMG , DamMCI , OsseMEM , PutterH , TrimbosB , FleurenG , et al. Clinical characteristics associated with development of recurrence and progression in usual‐type vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2013;23(8):1476‐83. ">van Esch 2013</a>, P value = 0.20). In <a href="./references#CD011837-bbs2-0008" title="VanEschEMG , DamMCI , OsseMEM , PutterH , TrimbosB , FleurenG , et al. Clinical characteristics associated with development of recurrence and progression in usual‐type vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2013;23(8):1476‐83. ">van Esch 2013</a>, only univariate Cox analysis was performed for PFS due to the small numbers involved. One woman (2%) in <a href="./references#CD011837-bbs2-0003" title="LeufflenL , BaermannP , RauchP , RoutiotT , BezdetnavaL , GuilleminF , et al. Treatment of vulvar intraepithelial neoplasia with CO2 laser vaporization and excision surgery. Journal of Lower Genital Tract Disease2013;17(4):446‐51. ">Leufflen 2013</a> developed invasive cancer 30 months after treatment. We considered the evidence on PFS overall for this treatment comparison to be of a very low quality due to design limitations. </p> </section> <section id="CD011837-sec-0094"> <h6 class="title">Severe adverse events</h6> <p>Severe adverse events of treatment were not reported in these retrospective studies.</p> <p>Other review outcomes were not reported.</p> </section> </section> <section id="CD011837-sec-0095"> <h5 class="title">7. Loop electrosurgical excision (LEEP) versus surgical excision and laser vaporisation</h5> <section id="CD011837-sec-0096"> <h6 class="title">Recurrence</h6> <p>Only one NRS involving 62 women evaluated the relative effects of LEEP, conventional surgical excision and laser vaporisation on time to recurrence for 20, 22 and 20 women, respectively (<a href="./references#CD011837-bbs2-0010" title="VlastosAT , LevyLB , MalpicaA , FollenM . Loop electrosurgical excision procedure in vulvar intraepithelial neoplasia treatment. Journal of Lower Genital Tract Disease2002;6(4):232‐8. ">Vlastos 2002</a>). Overall, 15 women in the cohort experienced recurrences during follow‐up. Mean time to recurrence was 16 months, 15 months and 25 months for LEEP, excision and laser vaporisation, respectively, at a mean time to follow‐up of 20, 32 and 51 months, respectively. Recurrence‐free survival was not different between treatment types and was reported as a P value only (P value = 0.194) with the following text: "There were no statistically significant differences among the therapies for time to recurrence, whether compared…. as LEEP versus wide local excision (WLE), LEEP versus LV, and WLE versus LV." We judged this to be very low‐quality evidence. We did not include the recurrence rate data from this study, which favoured LEEP and excision over laser vaporisation, as these data did not appear to be adjusted for multifocality (which was less frequent in the LEEP group) and the laser vaporisation group was followed up for a significantly longer period of time. </p> </section> <section id="CD011837-sec-0097"> <h6 class="title">Progression to vulval cancer</h6> <p>There were no cases of vulval cancer during follow‐up in any of the treatment groups in <a href="./references#CD011837-bbs2-0010" title="VlastosAT , LevyLB , MalpicaA , FollenM . Loop electrosurgical excision procedure in vulvar intraepithelial neoplasia treatment. Journal of Lower Genital Tract Disease2002;6(4):232‐8. ">Vlastos 2002</a>. </p> </section> <section id="CD011837-sec-0098"> <h6 class="title">Severe adverse events</h6> <p>Adverse effect data were inadequately reported and could not be extracted. However, the authors also reported that LEEP was performed on an outpatient basis and was associated with statistically significantly less hospital stay than the other modalities (0/20 versus 9/22 versus 18/20 for LEEP, WLE and laser vaporisation, respectively; P value = 0.0001). </p> <p>Other review outcomes were not reported.</p> </section> </section> <section id="CD011837-sec-0099"> <h5 class="title">8. Excision versus imiquimod</h5> <p>Limited data from <a href="./references#CD011837-bbs2-0008" title="VanEschEMG , DamMCI , OsseMEM , PutterH , TrimbosB , FleurenG , et al. Clinical characteristics associated with development of recurrence and progression in usual‐type vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2013;23(8):1476‐83. ">van Esch 2013</a>, which could potentially contribute to this comparison, were too sparse to be meaningful. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011837-sec-0100" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011837-sec-0100"></div> <section id="CD011837-sec-0101"> <h3 class="title" id="CD011837-sec-0101">Summary of main results</h3> <p>Five randomised controlled trials (RCTs) (297 women) evaluated medical interventions (imiquimod, cidofovir and I3C) and one RCT (30 women) compared two surgical modalities (laser vaporisation versus Cavitron ultrasonic surgical aspiration (CUSA)). Evidence derived from these RCTs ranged from low to high quality. No RCTs compared the standard of care (surgical excision) to medical treatments, other surgical modalities or photodynamic therapy. We therefore looked to five non‐randomised studies (NRSs) to provide some evidence on these comparisons. However, data from these NRSs were presented in different ways and meta‐analysis was not possible for the relevant review outcomes. Thus, we considered the evidence derived from these NRSs on the relative effects of these interventions on vulval intraepithelial neoplasia (VIN) recurrence and progression to vulval cancer to be of low to very low quality. </p> <section id="CD011837-sec-0102"> <h4 class="title">Medical interventions</h4> <section id="CD011837-sec-0103"> <h5 class="title">Imiquimod versus placebo</h5> <p>Three trials involving 104 women contributed data to this comparison (<a href="./full#CD011837-tbl-0001">summary of findings Table for the main comparison</a>). At five to six months from the start of treatment, women with usual‐type VIN (uVIN) who received imiquimod were more likely to achieve complete or partial clearance of lesions (risk ratio (RR) 11.95, 95% confidence interval (CI) 3.21 to 44.51; <i>high‐quality evidence</i>). Complete response at five to six months occurred in 36/62 women (58%) in the imiquimod group compared with 0/42 (0%) in the control group. Evidence from one study suggested that a complete response at six months was likely to be sustained at 12 months (complete response 9/24 (37.5%) in the imiquimod group versus 0/23 controls; RR 9.10, 95% CI 2.38 to 34.77) and longer, particularly in women with small VIN lesions. Imiquimod was associated with more local side effects than placebo, including localised pain, oedema, erythema and erosion. None of the women experiencing side effects discontinued treatment; rather, side effects were managed by reducing the number of applications. Only one trial reported progression to vulval cancer at 12 months, which occurred in one out of 24 women in the imiquimod arm and two out of 23 women in the placebo arm. The same trial also reported increased clearance of human papilloma virus (HPV) infection with imiquimod treatment. There was no difference in quality of life measures between groups in this trial. </p> </section> <section id="CD011837-sec-0104"> <h5 class="title">Imiquimod versus cidofovir</h5> <p>Moderate‐quality evidence from one well‐conducted RCT involving 180 women suggested that cidofovir was as effective as imiquimod with respect to response rates at six months after randomisation (approximately 46% complete response overall), but the study was not powered to demonstrate a difference between the two treatment modalities and longer follow‐up data are still to be reported. Interim findings from 55 complete responders suggested that complete response may be sustained at 12 months in both treatment groups. Adverse effects occurred with similar frequency between the treatment groups, with the exception of fatigue and headache, which were more common with imiquimod (<a href="./full#CD011837-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD011837-sec-0105"> <h5 class="title">Other medical interventions</h5> <p>Based on the limited evidence from one small trial of 3‐indole‐carbinol, it is unclear whether this natural compound has any role to play in the treatment of VIN. We found no evidence on HPV vaccines to treat uVIN; however, we identified one ongoing trial of an HPV vaccine (Gardasil®) plus imiquimod versus imiquimod only <a href="./references#CD011837-bbs2-0051" title="PoelgeestM , HelmerhorstT . Clinical and immunological effects of imiquimod and HPV‐vaccination compared to imiquimod alone in female patients with usual type VIN ‐ effects of HPV‐vaccination and imiquimod in VIN patients. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐008251‐42 (accessed 6 February 2015)2009. ">EUCTR2008‐008251‐42‐NL</a>. </p> </section> </section> <section id="CD011837-sec-0106"> <h4 class="title">Surgical interventions</h4> <p>Low‐quality evidence suggested that there may be little difference between excision and laser vaporisation procedures in the risk of VIN recurrence or progression to vulval cancer. However, these NRSs were underpowered to detect a difference. Rates of recurrence ranged from 22% to 51%, with the wide range probably due to methodological limitations and differences between included NRSs. The best NRS was at a low risk of bias and findings were adjusted for important confounders (<a href="./references#CD011837-bbs2-0008" title="VanEschEMG , DamMCI , OsseMEM , PutterH , TrimbosB , FleurenG , et al. Clinical characteristics associated with development of recurrence and progression in usual‐type vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2013;23(8):1476‐83. ">van Esch 2013</a>). Recurrence occurred in 51% of women (37/70) overall, at a median of 14 months, and was more common in multifocal than unifocal lesions (66% versus 34%). Vulval cancer occurred in 11 women (15.1%) overall at a median of 71.5 months (9 to 259 months); however due to the small number of events, multivariate analysis was not performed for this outcome. The risk of vulval cancer did not differ significantly between excision and laser vaporisation in any of the other NRSs included; again, events were too few for robust findings. </p> </section> <section id="CD011837-sec-0107"> <h4 class="title">Medical interventions or photodynamic therapy versus surgical interventions</h4> <p>We found no evidence on the relative effectiveness of medical treatment options compared with surgical treatment options. Very low‐quality evidence from one NRS suggested that photodynamic therapy may be as effective as surgical options (laser vaporisation or excision) and more evidence is needed to support this finding. </p> </section> </section> <section id="CD011837-sec-0108"> <h3 class="title" id="CD011837-sec-0108">Overall completeness and applicability of evidence</h3> <p>Currently, the evidence on the use of medical treatments, such as imiquimod and cidofovir, for uVIN is encouraging, but many uncertainties remain. Trials of imiquimod versus placebo excluded immunosuppressed women and it remains uncertain whether uVIN lesions in these women will respond to topical treatments as well as immunocompetent women. The trial of imiquimod versus cidofovir reported complete responses at six months after randomisation in three out of eight immunosuppressed women (37.5%) suggesting that these topical treatments may also benefit these women, but more evidence from long‐term studies is needed. </p> <p>Most RCTs of medical interventions reported response rates and there were very few available data on the effect of treatments on the risk of vulval cancer. Only one RCT to date has followed complete responders for more than five years (<a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>), and the findings suggested that a complete and sustained response may be more likely with smaller lesions. However, due to the limited data available, we were unable to draw conclusions about possible differences in the effectiveness of medical treatment according to focality or lesion size. It remains unclear what the optimal dose regimens should be for medical treatment, what type of lesions are most likely to respond to treatment and how treatment‐related symptoms are best relieved. Medical treatments generally require treatment to be administered over a prolonged course of time, and may be associated with distressing treatment‐related side effects. Therefore, whilst the evidence suggests that they are reasonably well‐tolerated, more evidence is needed on quality of life and women's satisfaction with treatment relative to other treatment modalities. </p> <p>Various investigators have expressed concerns that non‐excisional therapeutic options (including laser vaporisation, photodynamic therapy and topical treatments) may be associated with higher recurrence and progression rates, as reported rates of occult (microinvasive) vulval cancer following histological examination of excised VIN specimens range from 12% to 22 % (<a href="./references#CD011837-bbs2-0080" title="HusseinzadehN , RecintoC . Frequency of invasive cancer in surgically excised vulvar lesions with intraepithelial neoplasia (VIN 3). Gynecologic Oncology1999;73(1):119‐20. ">Husseinzadeh 1999</a>; <a href="./references#CD011837-bbs2-0091" title="ModesittSC , WatersAB , WaltonL , FowlerW , VanLeL . Vulvar intraepithelial neoplasia III: occult cancer and the impact of margin status on recurrence. Obstetrics and Gynecology1998;92(6):962‐6. ">Modesitt 1998</a>; <a href="./references#CD011837-bbs2-0039" title="SideriM , SpinaciL , SpoltiN , SchettinoF . Evaluation of CO(2) laser excision or vaporization for the treatment of vulvar intraepithelial neoplasia. Gynecologic Oncology1999;75(2):277‐81. ">Sideri 1999</a>). This review did not find any evidence to address these concerns. Longer‐term data from the <a href="./references#CD011837-bbs2-0007" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a> trial are awaited with interest. </p> <p>The evidence comparing the effectiveness of laser vaporisation and surgical excision is conflicting and many uncertainties remain regarding the relative effectiveness of these treatments. This is largely because the choice of treatment in the included retrospective NRSs was usually determined by lesion characteristics, with surgical excision being favoured by clinicians for unifocal (and dVIN lesions), and laser favoured for multifocal lesions. Even though the investigators performed multivariate analysis, NRS quality varied and findings were inconsistent. We considered one NRS that found no statistically significant difference in recurrence rates between excision and laser vaporisation to be the best evidence for the relative effectiveness of these two modalities (<a href="./references#CD011837-bbs2-0008" title="VanEschEMG , DamMCI , OsseMEM , PutterH , TrimbosB , FleurenG , et al. Clinical characteristics associated with development of recurrence and progression in usual‐type vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2013;23(8):1476‐83. ">van Esch 2013</a>). </p> <p>Alternative surgical procedures tested that might be as effective as surgical excision and laser vaporisation on recurrence rates included Cavitron ultrasonic surgical aspiration (CUSA) and loop electrosurgical excision (LEEP) procedures, but the evidence is sparse and the applicability uncertain. Limited evidence suggested that these alternative procedures may also have other benefits, such as lower costs, shorter hospital stay and a specimen yielded for histology. </p> <section id="CD011837-sec-0109"> <h4 class="title">Medical interventions versus surgical interventions</h4> <p>We found no evidence on the effectiveness of medical interventions relative to surgical interventions. However, we identified one ongoing Austrian trial assessing imiquimod versus surgery (excision or ablation) for uVIN, which is due to complete in September 2016. The investigators plan to recruit 110 women (<a href="./references#CD011837-bbs2-0054" title="TrutnovskyG , TamussinoK . Primary imiquimod treatment versus surgery for vulvar intraepithelial neoplasia. https://clinicaltrials.gov/show/NCT01861535 (accessed 9 February 2015)2013. ">NCT01861535</a>). </p> </section> <section id="CD011837-sec-0110"> <h4 class="title">Other interventions</h4> <p>Very low‐quality evidence on photodynamic therapy relative to surgical treatments suggested that photodynamic therapy may be as effective in treating uVIN. An ongoing trial of photodynamic therapy versus imiquimod for uVIN (or lichen sclerosis) may make an important contribution to the body of evidence (<a href="./references#CD011837-bbs2-0052" title="BlokL . 5‐Aminolevulinic acid photodynamic therapy for the treatment of pre‐malignant disorders of the vulva. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐003134‐13 (accessed 9 February 2015)2011. ">EUCTR2011‐003134‐13‐NL</a>). </p> <p>The role for natural compounds, e.g. IC3, SR‐T100 (solanum incanum extract) and sinecatechins (from green tea leaves), if any, in uVIN is still unknown. An ongoing study, <a href="./references#CD011837-bbs2-0053" title="KaurB . Phase II clinical trial investigating the use of EPIgallocatechin‐3‐gallate (Veregen) in the treatment of vulval intraepithelial neoplasia. http://www.isrctn.com/ISRCTN98495886 (accessed 9 February 2015)2013. ">ISRCTN98495886</a>, is currently evaluating SR‐T100, a traditional Chinese herbal medicine that has purportedly been used to treat cancer for centuries and is reported to induce apoptosis in squamous carcinoma cells (<a href="./references#CD011837-bbs2-0115" title="WuCH , LiangCH , ShiuLY , ChangLC , LinTS , LanCC , et al. Solanum incanum extract (SR‐T100) induces human cutaneous squamous cell carcinoma apoptosis through modulating tumor necrosis factor receptor signaling pathway. Journal of Dermatological Science2011;63(2):83‐92. ">Wu 2011</a>) for VIN. Other ongoing trials are evaluating HPV vaccination in combination with imiquimod (<a href="./references#CD011837-bbs2-0051" title="PoelgeestM , HelmerhorstT . Clinical and immunological effects of imiquimod and HPV‐vaccination compared to imiquimod alone in female patients with usual type VIN ‐ effects of HPV‐vaccination and imiquimod in VIN patients. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐008251‐42 (accessed 6 February 2015)2009. ">EUCTR2008‐008251‐42‐NL</a>; <a href="./references#CD011837-bbs2-0055" title="KenterG , NijmanHW . Randomised controlled study on the effects of imiquimod, a TLR 7 activating agent, on the HPV16‐specific immune response following HPV16 E6/E.7 synthetic long peptides vaccination in women with HPV16 positive high grade vulvar/vaginal intraepithelial neoplasia. http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1526 (accessed 9 February 2015)2008. ">NTR1526</a>), and photodynamic therapy versus imiquimod (<a href="./references#CD011837-bbs2-0052" title="BlokL . 5‐Aminolevulinic acid photodynamic therapy for the treatment of pre‐malignant disorders of the vulva. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐003134‐13 (accessed 9 February 2015)2011. ">EUCTR2011‐003134‐13‐NL</a>) for women with uVIN. </p> </section> </section> <section id="CD011837-sec-0111"> <h3 class="title" id="CD011837-sec-0111">Quality of the evidence</h3> <p>We graded the evidence on the effectiveness of imiquimod for achieving and sustaining a complete response as high and moderate quality, respectively, and the evidence for the effectiveness of cidofovir as moderate quality. Low‐quality evidence showed that excision and laser vaporisation were equally effective, and very low quality evidence showed that there was no difference in progression to vulval cancer between these two surgical modalities; however, the analyses lacked power. Low‐quality evidence suggested that CUSA was similarly effective to laser vaporisation, and very low‐quality evidence suggested that LEEP or photodynamic therapy were comparable to laser vaporisation and excision in preventing recurrence. </p> </section> <section id="CD011837-sec-0112"> <h3 class="title" id="CD011837-sec-0112">Potential biases in the review process</h3> <p>In the protocol we stated that we would only include NRSs that used statistical adjustment for baseline case mix using multivariable analyses. Extent of disease and multifocality were significant confounders of NRSs involving VIN treatment, as these variables often influenced the type of treatment chosen in practice. Hence, we excluded most of the comparative NRSs for not using appropriate statistical adjustment of confounders where important differences in baseline case mix were evident or suspected. Although it was not stated in the protocol, we extracted the log hazard ratio (HR) and its variance for time‐to‐event outcomes (e.g. time to recurrence), if reported instead of or as well as dichotomous outcomes in the NRSs. These data were reported as a narrative and could not be pooled. </p> <p>In one included NRS (<a href="./references#CD011837-bbs2-0010" title="VlastosAT , LevyLB , MalpicaA , FollenM . Loop electrosurgical excision procedure in vulvar intraepithelial neoplasia treatment. Journal of Lower Genital Tract Disease2002;6(4):232‐8. ">Vlastos 2002</a>), the text stating that "Lesions...were multifocal in all patients" was contradicted by a table showing multifocal VIN as a variable with data indicating proportions of 50%, 68% and 75% for the LEEP, excisional and laser ablation interventions, respectively. We attempted to obtain clarity from the authors regarding these contradictory data but were unsuccessful. However, we gave the study the benefit of the doubt and assumed that the text was correct, thereby enabling its inclusion in the review in the absence of the authors controlling for multifocality. As mentioned, none of the NRSs contributed data to meta‐analysis and we judged this study to be at a high risk of bias. </p> <p>We excluded one prospective NRS comparing 32 women treated with imiquimod and 36 treated with cold knife excision (<a href="./references#CD011837-bbs2-0025" title="FregaA , SestiF , SopracordevoleF , BiamontiA , ScirpaP , MilazzoGN , et al. Imiquimod 5% cream versus cold knife excision for treatment of VIN 2/3: a five‐year follow‐up. European Review for Medical and Pharmacological Sciences2013;17(7):936‐40. ">Frega 2013</a>), based on our inclusion criteria requiring adjustment of NRSs for baseline case mix, and an unsuccessful attempt to contact the authors for clarity. Women with immunosuppression were excluded and other baseline characteristics between the groups did not appear to be significantly different, except perhaps for VIN grade (81% of women in the imiquimod group had VIN 3 versus 61% in the excision group), which was positively associated with recurrence in this study. Had statistical adjustments been performed, the study might have made a greater contribution to the 'medical versus surgical' debate. After a five‐year follow‐up, recurrence plus treatment failure in the imiquimod group was 69% (22/32) compared with 45% (17/38) in the surgery group. Complete response was lower with imiquimod at 31% (10/32) versus 55% (21/38) in the surgery group (and lower than that reported in the included RCTs). Surgical conversion occurred in 53% of women (17/32) in the imiquimod group, with two women in the imiquimod group and three in the surgery group developing invasive cancer in spite of treatment. </p> <p>We excluded an older RCT of 5‐fluorouracil (5‐FU) as maintenance treatment compared with no additional treatment following ablation/removal of the lesion/s in 90 women (<a href="./references#CD011837-bbs2-0032" title="KrebsHB . Prophylactic topical 5‐fluorouracil following treatment of human papillomavirus‐associated lesions of the vulva and vagina. Obstetrics and Gynecology1986;68(6):837‐41. ">Krebs 1986</a>). Participants in this trial had vulval or vaginal HPV‐related lesions including condylomata accuminata, and the proportion of participants with vulval lesions and VIN 2/3 was not clear. Various previous treatments were used alone and in combination to achieve a complete response (including podophyllin, 5‐FU, cryotherapy, local excision and laser) before women were randomised to receive 5‐FU cream or no 5‐FU cream. <a href="./references#CD011837-bbs2-0032" title="KrebsHB . Prophylactic topical 5‐fluorouracil following treatment of human papillomavirus‐associated lesions of the vulva and vagina. Obstetrics and Gynecology1986;68(6):837‐41. ">Krebs 1986</a> reported a statistically significant difference in recurrences in favour of the 5‐FU maintenance group of this study (six in the treated group versus 17 in the untreated group), with 87% of recurrences detected within six months of follow‐up (mean follow‐up was 14.4 months). 5‐FU in the context of maintenance, applied once every two weeks for six months, was apparently well tolerated and no "undesirable side effects" were reported or observed. After much discussion, we excluded the trial on the basis that the participants did not clearly fulfil the inclusion criteria for this review. However, the combination of surgical treatment with 'maintenance' medical treatment has not been evaluated in any other trials of uVIN treatment, and so this trial is of interest. </p> <p>We also excluded a study that evaluated both laser vaporisation and LEEP in the same participants with VIN 3 (<a href="./references#CD011837-bbs2-0023" title="FerenczyA , Wright JrTC , RichartRM . Comparison of CO2 laser surgery and loop electrosurgical excision/fulguration procedure (LEEP) for the treatment of vulvar intraepithelial neoplasia (VIN). International Journal of Gynecological Cancer1994;4(1):22‐8. ">Ferenczy 1994</a>). In this study, half of each lesion was treated with one modality and the other half treated with the other modality. The investigators concluded that LEEP and laser vaporisation produced similar success rates; however, participants underwent multiple treatments with either modality and we could not attribute data to one modality or the other; therefore, we excluded this study. It is unlikely that including this study would have changed the assessment of the quality of the evidence on recurrence rates for LEEP versus laser vaporisation, which we judge to be very low‐quality evidence. </p> </section> <section id="CD011837-sec-0113"> <h3 class="title" id="CD011837-sec-0113">Agreements and disagreements with other studies or reviews</h3> <p>Interpretation of head‐to‐head comparisons of treatment effectiveness using NRSs is difficult as the clinical presentation of uVIN is very heterogeneous and the choice of treatment has usually been influenced by several factors, particularly lesion focality, lesion size and clinician/patient preferences. Among NRSs, unifocality was frequently associated with surgical excision, whereas multifocality was associated with combined interventions and/or medical or ablative interventions. Adjusting for baseline case mix helps to reduce the effect of such confounding but does not guarantee robust results. </p> <p>In this review, both RCTs and NRSs consistently found that multifocality was the greatest risk factor for uVIN recurrence and progression to vulval cancer. Immunosuppression was also strongly associated with progression to vulval cancer in two of the included NRSs (<a href="./references#CD011837-bbs2-0002" title="FehrMK , BaumannM , MuellerM , FinkD , HeinzlS , ImeschP , et al. Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia. Journal of Gynecologic Oncology2013;24(3):236‐41. ">Fehr 2013</a>; <a href="./references#CD011837-bbs2-0008" title="VanEschEMG , DamMCI , OsseMEM , PutterH , TrimbosB , FleurenG , et al. Clinical characteristics associated with development of recurrence and progression in usual‐type vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2013;23(8):1476‐83. ">van Esch 2013</a>). As few women in the included RCTs of medical treatment were immunosuppressed, it is uncertain whether the findings on effectiveness apply to immunosuppressed women with uVIN and this needs further study. </p> <p>As mentioned above, we excluded one NRS that did not adjust for baseline case mix (<a href="./references#CD011837-bbs2-0025" title="FregaA , SestiF , SopracordevoleF , BiamontiA , ScirpaP , MilazzoGN , et al. Imiquimod 5% cream versus cold knife excision for treatment of VIN 2/3: a five‐year follow‐up. European Review for Medical and Pharmacological Sciences2013;17(7):936‐40. ">Frega 2013</a>). In this study, women undergoing treatment for uVIN (imiquimod or surgery) were followed up for at least five years, and the overall findings favoured surgery over imiquimod. In the imiquimod arm, the complete response rate was initially 13/32 (41%) after one course of imiquimod, and then two partial responders achieved a complete response after a second course, which increased the complete response to 47%, which is similar to the rates reported in the included RCTs. However, five women in this study subsequently experienced uVIN recurrence and underwent surgery. The sustained response rate of 31% (10 out of 32 women) over the five‐year period was lower than that suggested by the long‐term follow‐up data of <a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> of 37.5%. In addition, these data do not confirm the <a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> findings, that a complete response is likely to be sustained, as a third of complete responders in <a href="./references#CD011837-bbs2-0025" title="FregaA , SestiF , SopracordevoleF , BiamontiA , ScirpaP , MilazzoGN , et al. Imiquimod 5% cream versus cold knife excision for treatment of VIN 2/3: a five‐year follow‐up. European Review for Medical and Pharmacological Sciences2013;17(7):936‐40. ">Frega 2013</a> had uVIN recurrence. Women who sustained a complete response in <a href="./references#CD011837-bbs2-0009" title="TerlouA , VanSetersM , SantegoetsLAM , Heijmans‐AntonissenC , BlokLJ , VanBeurdenM , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: results of long‐term follow‐up (&gt; 5 years). Reproductive Sciences (Thousand Oaks, Calif), 57th Annual Scientific Meeting of the Society for Gynecologic Investigation, SGI 2010 Orlando, FL United States. SAGE Publications Inc., 2010. TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. vanSetersM , vanBeurdenM , tenKateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> had small lesions. Factors that predict complete response to medical treatment need further exploration. In addition, these inconsistent findings highlight the importance of long‐term follow‐up of all women who undergo treatment for uVIN. </p> <p>Another excluded retrospective study identified women who underwent treatment for HPV‐related cervical disease or had a diagnosis of vulval or vaginal HPV‐related disease from two large HPV vaccination RCTs (<a href="./references#CD011837-bbs2-0031" title="JouraEA , GarlandSM , PaavonenJ , FerrisDG , PerezG , AultKA , et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ2012;344:e1401. ">Joura 2012</a>). The study assessed the relative impact of vaccination and placebo on subsequent HPV‐related disease (including cervical intraepithelial neoplasia (CIN), genital warts, vaginal intraepithelial neoplasia (VAIN) and VIN). However, it was not clear what proportion of women had uVIN at baseline or subsequently, as women with genital warts and/or VAIN were included. Among women who had a baseline diagnosis of vulval or vaginal disease (including warts), a reduced rate of <i>any</i> subsequent HPV‐related disease (including CIN and warts) was noted in the vaccination group compared with the placebo group (70/211 (20%) versus 163/422 (31%)) and the impact on vulval disease was driven mainly by a reduction in the incidence in genital warts. Rates of subsequent "VIN 2/3 or VAIN 2/3" were 2.6% and 3.4% for the vaccination and placebo groups, respectively. Although this study did not meet our inclusion criteria, its findings are of interest. They suggest that vaccination programmes may have an impact, not only on preventing HPV‐related disease, but also on improving outcomes in women with pre‐existing HPV‐related disease, such as uVIN. </p> <p>We did not include trials of the effectiveness of prophylactic vaccinations on preventing uVIN as this was beyond the scope of the review. However, findings from a RCT comparing HPV vaccination plus imiquimod versus imiquimod only are awaited with interest (<a href="./references#CD011837-bbs2-0051" title="PoelgeestM , HelmerhorstT . Clinical and immunological effects of imiquimod and HPV‐vaccination compared to imiquimod alone in female patients with usual type VIN ‐ effects of HPV‐vaccination and imiquimod in VIN patients. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐008251‐42 (accessed 6 February 2015)2009. ">EUCTR2008‐008251‐42‐NL</a>). </p> <p>We did not find any comparative studies evaluating smoking cessation interventions to treat or prevent recurrence of uVIN. However, smoking is a known risk factor for the development of uVIN and, like <a href="./references#CD011837-bbs2-0008" title="VanEschEMG , DamMCI , OsseMEM , PutterH , TrimbosB , FleurenG , et al. Clinical characteristics associated with development of recurrence and progression in usual‐type vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2013;23(8):1476‐83. ">van Esch 2013</a>, we believe that smoking cessation interventions should be integral to uVIN management. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011837-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram (searches to September 2015)." data-id="CD011837-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram (searches to September 2015).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/full#CD011837-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011837-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/full#CD011837-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical imiquimod versus placebo, Outcome 1 Response to treatment at 5 to 6 months." data-id="CD011837-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Topical imiquimod versus placebo, Outcome 1 Response to treatment at 5 to 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical imiquimod versus placebo, Outcome 2 Response to treatment at 12 months." data-id="CD011837-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Topical imiquimod versus placebo, Outcome 2 Response to treatment at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical imiquimod versus placebo, Outcome 3 Progression to vulval cancer at 12 months." data-id="CD011837-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Topical imiquimod versus placebo, Outcome 3 Progression to vulval cancer at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical imiquimod versus placebo, Outcome 4 HPV DNA persistence." data-id="CD011837-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Topical imiquimod versus placebo, Outcome 4 HPV DNA persistence.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical imiquimod versus placebo, Outcome 5 Fatigue." data-id="CD011837-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Topical imiquimod versus placebo, Outcome 5 Fatigue.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical imiquimod versus placebo, Outcome 6 Headache." data-id="CD011837-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Topical imiquimod versus placebo, Outcome 6 Headache.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical imiquimod versus placebo, Outcome 7 Erythema." data-id="CD011837-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Topical imiquimod versus placebo, Outcome 7 Erythema.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical imiquimod versus placebo, Outcome 8 Erosion." data-id="CD011837-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Topical imiquimod versus placebo, Outcome 8 Erosion.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical imiquimod versus placebo, Outcome 9 Oedema." data-id="CD011837-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Topical imiquimod versus placebo, Outcome 9 Oedema.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical imiquimod versus placebo, Outcome 10 Pain." data-id="CD011837-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Topical imiquimod versus placebo, Outcome 10 Pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical imiquimod versus placebo, Outcome 11 Pruritis." data-id="CD011837-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Topical imiquimod versus placebo, Outcome 11 Pruritis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical imiquimod versus placebo, Outcome 12 Local side effects." data-id="CD011837-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Topical imiquimod versus placebo, Outcome 12 Local side effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical imiquimod versus placebo, Outcome 13 No side effects." data-id="CD011837-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Topical imiquimod versus placebo, Outcome 13 No side effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical imiquimod versus placebo, Outcome 14 Dose reductions." data-id="CD011837-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Topical imiquimod versus placebo, Outcome 14 Dose reductions.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical imiquimod versus cidofovir, Outcome 1 Response to treatment at 6 months." data-id="CD011837-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Topical imiquimod versus cidofovir, Outcome 1 Response to treatment at 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical imiquimod versus cidofovir, Outcome 2 Progressive disease." data-id="CD011837-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Topical imiquimod versus cidofovir, Outcome 2 Progressive disease.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical imiquimod versus cidofovir, Outcome 3 New lesions during treatment." data-id="CD011837-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Topical imiquimod versus cidofovir, Outcome 3 New lesions during treatment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical imiquimod versus cidofovir, Outcome 4 Total serious adverse events." data-id="CD011837-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Topical imiquimod versus cidofovir, Outcome 4 Total serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical imiquimod versus cidofovir, Outcome 5 Pain." data-id="CD011837-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Topical imiquimod versus cidofovir, Outcome 5 Pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical imiquimod versus cidofovir, Outcome 6 Pruritis." data-id="CD011837-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Topical imiquimod versus cidofovir, Outcome 6 Pruritis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical imiquimod versus cidofovir, Outcome 7 Erosion." data-id="CD011837-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Topical imiquimod versus cidofovir, Outcome 7 Erosion.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical imiquimod versus cidofovir, Outcome 8 Fatigue." data-id="CD011837-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Topical imiquimod versus cidofovir, Outcome 8 Fatigue.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical imiquimod versus cidofovir, Outcome 9 Headache." data-id="CD011837-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Topical imiquimod versus cidofovir, Outcome 9 Headache.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical imiquimod versus cidofovir, Outcome 10 Skin reactions." data-id="CD011837-fig-0026" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Topical imiquimod versus cidofovir, Outcome 10 Skin reactions.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical imiquimod versus cidofovir, Outcome 11 Treatment discontinuation." data-id="CD011837-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Topical imiquimod versus cidofovir, Outcome 11 Treatment discontinuation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Carbon dioxide laser versus ultrasonic surgical aspiration, Outcome 1 Disease recurrence after 1 year follow‐up." data-id="CD011837-fig-0028" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Carbon dioxide laser versus ultrasonic surgical aspiration, Outcome 1 Disease recurrence after 1 year follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Carbon dioxide laser versus ultrasonic surgical aspiration, Outcome 2 Subjective pain." data-id="CD011837-fig-0029" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Carbon dioxide laser versus ultrasonic surgical aspiration, Outcome 2 Subjective pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Carbon dioxide laser versus ultrasonic surgical aspiration, Outcome 3 Dysuria or burning." data-id="CD011837-fig-0030" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Carbon dioxide laser versus ultrasonic surgical aspiration, Outcome 3 Dysuria or burning. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Carbon dioxide laser versus ultrasonic surgical aspiration, Outcome 4 Infection (yeast, UTI, other)." data-id="CD011837-fig-0031" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Carbon dioxide laser versus ultrasonic surgical aspiration, Outcome 4 Infection (yeast, UTI, other). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Carbon dioxide laser versus ultrasonic surgical aspiration, Outcome 5 Abnormal discharge." data-id="CD011837-fig-0032" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Carbon dioxide laser versus ultrasonic surgical aspiration, Outcome 5 Abnormal discharge. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011837-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/urn:x-wiley:14651858:media:CD011837:CD011837-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_t/tCD011837-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Carbon dioxide laser versus ultrasonic surgical aspiration, Outcome 6 Eschar." data-id="CD011837-fig-0033" src="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Carbon dioxide laser versus ultrasonic surgical aspiration, Outcome 6 Eschar. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/media/CDSR/CD011837/image_n/nCD011837-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011837-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings for imiquimod versus placebo</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Imiquimod compared with placebo for usual‐type vulval intraepithelial neoplasia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with usual‐type vulval intraepithelial neoplasia </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> imiquimod 5% cream </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk (risk in study population)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Imiquimod</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment at 5 to 6 months ‐ overall response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>285 per 1000</b> <br/> (76 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 11.95</b> (3.21 to 44.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment at 5 to 6 months ‐ complete response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 14.40</b> (2.97 to 69.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment at 12 months ‐ overall response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>87 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>791 per 1000</b> <br/> (207 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 9.10</b> (2.38 to 34.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment at 12 months ‐ complete response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 18.24</b> (1.12 to 296.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression to vulval cancer at 12 months</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>56 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> <br/> (3 to 288) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.48</b> (0.05 to 4.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,2</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>HPV DNA persistence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>923 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>397 per 1000</b> </p> <p>(240 to 665)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.43</b> (0.26 to 0.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain ‐ any grade</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>269 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>922 per 1000</b> <br/> (484 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.43</b> (1.80, 6.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose reductions</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>218 per 1000</b> <br/> (45 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 7.77</b> (1.61 to 37.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>The risk in the cidofovir group is based on the assumed risk on the comparison group and the relative effect of the intervention and its 95% CI.<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded due to imprecision. </p> <p><sup>2</sup>Downgraded due to sparse data (few events). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings for imiquimod versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/full#CD011837-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011837-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings for imiquimod versus cidofovir</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Imiquimod compared with cidofovir for usual‐type vulval intraepithelial neoplasia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with usual‐type vulval intraepithelial neoplasia </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> imiquimod 5% cream </p> <p><b>Comparison:</b> 1% cidofovir gel </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk (risk in study population)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Cidofovir</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Imiquimod</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment at 6 months ‐ overall response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>618 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>569 per 1000</b> </p> <p>(451 to 729)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92</b> </p> <p>(0.73 to 1.18)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment at 6 months ‐ complete response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>461 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>461 per 1000</b> <br/> (336 to 631) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b> </p> <p>(0.73 to 1.37)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain ‐ any grade</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>516 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>598 per 1000</b> <br/> (475 to 758) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.16</b> <br/> (0.92 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fatigue ‐ any grade</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>607 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>759 per 1000</b> <br/> (619 to 941) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.25</b> </p> <p>(1.02 to 1.55)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Headache ‐ any grade</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>440 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>656 per 1000</b> <br/> (493 to 871) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.49</b> </p> <p>(1.12 to 1.98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total serious adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>369 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>465 per 1000</b> <br/> (325 to 668) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.26</b> </p> <p>(0.88 to 1.81)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment discontinuation</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>168 per 1000</b> <br/> (82 to 345) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.33</b> </p> <p>(0.65 to 2.74)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>176</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>*The risk in the cidofovir group is based on the assumed risk on the comparison group and the relative effect of the intervention and its 95% CI.<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded due to imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings for imiquimod versus cidofovir</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/full#CD011837-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011837-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings for surgical interventions and photodynamic therapy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Surgical interventions compared with photodynamic therapy or other interventions for usual‐type vulval intraepithelial neoplasia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with usual‐type vulval intraepithelial neoplasia </p> <p><b>Settings:</b> hospital or clinic </p> <p><b>Intervention:</b> surgical excision, laser vaporisation or other options </p> <p><b>Comparison:</b> surgical excision, laser vaporisation or other surgical procedure </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Intervention versus comparison</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI) or P value</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b> Surgical excision versus laser vaporisationor other </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Recurrence‐free survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No difference</p> <p><b>P value = 0.142</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 women (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This NRS had a relatively low risk of bias and adjusted appropriately on multivariate analysis </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Laser vaporisation versus CUSA</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Recurrence rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.53</b> </p> <p>(0.56 to 4.15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 women (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>2</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This RCT lacked power to detect a difference</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b> Photodynamic therapy versus laser vaporisationand surgical excision</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Disease‐free survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No difference</p> <p><b>P value = 0.67</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 women</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>3</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This NRS had serious design limitations</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>LEEP versus laser vaporisation and surgical excision</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Recurrence‐free survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No difference</p> <p><b>P value = 0.194</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 women (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>3</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This NRS had serious design limitations</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>CUSA:</b> Cavitron ultrasonic surgical aspiration; <b>LEEP:</b> loop electrosurgical excision procedure; <b>NRS:</b> non‐randomised study; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Evidence from a non‐randomised study that adjusted for confounders. </p> <p><sup>2</sup>Downgraded twice due to imprecision. </p> <p><sup>3</sup>Evidence from a non‐randomised study with a high risk of bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings for surgical interventions and photodynamic therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/full#CD011837-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011837-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Terminology changes for vulval intraepithelial neoplasia (VIN)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ISSVD 1986</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ISSVD 2004</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LAST 2012</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VIN 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flat condyloma or HPV effect</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LSIL</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VIN 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>VIN, usual type</p> <p>a. VIN, warty type</p> <p>b. VIN, basaloid type</p> <p>c. VIN, mixed</p> <p>(warty/basaloid) type</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HSIL</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VIN 3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Differentiated VIN</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VIN, differentiated type</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>Table derived from <a href="./references#CD011837-bbs2-0081" title="ISSVD . 2014 Bibliography. Current ISSVD terminology. http://issvd.org/wordpress/wp‐content/uploads/2014/02/2014‐BIBLIOGRAPHY‐CURRENT‐ISSVD‐TERMINOLOGYrev.pdf2014. ">ISSVD 2014</a>. </p> <p>Abbreviations: HSIL: high‐grade squamous intraepithelial lesion; ISSVD: International Society for the Study of Vulvovaginal Disease; LSIL: low‐grade squamous intraepithelial lesions </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Terminology changes for vulval intraepithelial neoplasia (VIN)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/full#CD011837-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011837-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Topical imiquimod versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Response to treatment at 5 to 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Overall response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.95 [3.21, 44.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Complete response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.40 [2.97, 69.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Partial response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.88 [0.75, 19.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Response to treatment at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Overall response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Complete response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Partial response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Progression to vulval cancer at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 HPV DNA persistence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Fatigue <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Erythema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Grade 1 to 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Grade ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Any grade</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Erosion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Grades 1 to 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Grade ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Any grade</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Pruritis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Local side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 No side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Dose reductions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.77 [1.61, 37.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Topical imiquimod versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011837-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Topical imiquimod versus cidofovir</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Response to treatment at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Overall response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Complete response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Partial response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Progressive disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 New lesions during treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Grade 1 to 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Grade ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Any grade</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Pruritis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Grade 1‐2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Grade ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Any grade</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Erosion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Grade 1 to 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Grade ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Any grade</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Fatigue <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Grade 1 to 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Grade ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Any grade</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Grade 1 to 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Grade ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Any grade</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Skin reactions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Grade 1‐2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Grade ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Any grade</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Treatment discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Topical imiquimod versus cidofovir</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011837-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Carbon dioxide laser versus ultrasonic surgical aspiration</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Disease recurrence after 1 year follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Subjective pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Dysuria or burning <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Infection (yeast, UTI, other) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Abnormal discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Eschar <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Carbon dioxide laser versus ultrasonic surgical aspiration</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011837.pub2/references#CD011837-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011837.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011837-note-0001">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011837-note-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011837-note-0011">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011837\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011837\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011837\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011837\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011837\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011837\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011837\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011837\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011837\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011837\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011837\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011837\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011837\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011837\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011837\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011837\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011837\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011837\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=gpg7sF9V&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011837.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011837.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011837.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011837.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011837.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719617742"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011837.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719617746"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011837.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ded23ad3d9373',t:'MTc0MDcxOTYxOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 